

- Wang, X.L., 1263  
 Wang, Y.-H., 718  
 Wang, Z., 992  
 Wanke, T., 137  
 Wareham, N.J., 1551  
 Watson, R.L., 699  
 Wattigney, W.A., 235  
 Watts, G.F., 1101  
 Weaver, D.S., 463  
 Weber, J.-M., 357  
 Weltan, S.M., 415  
 Wernerman, J., 1388  
 Westerterp, K.R., 1004  
 Westerveld, H.T., 827  
 Westra, S.J., 76  
 Weststrate, J.A., 1004  
 Wiese, T.J., 229  
 Wiklund, O., 370  
 Wilcken, D.E.L., 1263  
 Wilcox, H., 1108  
 Williamson, M.P., 120  
 Wilson, L.L., 738  
 Wilson, P.W.F., 1267  
 Wing, R.R., 268  
 Winters, S.J., 935  
 Wolfe, R.R., 357, 1153  
 Wolthers, T., 1016  
 Wong, J., 1487  
 Wynn, V., 328  
 Xue, C., 1368  
 Yada, T., 184  
 Yamahita, J.-i., 1354  
 Yamamoto, M., 206  
 Yamamoto, T., 1354  
 Yamasaki, Y., 150  
 Yamori, Y., 457  
 Yarasheski, K.E., 254  
 Yasuda, H., 1189  
 Yasuda, K., 206  
 Yasuda, N., 1330  
 Yasunari, K., 1326  
 Yokokawa, K., 1326  
 Yorek, M.A., 229  
 Yoshida, T., 787  
 Yoshikawa, J., 1323, 1326  
 Yoshimasa, Y., 1095  
 Yoshimoto, K., 787  
 Yoshinari, M., 155  
 Yoshizumi, H., 155  
 Young, A.A., 1  
 Yudkin, J.S., 652, 961  
 Zachwieja, J.J., 254  
 Zajac, J.D., 622  
 Zammarchi, E., 957  
 Zawulich, K.C., 273  
 Zawulich, W.S., 273  
 Zhang, J., 1312  
 Zhang, X.-J., 767  
 Zhao, B., 822  
 Zhong, R., 120  
 Zhou, Y.-P., 981  
 Zhu, M., 1360  
 Ziegler, O., 430  
 Zimmermann, M.G., 747  
 Zimmet, P.Z., 627  
 Zipf, W.B., 1514  
 Zmuda, J.M., 935  
 Zwick, H., 137

## SUBJECT INDEX

- A-4166 [*N*[(*trans*-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine], somatostatin and insulin secretion due to, 184-189  
 AA (acetoacetate) in familial leucine-sensitive hypoglycemia, glucose effects on, 958  
 AASs, *see* Anabolic androgenic steroids  
 Ab(s) (antibodies), pancreatic cell islet, characteristics of subjects positive to, who progressed to IDDM, 310  
 Abdominal adipose tissue (AT)  
   distribution of, and metabolic risk factors, race and, 1119-1124  
   hormone replacement therapy effects on, in postmenopausal subjects, 1260  
   in NIDDM, 1290  
   *see also* Visceral adipose tissue  
 Ablation, medial basal hypothalamic, effects of, on EtOH-induced PRL release, 1332  
 Acarbose  
   effects of, on blood glucose after sucrose ingestion, 1370-1371  
   effects of, on fecal nutrients, colonic pH, short-chain fatty acids, and rectal proliferative indices, 1179-1187  
 ACE, *see* Angiotensin-converting enzyme gene; Angiotensin-converting enzyme inhibitor(s)  
 Acetoacetate (AA) in familial leucine-sensitive hypoglycemia, glucose effects on, 958  
 Acetyl-L-carnitine (ALC) in STZ-DM  
   deficiency in, and altered nerve *myo*-inositol content, Na<sup>+</sup>/K<sup>+</sup> ATPase activity, and MNCV, 865-871  
   effects of sorbinil and, on peripheral nerve structure, chemistry, and function, 902-907  
 N-Acetylcyclic cystathionine, LC/APCI-MS in identification of cyclic cystathionine sulfoxide and, in cystathioninuria, 1312-1316  
 Acetylhydrolase-platelet-activating factor (AH-PAF) in nephrotic syndrome, 823, 825-826  
 Acidic sterols, fecal excretion of, in sitosterolemia, 675  
 Aciduria, dicarboxylic, due to MCTs, abnormal FA oxidation, and fasting in children, compared, 162-167  
 Acipimox (ACX)  
   effects of decreasing plasma FFAs by, on hepatic glucose metabolism in normal subjects, 1408-1414  
   *see also* Acipimox, effects of, on GH response to GHRH in obesity  
 Acipimox (ACX), effects of, on GH response to GHRH in obesity alone or combined with arginine in obese women, 342-346  
   long-term therapy with ACX potentiating GH response to GHRH by decreasing serum FFAs in obese men, 594-597  
 m-Aconitase, PRL-regulating citrate oxidation and, in prostate epithelial cells, 442-449  
 Acromegalic pituitary adenomas, PKC and cAMP responses to GH secretion in, 206-210  
 Acromegaly, functional liver mass and plasma flow in, before and after long-term octreotide therapy, 109-113  
 ACTH, *see* Corticotropin  
 Activated partial thromboplastin time (APTT) in hypercholesterolemic thrombophilia, 967, 968  
 Acute asthma, plasma adrenomedullin in, 1323-1325  
 Acute hypoglycemia, effects of, on rCBF in IDDM, impaired hypoglycemia awareness, 974-980  
 ACX, *see* Acipimox  
 Adenine nucleotides  
   RBC, effects of xylitol on, 1356, 157  
   *see also* ADP; AMP; ATP  
 Adenomas, pituitary acromegalic, PKC and cAMP responses to GH secretion in, 206-210  
 Adenosine diphosphate, *see* ADP  
 Adenosine monophosphate, *see* AMP  
 Adenosine triphosphatase, *see* Na<sup>+</sup>/K<sup>+</sup> ATPase  
 Adenosine triphosphate, *see* ATP  
 Adenoviral delivery of LDL receptors to hyperlipidemic subjects, HDLs and, 1447-1457  
 Adhesive (and proliferative) properties of VSMCs, nonenzymatic glycation of Fn impairing, 285-292

- Adipocyte(s)  
 AT FAs and size and number of, in boys from birth to 9 years of age, 1395-1401  
 basal and insulin-stimulated glucose transport in, TNF- $\alpha$  effects on, 1089-1094  
 GH effects on newly differentiated, 34-42  
 glucose oxidation to CO<sub>2</sub>, effects of Mg deficiency on, 839-840  
 hormone replacement therapy effects on size of, in postmenopausal subjects, 1258-1259  
 Adipocyte precursor cells, GH effects on newly differentiated adipocytes and, 34-42  
 Adipose tissue (AT; body fat)  
 abdominal, *see* Abdominal adipose tissue  
 FAs in, and size and number of adipocytes in boys from birth to 9 years of age, 1395-1401; *see also* Adipocyte(s); Adipocyte precursor cells  
 and fibrinolytic potential, 1429  
 in healthy Indian and Swedish men, cardiovascular risk factors and, 634-644  
 intercapsular brown, and CL316,243 effects on SNS activity, 788  
 and intramuscular TG content, 949  
 of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109  
 in NIDDM, role of loss of, in exercise-induced improvement in plasma lipids, 1383-1395  
 oral albuterol effects on, 715  
 and regional FFA kinetics, 663  
 and relationship between hepatic and peripheral insulin resistance and PAI-1, 1244  
 relationship between plasma insulin level, BP in normal, diabetic, and DKA subjects, and production of PGE<sub>2</sub>, PGI<sub>2</sub>, and 6-keto-PGF<sub>1 $\alpha$</sub>  by, 691-698  
 relationship of plasma TGs, HDL-C, and apo B to postheparin LPL activity and, 263  
 subcutaneous, *see* Subcutaneous adipose tissue  
 visceral, *see* Visceral adipose tissue  
*see also* Adiposity; Fat-free mass  
 Adiposity  
 influence of age, sex and, on metabolically active component of FFM, 992-997  
*see also* Adipose tissue; Obesity  
 Adolescent boys  
 autonomically mediated physiological responses to experimentally induced mental stress in, IRS and, 614-621  
 insulin resistance in Swedish, 908-914  
 pubertal obese, urate changes in, 203-210  
*see also* Adolescent obesity  
 Adolescent girls  
 Swedish, insulin resistance in, 908-914  
*see also* Adolescent obesity  
 Adolescent obesity  
 adult obesity and multiple cardiovascular risk factors associated with, 235-240  
 DHEA in morbid, effects of weight, body composition, lipids, and insulin resistance on, 1011-1015  
 urate changes in pubertal obese boys, 203-210  
 ADP (adenosine diphosphate)  
 muscle protein synthesis and degradation and, 1281  
 RBC, xylitol effects on, 1357  
 $\alpha$  (alpha)-Adrenergic hormones, role of, in regulation of gluconeogenesis, 392-394  
 $\beta_3$  (beta<sub>3</sub>)-Adrenoceptor agonist, CL316,243 as, effects of, on SNS activity, 787-791  
 Adrenocorticotropin, *see* Corticotropin  
 Adrenomedullin (AM), plasma, in acute asthma, 1323-1325  
 Adult(s), *see* Adult-onset insulin-dependent diabetes mellitus; Men; Normal adult subjects; Women; Young adults *and specific conditions*  
 Adult-onset insulin-dependent diabetes mellitus (IDDM), effects of intensive therapy on insulin sensitivity and insulin reserve in, 1508-1513  
 Adverse effects of VS, 1131-1132  
 Aerobic exercise, effects of resistance and, on body composition and metabolism following diet-induced weight loss, 179-183  
 Age  
 and abdominal AT distribution, metabolic risk factors and, 1120  
 of acromegalic subjects, *see* Age of acromegalic subjects  
 and androgen regulation of GHBP, 1522  
 of Bardet-Biedel syndrome children, 1232, 1233  
 birth to 9 years of, AT FAs and size and number of adipocytes from, in boys, 1395-1401  
 and body composition of healthy Indian and Swedish men, 635  
 of CAD subjects, 1377  
 of cancer patients, response to radiation therapy and, 768  
 of CHD subjects, 670  
 and circadian relationships between serum Ca, serum phosphate, and circulating ANPs, 1022  
 of diabetic subjects, *see* Age of diabetic subjects  
 and effects of parasympathetic denervation of liver and pancreas on glucose kinetics, 988  
 exercise and, *see* Age, and exercise  
 of FHLB subjects, 1297  
 of FHTG and FDL subjects, 1308  
 and fibrinolytic potential, 1429  
 of GH-deficient men, 363, 371  
 and glucose processing during FSIGT, 599  
 of hirsute women, *see* Age of hirsute women  
 of hospitalized subjects, 1558, 1559  
 of hypercholesterolemic subjects, *see* Age of hypercholesterolemic subjects  
 and hyperinsulinemia associated with VPCs, 1250-1252  
 of hypertensive subjects, *see* Age of hypertensive subjects  
 of hyperthyroidic subjects, and effects of early changes in plasma glucagon on GH response in, 1030  
 of hypoglycemic subjects, 1423  
 influence of adiposity, sex and, on metabolically active component of FFM, 992-997  
 and insulin effects, *see* Age, and insulin  
 insulin resistance and, *see* Age, insulin resistance and  
 of Laron syndrome subjects, 1264  
 of multiple trauma subjects, 451  
 of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109  
 and O<sub>2</sub> consumption in heart, hepatomesenteric bed, and brain, 1488  
 of obese subjects, *see* Age of obese subjects  
 and palmitic and stearic acid effects on serum lipids, Lps, and plasma CETP, 144  
 of postmenopausal women, 828  
 of premenopausal women, *see* Age of premenopausal women  
 of PWS subjects, 1515, 1516  
 and regional FFA kinetics, 663  
 and relationship between growth rate, GHBP, and GH, 425, 426  
 and relationship of plasma TGs, HDL-C, and apo B to postheparin LPL activity, 263  
 and relationship between psychosocial stress and IRS, 1535  
 of smokers, *see* Age of smokers  
 of  $\beta$ -thalassemia major subjects, 653  
 and urinary excretion of T and E<sub>2</sub>, 281  
 and visceral obesity, *see* Age, visceral obesity and

Age (*Continued*)

see also Aging; Children; Elderly subjects; Infancy; Puberty; Young adults

## Age, and exercise

and diet influence on glucose homeostasis and serum lipid levels, 436

and endogenous opioid response to exercise, 139

exercise effects on concentrations of serum TC and LDL-C related to Apo E phenotype in boys and young adults, 798

strenuous exercise effects on glycerol kinetics, 358

and substrate kinetics during prolonged exercise, 418

## Age, and insulin

insulin effects on HGP, 83

and insulin effects on intracellular Ca concentrations, insulin resistance and, 1403, 1405

insulin effects on levels of circulating vitamin E, 999

interstitial insulin in non-obese subjects, 952

## Age, insulin resistance and

age of nondiabetic Creole, Chinese, and Indian Mauritians, and relationship between weight gain and insulin resistance, 629, 631, 632

and insulin effects on intracellular Ca concentrations, 1403, 1405 and relationship between hepatic and peripheral insulin resistance and PAI-1, 1244

## Age, visceral obesity and

visceral adipose tissue and, 379-381

of visceral obesity-insulin resistance-dyslipidemic syndrome subjects, 885

## Age of acromegalic subjects

of acromegalic pituitary adenoma subjects, 207

functional liver mass and plasma flow and, 110

## Age of diabetic subjects

and sorbitol and glutathione in erythrocytes, 612

see also Age of IDDM subjects; Age of NIDDM subjects

## Age of hirsute women

BMD and, 516

hyperandrogenic, GnRH therapy and, 25

## Age of hypercholesterolemic subjects

with FH, GH and, 1417

with thrombophilia, 967

## Age of hypertensive subjects

with LVH, 1327

urapidil effects on plasma Fn and, 1222

## Age of IDDM subjects, 269

of adult-onset IDDM subjects, 1510

apo, Lp, and LDL size and, 1268, 1269

autonomic neuropathy and, 1066

blood cell membrane phospholipid composition and, 59

and endogenous opioid response to exercise, 139

with hypoglycemia, 975

and Na<sup>+</sup>/K<sup>+</sup> ATPase turnover and Na<sup>+</sup>/K<sup>+</sup> ATP erythrocyte concentration in IDDM, 928

in nonnephropathic IDDM, RBC membrane SLC kinetics and, 1204

progression of microalbuminuria and, 1102

with well-controlled IDDM, 1435

## Age of NIDDM subjects

and ACE and AGN gene polymorphism, 220

with amino acid polymorphism in HSL, 862, 864

apo, Lp, and LDL size and, 1268, 1269

autonomic neuropathy and, 1066

blood cell membrane phospholipid composition and, 59

cardiovascular risk factors and RBC membrane SLC and, 962

and effects of vanadyl sulfate on CHO and lipid metabolism, 1131

Age of NIDDM subjects (*Continued*)

and gliclazide effects on HGP suppression, 1197

with macrovascular disease, 134

and Na<sup>+</sup>/K<sup>+</sup> ATPase turnover and Na<sup>+</sup>/K<sup>+</sup> ATP erythrocyte concentration in NIDDM, 928

of NIDDM Mexican-Americans and non-Hispanic whites, 877, 879

of normotriglyceridemic NIDDM subjects, 64

oral glucose effects on CCK release and, 197

with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783

of untreated NIDDM subjects, 493

## Age of obese adolescents

cardiovascular risk factors and, 235

effects of insulin resistance, lipids, and body weight on DHEA in morbidly obese adolescents, 1012

urate changes in pubertal boys, 204

## Age of obese subjects

HDL-C in obese 10-year-old girls, race and, 469-474

interstitial insulin and, 952

of premenopausal obese women with VAT and SAT, HPA axis activity and, 352

see also Age of obese adolescents; Age, visceral obesity and

## Age of premenopausal women

of non-obese premenopausal women, lipid and CHO metabolic risk markers for CHD in, 329

of premenopausal obese women with VAT and SAT, HPA axis activity and, 352

## Age of smokers, 1552

and smoking effects on REE, 924

## Aging

in women, four-compartment model of body composition in, 43-48

see also Elderly subjects

AGN (angiotensinogen) genes, polymorphism of, in Japanese NIDDM subjects, 218-222

AH-PAF (acetylhydrolase-platelet-activating factor) in nephrotic syndrome, 823, 825-826

Alacepril, effects of, on hypertension and insulin resistance in STZ-DM, 457-462

## Alanine

arterial, portal vein, and hepatic vein, stress hormone effects on, in conscious subjects, 576

MH 7777 effects on concentrations of, 851

octreotide effects on, in IDDM, 214

plasma, effects of *N*-carbamyl glutamate on, in familial leucine-sensitive hypoglycemia, 959

## Albumin

stress hormone effects on protein synthesis in, in normal adult subjects, 1388-1394

see also Albumin in IDDM; Albumin in NIDDM; Albuminuria

## Albumin in IDDM

RBC membrane phospholipid composition and, 59

urinary excretion of, see Urinary excretion, albumin, in NIDDM

## Albumin in NIDDM

cardiovascular risk factors and RBC membrane SLC and, 962, 963

RBC membrane phospholipid composition and, 59

urinary excretion of, see Urinary excretion, albumin, in NIDDM

## Albuminuria

gonadectomy effects on development of STZ-DM, hypertension and, 155-161

see also Microalbuminuria; Proteinuria

Albuterol, effects of oral, on serum lipids and carbohydrate metabolism in men, 712-717

ALC, see Acetyl-L-carnitine in STZ-DM

- Alcohol and alcohol consumption  
 and hematologic parameters in hypercholesterolemic thrombophilia, 967  
 interactions of lung antioxidant defense system with Cu, dietary CHOs, and alcohol in male and female subjects, 49-56  
 smoking and, 1552, 1553  
*see also* Alcohol and alcohol consumption in IDDM; Beer; Ethanol
- Alcohol and alcohol consumption in IDDM, 269, 270  
 in nonneuropathic IDDM, RBC membrane SLC kinetics and, 1204  
 RBC membrane phospholipid composition and, 59
- Aldose reductase inhibitor(s) (ARIs)  
 sorbinil as, effects of supplementation with *myo*-inositol and, on polyphosphoinositide turnover in peripheral nerve in STZ-DM, 320-327  
 tolrestat as, effects of, on nerve regeneration in STZ-DM, after crush injury, 1189-1195
- Alkaline phosphatase, cellular, effects of vitamin B<sub>12</sub> on activity of, and on proliferation of bone marrow osteoprogenitor cells and UMR106 osteoblastic cells, 1443-1446
- Alpha ( $\alpha$ )-adrenergic hormones, role of in regulation of gluconeogenesis, 392-394
- Alpha ( $\alpha$ ) cells  
 pancreatic, function of, in partially pancreatectomized subjects, as model of spontaneous NIDDM, 1360-1367  
 time course of defective response of, to hypoglycemia in IDDM, 1422-1426
- 17Alpha ( $\alpha$ )-dihydroequilin, antioxidant effects of, on lipid peroxidation, 411-414
- 5 Alpha ( $\alpha$ )-Dihydrotestosterone (DHT), GHBP regulation by, 1521-1526
- Alpha ( $\alpha$ )-glucosidase, L-arabinose effects on, after sucrose ingestion, 1369-1370
- Alpha ( $\alpha$ )-glucosidase inhibitor, voglibose as, effects of, on dyslipidemia and insulin sensitivity in nondiabetic hyperinsulinemia, 731-737
- Alpha ( $\alpha$ )-lipoprotein, *see* High-density lipoprotein(s)
- Alpha ( $\alpha$ )-tocopherol, *see* Vitamin E
- AM (adrenomedullin), plasma, in acute asthma, 1323-1325
- Amino acids  
 polymorphism of, in HSL of Japanese NIDDM subjects, 862-864  
*see also* Plasma amino acids and *specific amino acids*
- Aminoguanidine, rapid reversal of neurovascular effects of STZ-DM with, 1147-1152
- Ammonia (NH<sub>3</sub>), splenocyte, MH 7777 effects on metabolism of, 853
- Ammonium (NH<sub>4</sub>), familial leucine-sensitive hypoglycemia with concomitant hyperammonemia, 957-960
- AMP (adenosine monophosphate)  
 cyclic, *see* cAMP  
 muscle protein synthesis and degradation and, 1281  
 RBC, effects of xylitol on, 1357
- Amylase, L-arabinose effects on, after sucrose ingestion, 1369-1370
- Amylin, CCK, GLP-1 and, in gastric emptying, 1-3
- $\Delta 4$ An, *see* Androstenedione
- Anabolic androgenic steroids (AASs)  
 effects of abuse of, on serum ubiquinone and dolichol levels, 844-847  
*see also specific anabolic androgenic steroids*
- Androgenic steroids  
 anabolic, effects of abuse of, on serum ubiquinone and dolichol levels, 844-847  
 regulating GHBP, 1521-1526  
*see also* Hyperandrogenic women and *specific androgenic steroids*
- Androstenedione ( $\Delta 4$ An)  
 hormone replacement therapy effects on, in postmenopausal subjects, 1258, 1260  
*see also* Androstenedione in hirsute women
- Androstenedione ( $\Delta 4$ An) in hirsute women  
 BMD and, 516  
 effects of GnRH in severely hirsute hyperandrogenic women on, 25  
 in obese women, 72-75
- Anesthetized subjects  
 effects of decreasing plasma FFAs by ACX on hepatic glucose metabolism in, 1409-1410  
 tracer kinetics in measurement of muscle protein synthesis and degradation in, 1279-1283
- Angiotensin-converting enzyme (ACE) gene, polymorphism of, in Japanese NIDDM subjects, 218-222
- Angiotensin-converting enzyme (ACE) inhibitor(s), trandolapril as, effects of, alone or in combination with verapamil, on glucose transport in insulin-resistant skeletal muscle, 535-541
- Angiotensinogen (AGN) genes, polymorphism of, in Japanese NIDDM subjects, 218-222
- ANPs, *see* Atrial natriuretic peptides
- ANS (autonomic nervous system), HPA axis activity and its relationship to, in obese premenopausal women with VAT and SAT, effects of CRF/AVP and stress tests on, 351-356
- Anterior pituitary- and pituitary-dependent target organ function in HIV-infected men, 738-746
- Anthropometric parameters  
 of adolescent boys, and autonomically mediated physiological responses to experimentally induced mental stress in IRS, 616-618  
*see also specific anthropometric parameters; for example:* Body weight
- Antibodies (Abs), pancreatic islet cell, characteristics of subjects positive for, who progressed to IDDM, 310
- Antigen, PAI-1, relationship between hepatic and peripheral insulin resistance and, 1244-1245
- Antihypertensive therapy, *see specific antihypertensive agents*
- Antilipolytic effects  
 of DZ in obesity, 334-341  
*see also specific antilipolytics*
- Antioxidants  
 antioxidant effects of 4-hydroxyestrone and 17 $\alpha$ -dihydroequilin on lipid peroxidation, 411-414  
 lung defense system against, in male and female subjects, interacting with alcohol, Cu, and dietary CHOs, 49-56
- Antiproteinuria therapy, serum lathosterol-to-cholesterol ratio is not elevated in glomerular proteinuria and not associated with improved hyperlipidemia in response to, 723-730
- Antithrombin-III (AT-III) in hypercholesterolemic thrombophilia, 967, 968
- Aortic glycation, hormonal replacement therapy effects on, in postmenopausal subjects, 1259, 1260
- Apo(s), *see* Apolipoprotein(s)
- Apolipoprotein(s) (apos)  
 metabolism of, in genetic hypercholesterolemia, 7  
 size of, in IDDM and NIDDM, 1267-1272  
*see also specific apolipoproteins*
- Apolipoprotein A (apo A) in IDDM, progression of microalbuminuria and, 1103
- Apolipoprotein A-I (apo A-I)  
 and exercise effects on concentrations of serum TC and LDL-C related to apo E phenotype in boys and young adults, 798  
 in FH, GH and, 1418  
 in FH/LB, 1297

- Apolipoprotein A-I (apo A-I) (*Continued*)  
 in FHTG and FDL, 1308  
 in glomerular proteinuria, 726  
 and HDL-C in 10-year-old obese girls, 471, 472  
 in high SFA diet, 553  
 in IDDM, *see* Apolipoprotein A-I in IDDM  
 in NIDDM, *see* Apolipoprotein A-I in NIDDM  
 of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109  
 palmitic and stearic acid effects on, 146  
 plasma, *see* Plasma apolipoprotein A-I  
 in uremia, 688  
 and urinary excretion of E<sub>2</sub> and T, 281-283  
 in visceral obesity-insulin resistance-dyslipidemic syndrome, 885, 886  
 voglibose effects on, in nondiabetic hyperinsulinemia, 734
- Apolipoprotein A-I (apo A-I) in IDDM  
 intraperitoneal insulin effects on, 432  
 progression of microalbuminuria and, 1103  
 size of, 1268, 1269
- Apolipoprotein A-I (apo A-I) in NIDDM  
 in normotriglyceridemic NIDDM, 64, 67  
 plasma, role of AT loss in exercise-induced improvement in, 1384  
 size of, 1268, 1269
- Apolipoprotein A-II (apo A-II)  
 in FH, GH and, 1418  
 of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109
- Apolipoprotein A-III (apo A-III) of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109
- Apolipoprotein B (apo B)  
 editing RNA of, in genetic obesity, 1056-1058  
 estrogen increasing LDL receptor catabolism independent of, in hyperlipidemia, 889-896  
 and exercise effects on concentrations of serum TC and LDL-C related to apo E phenotype in boys and young adults, 798  
 in FH, GH and, 1418  
 in FHLB, 1297  
 in FHTG and FDL, 1308  
 GH therapy effects on, 1017  
 in glomerular proteinuria, 726  
 in IDDM, *see* Apolipoprotein B in IDDM  
 in NIDDM, *see* Apolipoprotein B in NIDDM  
 of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109  
 palmitic and stearic acid effects on, 146  
 relation between plasma TGs, HDL-C and, to postheparin LPL activity dependent on apo E polymorphism, 261-267  
 in uremia, 688  
 and urinary excretion of E<sub>2</sub> and T, 281-283  
 voglibose effects on, in nondiabetic hyperinsulinemia, 734
- Apolipoprotein B (apo B) in IDDM  
 intraperitoneal insulin effects on, 432  
 as predictor of microalbuminuria progression in IDDM, 1101-1107  
 size of, 1268, 1269
- Apolipoprotein B (apo B) in NIDDM  
 in normotriglyceridemic, 64, 67  
 plasma, role of AT loss in exercise-induced improvement in, 1384  
 size of, 1268, 1269
- Apolipoprotein B:A1 (apo B:A1) in normotriglyceridemic NIDDM, 64, 67
- Apolipoprotein B-43.7 (apo B-43.7) in FHLB, 1296-1304
- Apolipoprotein B-100 (apo B-100)  
 in FHLB, 1299-1302  
 in high SFA diet, 553
- Apolipoprotein E (apo E)  
 in FHLB, 1297  
*see also* Apolipoprotein E genotype; Apolipoprotein E phenotype; Apolipoprotein E polymorphism
- Apolipoprotein E (apo E) genotype in FH, GH and, 1417
- Apolipoprotein E (apo E) phenotype, exercise effects on serum TC and serum LDL-C concentrations related to, in boys and young adults, 797-803
- Apolipoprotein E (apo E) polymorphism  
 influence of, on postprandial Lp metabolism in normotriglyceridemic NIDDM, 63-71  
 relationship between plasma TGs, HDL-C, apo B and, to postheparin LPL activity dependent on, 261-267
- Apoptosis, proximal tubular cell, induced by glucose loading, 1348-1353
- APTT (activated partial thromboplastin time) in hypercholesterolemic thrombophilia, 967, 968
- L-Arabinose inhibiting intestinal sucrase and suppressing glycemic response after sucrose ingestion, 1368-1374
- Arachidonic acid in STZ-DM, effects of sorbinil and ALC on, 905
- Arginine (ARG)  
 ACX effects on GH response to GHRH alone or combined with, in obese women, 342-346  
 differential beta-cell response to glucose, glucagon and, during progression to IDDM, 306-314  
 MH 7777 effects on concentrations of, 851  
 L-N<sup>G</sup>-monomethyl-, effects of, on mononuclear splenocytes and NO generation with mld-STZ, 940-946  
 plasma insulin response to, in spontaneous NIDDM, 1361-1363, 1365
- Arginine-vasopressin (AVP)/corticotropin-releasing factor (CRF) test, effects of stress test and, on HPA axis activity and its relationship to AN in premenopausal obese women with SAT and VAT, 351-356
- ARIs, *see* Aldose reductase inhibitor(s)
- Arterial alanine, stress hormone effects on, in conscious subjects, 576
- Arterial cortisol, intrarenal glucagon action on, 385
- Arterial free fatty acids (FFAs)  
 hyperglycemia effects on, during ischemia, 546  
 intrarenal glucagon action on, 385
- Arterial glucose  
 hepatic, in conscious subjects, glyburide effects on, 580  
 intrarenal glucagon action on, 385
- Arterial insulin, intrarenal glucagon action on, 385
- Arterial K (potassium), intrarenal glucagon action on, 385
- Arterial lactate  
 hyperglycemia effects on, during ischemia, 546  
 intrarenal glucagon action on, 385  
 stress hormone effects on, in conscious subjects, 576
- Arterial Na (sodium), intrarenal glucagon action on, 385
- Arterial plasma glucagon (G), stress hormone effects on, in conscious subjects, 573
- Arterial plasma glucose, hyperglycemia effects on, during ischemia, 546
- Arterial pressure, *see* Blood pressure
- Asparagine, MH 7777 effects on concentrations of, 851
- Aspartate, MH 7777 effects on, 851-853
- Aspartate transaminase (AST) in beta-thalassemia major, 653
- Asthma, acute, plasma adrenomedullin in, 1323-1325
- AT, *see* Adipose tissue

- Atenolol, effects of urapidil and, on plasma Fn in essential hypertension, compared, 1221-1229
- Atherogenic diet, nandrolone decanoate effects on plasma lipids and coronary arteries of females on moderately, 463-468
- Athletes, *see* Exercise
- Atmospheric pressure chemical ionization interface system, liquid chromatography-mass spectrometry with, *N*-acetylcystathionine and cyclic cystathionine sulfoxide in cystathioninuria identified with, 1312-1316
- ATP (adenosine triphosphate)  
inhibition of A-4166-induced insulin and somatostatin release by  $K^+$  channel opener sensitive to, 185-186  
muscle protein synthesis and degradation and, 1281  
 $Na^+/K^+$ , in erythrocytes of IDDM and NIDDM subjects, 927-934  
RBC, xylitol effects on, 1357  
in whole blood, 52
- ATPase, *see*  $Na^+/K^+$  ATPase
- Atrial natriuretic peptides (ANPs)  
circulating, circadian relationships between serum Ca, serum phosphate and, in healthy subjects, 1021-1028  
circulating endothelin modulated by, 315-319
- Atropine, effects of, on CCK, 198
- AT-III (antithrombin-III) in hypercholesterolemic thrombophilia, 967, 968
- Autonomic nervous system (AN), HPA axis activity and its relationship to, in premenopausal obese women with VAT and SAT, effects of CRF/AVP and stress tests on, 351-356
- Autonomic neuropathy, plasma met-enkephalin in IDDM and NIDDM and, 1065-1068
- Autonomically mediated physiological responses to experimentally induced mental stress in adolescent boys, IRS and, 614-621
- Autophosphorylation, IR, 1475-1477  
in leprechaunism, 1495
- AVP (arginine-vasopressin)/CRF (corticotropin-releasing factor) test, effects of stress test and, on HPA axis activity and its relationship to AN in premenopausal obese women with SAT and VAT, 351-356
- Awareness of hypoglycemia, IDDM with impaired, effects of acute hypoglycemia on rCBF in, 974-980
- Bacteria, digoxin-metabolizing fecal, acarbose effects on, 1182, 1183
- Bardet-Biedel syndrome (BBS), empty sellae, impaired testosterone secretion, and defective hypothalamic-pituitary growth and gonadal axes in children with, 1230-1234
- Basal glucose transport in muscle and fat cells, TNF- $\alpha$  effects on, 1089-1094
- BBS (Bardet-Biedel syndrome), empty sellae, impaired testosterone secretion, and defective hypothalamic-pituitary growth and gonadal axes in children with, 1230-1234
- BCM (body cell mass), FFM relation to, 992-997
- Beef tallow, effects of, on expression of insulin signal-transduction pathway intermediate gene, 1080-1088
- Beer, gastric emptying of, in Mexican-Americans and in NHWs, 1174-1178
- Beta<sub>3</sub> ( $\beta_3$ )-adrenoceptor agonist, CL316,243 as, effects of, on SNS activity, 787-791
- Beta ( $\beta$ ) cells  
FA effects on glucose-regulated function of, pancreatic islet TGs and FA oxidation effects on glucose metabolism associated with, 981-986  
hepatic insulin extraction and activity of, following dexamethasone administration in healthy subjects, 486-492  
in IDDM, *see* Beta cells in IDDM
- Beta ( $\beta$ ) cells in IDDM  
differential response of, to glucose, glucagon, and arginine during progression to IDDM, 306-314  
insulin effects on beta-cell function in subjects at high risk for IDDM, 873-875
- Beta ( $\beta$ )-endorphin, responses of PRL and, to hypoglycemia in well-controlled IDDM, 1434-1440
- 17Beta ( $\beta$ )-estradiol ( $E_2$ ) reducing postprandial HDL-C in postmenopausal women, 827-832
- Beta-hydroxybutyric acid, *see*  $\beta$ -Hydroxybutyric acid
- Beta ( $\beta$ )-lipoprotein, *see* Low-density lipoprotein(s)
- Beta<sub>2</sub> ( $\beta_2$ )-microglobulin, *see*  $\beta_2$ -Microglobulin
- Beta ( $\beta$ )-thalassemia major, glucose intolerance in, related to insulin resistance and hepatic dysfunction, 652-657
- Bicarbonate ( $HCO_3$ ) in Bardet-Biedel syndrome children, 1231
- Binding protein, *see* Growth hormone-binding protein; Insulin-like growth factor binding protein-1; Insulin-like growth factor binding protein-3
- Biphosphatase, fructose-1,6-, impaired regulation of hepatic, in obese NIDDM subjects, 622-626
- Biphosphate ( $P_2$ ), fructose-2,6-, and regulation of hepatic FBPase in obese NIDDM subjects, 622-626
- Birth to 9 years of age, AT FAs and size and number of adipocytes from, in boys, 1395-1401
- Blood flow  
hepatic portal, differential effects of pathophysiological versus physiological concentrations of plasma E and NE on KB metabolism and, 1214-1220  
hyperglycemia effects on, during ischemia, 544, 545  
plasma, glyburide effects on, in conscious subjects, 580  
regional cerebral, effects of acute hypoglycemia on, in IDDM with impaired awareness of hypoglycemia, 974-980
- Blood glucagon, xylitol effects on, 1335
- Blood glucose  
fasting, *see* Fasting blood glucose  
in FHTG and FDL, omega-FA and fenofibrate effects on, 1306  
in IDDM, *see* Blood glucose in IDDM  
relationship between plasma insulin, total ketone levels and, in normal, DM, and DKA subjects, 693, 695  
in spontaneous NIDDM, 1361-1362  
in STZ-DM, *see* Blood glucose in STZ-DM  
xylitol effects on, 1335  
D-xylose, acarbose, and L-arabinose effects on, after sucrose ingestion, 1370-1371
- Blood glucose in IDDM  
intraperitoneal insulin effects on, 432  
in nonnephropathic IDDM, RBC membrane SLC kinetics and, 1204
- Blood glucose in STZ-DM  
body weight and, 321  
effects of ALC replacement on, 868
- Blood lactate, and exercise with pivalic acid-induced carnitine deficiency, 1504
- Blood lactic acid, xylitol effects on, 1358
- Blood pH, effects of intrarenal glucagon action on, 385
- Blood pressure (BP)  
and abdominal AT distribution, metabolic risk factors and, 1121  
of adolescents with insulin resistance, 909-911  
in Bardet-Biedel syndrome, 1233  
in FH, GH and, 1417  
in glomerular proteinuria, 725  
in healthy men, *see* Blood pressure in healthy men  
of hospitalized subjects, 1558, 1559  
of hyperandrogenic hirsute women, GnRH therapy and, 25  
of hypercholesterolemic thrombophilia patients, 967

**Blood pressure (BP) (*Continued*)**

- hyperglycemia effects on, during ischemia, 544
- and hyperinsulinemia associated with VPCs, 1250-1252
- in IDDM, *see* Blood pressure in IDDM
- and insulin effects on levels of circulating vitamin E, 999
- insulin resistance and, and insulin effects on intracellular Ca concentrations, 1403, 1405
- in IRS, 1535, 1536
- in NIDDM, *see* Blood pressure in NIDDM
- in non-obese premenopausal women of different racial origins, lipid and CHO metabolic risk markers for CHD and, 328-333
- in normal, diabetic, and DKA subjects, relationship between AT production of PGI<sub>2</sub>, PGE<sub>2</sub>, and 6-keto-PGF<sub>1α</sub>, plasma insulin level and, 691-698
- and O<sub>2</sub> consumption in heart, hepatomesenteric bed, and brain, 1488
- in obesity, *see* Blood pressure in obesity
- of PWS subjects, 1515
- and relationship between hepatic and peripheral insulin resistance and PAI-1, 1244
- of young women on contraceptive steroids, 834
- see also* Hypertension
- Blood pressure (BP) in healthy men**
  - as CV risk factor in healthy Indian and Swedish men, 640
  - and ET-1 impact on basal and stimulated concentrations of LH, FSH, TSH, GH, ACTH, and PRL with and without nifedipine pretreatment, 659
- Blood pressure (BP) in IDDM**
  - in nonnephropathic IDDM, RBC membrane SLC kinetics and, 1204
  - progression of microalbuminuria and, 1102
- Blood pressure (BP) in NIDDM**
  - and ACE and AGN gene polymorphism, 220, 221
  - cardiovascular risk factors and RBC membrane SLC and, 962, 963
  - with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783
- Blood pressure (BP) in obesity**
  - cardiovascular risk factors and, in adolescent obesity, 235
  - pioglitazone effects on, 521
- Blood pyruvic acid, xylitol effects on, 1358**
- Blood urea nitrogen (BUN) in NIDDM with and without renal insufficiency, insulin effects on urinary phosphate excretion in, 783**
- Blood volume, finger, mental stress and, in adolescent boys with IRS, 614-621**
- BMD (bone mineral density), current, and menstrual history of young hirsute women, 515-518**
- BMI, *see* Body mass and body mass index**
- BNPs (brain natriuretic peptides) during ergometric exercise by hypertensive patients with LVH, 1326-1329**
- Body cell mass (BCM), FFM relation to, 992-997**
- Body composition**
  - CT-determined, in healthy Indian and Swedish men in relation to CV risk factors, 634-644
  - effects of, on DHEA in morbidly obese adolescents, 1011-1015
  - effects of cardiovascular fitness, Lp(a) and, on fibrinolysis, 1427-1433
  - energy expenditure and, 996-997
  - exercise effects on, *see* Body composition, exercise effects on
  - four-compartment model of, in aging women, 43-48
  - of GH-deficient men, effects of GH therapy on, 364
  - hormone replacement therapy effects on, in postmenopausal subjects, 1258-1259

**Body composition (*Continued*)**

- oral albuterol effects on, 714-716
- see also* Adipose tissue; Body weight; Fat-free mass; Muscle
- Body composition, exercise effects on**
  - in older men, effects of GH administration on, during resistance exercise, 256
  - resistance and aerobic exercise effects on metabolism and body composition following diet-induced weight loss, 179-183
- Body fat, *see* Adipose tissue**
- Body K (potassium), *see* Total body K**
- Body mass and body mass index (BMI)**
  - and abdominal AT distribution, metabolic risk factors and, 1120, 1121
  - of aging women, 44
  - of Bardet-Biedel syndrome children, 1232, 1233
  - of CAD patients, 1377, 1379, 1380
  - of CHD subjects, *see* Body mass and body mass index, CHD and
  - of diabetic subjects, *see* Body mass and body mass index of diabetic subjects
  - exercise and, *see* Body mass and body mass index, exercise and
  - and fibrinolytic potential, 1429
  - full- or reduced-fat diet effects on, 1005, 1009
  - of GH-deficient men, 363, 371
  - glucose and, *see* Body mass and body mass index, glucose and
  - of healthy Indian and Swedish men, 637, 641
  - of hirsute women, *see* Body mass and body mass index of hirsute women
  - of hospitalized subject, 1558-1560
  - of hypercholesterolemic subjects, *see* Body mass and body mass index of hypercholesterolemic subjects
  - and hyperinsulinemia associated with VPCs, 1250-1252
  - of hypertensive subjects, urapidil effects on plasma Fn and, 1222
  - of IDDM subjects, *see* Body mass and body mass index of IDDM subjects
  - and impaired glucose tolerance, 504
  - insulin effects and, *see* Body mass and body mass index, insulin and
  - and intramuscular TG content, 949
  - of IRS subjects, 1535
  - of Laron syndrome subjects, 1264
  - of multiple trauma subjects, 451
  - of NIDDM subjects, *see* Body mass and body mass index of NIDDM subjects
  - and O<sub>2</sub> consumption in heart, hepatomesenteric bed, and brain, 1488
  - of obese subjects, *see* Body mass and body mass index of obese subjects
  - oral albuterol effects on, 715
  - and palmitic and stearic acid effects on serum lipids, Lps, and plasma CETP, 144
  - of pubertal lean boys, urate changes and, 204
  - of PWS subjects, 1515, 1516
  - and relationship between growth rate, GHBP, and GH, 425, 426
  - and relationship between hyperinsulinemia and plasma PL SFAs, 224
  - and relationship of plasma TGs, HDL-C, and apo B to postheparin LPL activity, 263
  - of smokers, 1552
  - of  $\beta$ -thalassemia major subjects, 653
  - and urinary excretion of T and E<sub>2</sub>, 281
  - voglibose effects on, in nondiabetic hyperinsulinemia, 734
- Body mass and body mass index (BMI), CHD and**
  - and CHO effects in CHD, 670
  - and lipid and CHO metabolic risk markers for CHD in non-obese premenopausal women, 329

- Body mass and body mass index (BMI), exercise and diet effects on glucose homeostasis and serum lipid levels, 436
- endogenous opioid response to exercise in IDDM, 139
- exercise effects on concentrations of serum TC and LDL-C related to apo E phenotype in boys and young adults, 798
- and relationship between glucose metabolism and thermogenesis in obese NIDDM women with and without prior exercise, 748
- and substrate kinetics during prolonged exercise, 418
- Body mass and body mass index (BMI), glucose and effects of parasympathetic denervation of liver and pancreas on glucose kinetics, 988
- glucose processing during FSIGT, 599
- Body mass and body mass index (BMI), insulin and and insulin effects on HGP, 83
- and insulin effects on levels of circulating vitamin E, 999
- interstitial insulin and BMI in non-obese subjects, 952
- Body mass and body mass index (BMI), insulin resistance and and insulin effects on intracellular Ca concentrations, 1403, 1405
- relationship between hepatic and peripheral insulin resistance and PAI-1, 1244
- relationship between weight gain and insulin resistance in non-diabetic Creole, Indian, and Chinese Mauritians, 629-632
- Body mass and body mass index (BMI) of diabetic subjects
- sorbitol and glutathione in erythrocytes and, 612
- see also Body mass and body mass index of IDDM subjects; Body mass and body mass index of NIDDM subjects
- Body mass and body mass index (BMI) of hirsute women
- of hyperandrogenic hirsute women, GnRH therapy and, 25
- of obese hirsute women, 72
- Body mass and body mass index (BMI) of hypercholesterolemic subjects
- with FH, GH and, 1417
- with thrombophilia, 967
- Body mass and body mass index (BMI) of IDDM subjects
- apo, Lp, and LDL size and, 1268, 1269
- autonomic neuropathy and, 1066
- and endogenous opioid response to exercise, 139
- with hypoglycemia, 975
- intraperitoneal insulin effects on, 432
- progression of microalbuminuria and, 1102
- of well-controlled IDDM, 1435
- WHR and, 269, 270
- Body mass and body mass index (BMI) of NIDDM subjects
- and ACE and AGN gene polymorphism, 220
- with amino acid polymorphism in HSL, 362, 864
- apo, Lp, and LDL size and, 1268, 1269
- autonomic neuropathy and, 1066
- cardiovascular risk factors and RBC membrane SLC and, 962
- and effects of vanadyl sulfate on CHO and lipid metabolism, 1131
- and gliclazide effects on HGP suppression, 1197
- of NIDDM adolescents with insulin resistance, 909-911
- normotriglyceridemic, 64
- oral glucose and CCK release and, 197
- and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 877, 879
- of postmenopausal women, 828
- progression of microalbuminuria and, 1102
- and relationship between glucose metabolism and thermogenesis in obese NIDDM women with and without prior exercise, 748
- with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783
- of untreated NIDDM subjects, 493
- Body mass and body mass index (BMI) of NIDDM subjects (*Continued*)
- in visceral obesity-insulin resistance-dyslipidemic syndrome, 885
- of young women on contraceptive steroids, 834
- Body mass and body mass index (BMI) of obese subjects
- cardiovascular risk factors and, 235
- interstitial insulin and, 952
- of morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA in, 1012
- of obese women, see Body mass and body mass index of obese women
- of pubertal obese boys, urate changes and, 204
- visceral adipose tissue and, 379
- Body mass and body mass index (BMI) of obese women
- of hirsute obese women, 72
- with NIDDM, relationship between glucose metabolism and thermogenesis with and without prior exercise, 748
- of premenopausal women with VAT and SAT, HPA axis activity and, 352
- Body wasting (cachexia), T-cell leukemia-induced, 645-651
- Body water, total, in of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109
- Body weight (BW)
- of adolescents with insulin resistance, 909, 910; see also Adolescent obesity
- of aging women, 44, 45
- and body composition of healthy Indian and Swedish men, 635
- of cancer patients, response to radiation therapy and, 768
- of CHD subjects, 670
- and circadian relationships between serum Ca, serum phosphate, and circulating ANPs, 1022
- and CL316,243 effects on SNS activity, 788
- exercise and, see Body weight, exercise and
- of FHLB subjects, 1297
- of FHTG and FDL subjects, 1308
- and fibrinolytic potential, 1429
- gain in, see Weight gain
- of GH-deficient men, effects of GH therapy on, 364
- glucose and, see Body weight, glucose and
- hormone replacement therapy effects on, in postmenopausal subjects, 1259, 1260
- of hyperandrogenic hirsute women, GnRH therapy and, 25
- of hypercholesterolemic thrombophilia subjects, 967
- of hypertensive subjects with LVH, 1327
- of hypoglycemic patients, 1423
- of IDDM subjects, see Body weight of IDDM subjects
- and insulin effects on HGP, 83
- and insulin resistance with PCT, 122
- of Laron syndrome subjects, 1264
- loss in, see Weight loss
- of malnourished subjects, 1274
- of MH 7777 transplant recipients, 850
- of MIDD subjects, 529, 530
- of multiple trauma subjects, 451
- nandrolone decanoate effects on, 465
- of nephrotic syndrome subjects, 823
- of NIDDM subjects, see Body weight of NIDDM subjects
- of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109
- and O<sub>2</sub> consumption in heart, hepatomesenteric bed, and brain, 1488
- and palmitic and stearic acid effects on serum lipids, Lps, and plasma CETP, 144
- pioglitazone effects on, 521-523



# Body weight (BW) (*Continued*)

- recovery of, by identical twins after 5 years of overfeeding, 1042-1050
- and regional FFA kinetics, 663
- and relationship between hepatic and peripheral insulin resistance and PAI-1, 1244
- of smokers, 924
- starvation effects on, 971
- of STZ-DM subjects, *see* Body weight of STZ-DM subjects
- and urinary excretion of pyridinium cross-links of collagen, 511
- see also* Non-obese subjects; Obesity
- Body weight (BW), exercise and
  - and diet effects on glucose homeostasis and serum lipid levels, 436, 440
  - and endogenous opioid response to exercise, 139
  - in older men, effects of GH administration and resistance exercise on, 256
  - and strenuous exercise effects on glycerol kinetics, 358
- Body weight (BW), glucose and
  - and effects of parasympathetic denervation of liver and pancreas on glucose kinetics, 988
  - and glucose processing during FSIGT, 599
  - trandolapril and verapamil effects on glucose transport in insulin-resistant skeletal muscle and, 536, 537
- Body weight (BW) of IDDM subjects
  - blood cell membrane phospholipid composition and, 59
  - and endogenous opioid response to exercise, 139
  - loss of, intensive IDDM therapy and, 1510
- Body weight (BW) of NIDDM subjects
  - abdominal AT and, 1290
  - blood cell membrane phospholipid composition and, 59
  - and effects of vanadyl sulfate on CHO and lipid metabolism, 1131
  - with macrovascular disease, 134
  - and role of AT loss in exercise-induced plasma lipid improvement in NIDDM, 1384
  - of spontaneous NIDDM subjects, 1361-1362
  - of untreated NIDDM subjects, 493
- Body weight (BW) of STZ-DM subjects
  - blood glucose and, 321
  - effects of ALC replacement on, 867, 868
  - exercise effects on mitochondrial function, 811
  - and gonadectomy effects on development of hypertension, albuminuria, and STZ-DM, 159
  - and tolrestat effects on nerve regeneration following nerve crush injury, 1190, 1191
  - troglitazone effects on, 1169
- Bone, decreased cortical, and increased cancellous, in children with PHPT, 76-81
- Bone density, and influence of age, sex and adiposity on metabolically active component of FFM, 993
- Bone marrow osteoprogenitor cells, effects of vitamin B<sub>12</sub> on alkaline phosphatase activity in, and proliferation of, 1443-1446
- Bone mineral density (BMD), current, and menstrual history of young hirsute women, 515-518
- Boys
  - apo E phenotype in, varying effects of exercise on serum TC and LDL-C concentrations related to, 797-803
  - from birth to nine years of age, AT FAs and size and number of adipocytes in, 1395-1401
  - see also* Adolescent boys
- BP, *see* Blood pressure
- Brain
  - O<sub>2</sub> consumption in heart, hepatomesenteric bed and, of young and elderly men, sympathetic nervous activity with, 1487-1492
  - see also* Cerebral blood flow and entries beginning with term: Brain

- Brain natriuretic peptides (BNPs) during ergometric exercise by hypertensive patients with LVH, 1326-1329
- Brain tyrosine, IV  $\gamma$ -glutamyl tyrosine effects on catecholamine concentrations and, in normal subjects, 126-132
- Breath hydrogen, acarbose effects on, 1182-1183
- 1-Bromobenzo(b)furan-2-ylsulfonyl hydantoin (M16209), effects of, on insulin sensitivity, 1095-1100
- Buffering capacity of platelets in NIDDM, cardiovascular risk factors and RBC membrane SCL and, 962, 963
- BUN (blood urea nitrogen)
  - of hypertensive subjects with LVH, 1327
  - in NIDDM with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783
- Burn (thermal injury), effects of, on glucose utilization by skin, wound, small intestine, and skeletal muscle, 1161-1167
- BW, *see* Body weight
- C, *see* Cholesterol
- Ca (calcium)
  - increased erythrocyte Na influx and uptake of, in hyperthyroidism, erythrocyte membrane phospholipid level and, 707-711
  - intracellular, insulin effects on concentrations of, 1402-1407
  - serum, circadian relationships between circulating ANPs, serum phosphate and, in healthy subjects, 1021-1028
- Ca<sup>2+</sup> (calcium), intracellular, role of, in regulation of gluconeogenesis, 389-403
- Ca (calcium) channel blocker(s)
  - effects of, on A-4166-induced insulin and somatostatin release, 185, 186
  - verapamil as, effects of trandolapril alone or in combination with, on glucose transport in insulin-resistant skeletal muscle, 535-541
- Cachexia (body wasting), T-cell leukemia-induced, 645-651
- CAD (coronary artery disease), HDL relation to metabolic parameters and severity of, 1375-1382
- Calcium, *see* Ca
- cAMP (cyclic adenosine monophosphate)
  - intrarenal glucagon action on urinary excretion of, 385
  - and PKC responses to GH secretion in acromegalic pituitary adenomas, 206-210
  - role of, in regulation of gluconeogenesis, 390-392
- Campesterol in sitosterolemia, 675
- Cancellous bone in children with PHPT, 76-81
- Cancer, metabolic response to radiation therapy of, 767-773
- Carbachol, GLP-1 stimulating insulin secretion but not phosphoinositide hydrolysis from pancreatic islets desensitized by exposure to high glucose or, 273-278
- N-Carbamyl glutamate, effects of, in familial leucine-sensitive hypoglycemia, 959
- Carbohydrates (CHOs)
  - in CHD, *see* Carbohydrates in CHD
  - hormone replacement therapy effects on cardiovascular risk factors and metabolism of, in postmenopausal subjects, 1254-1262
  - interactions of lung antioxidant defense system with alcohol, Cu and, in male and female subjects, 49-56
  - in NIDDM, vanadyl sulfate effects on metabolism of, 1130-1136
  - oral albuterol effects on serum lipids and metabolism of, in men, 712-717
  - pancreas transplantation effects on metabolism of, 857, 859
  - PP thermogenesis and substrate utilization after ingestion of different, 1235-1242
  - prolonged exercise and, *see* Prolonged exercise, CHOs and

- Carbohydrates (CHOs) in CHD  
 CHO and lipid metabolic risk markers for CHD and blood pressure in non-obese premenopausal women of different racial origins, 328-333  
 effects of high- versus low-glycemic CHOs on insulin and glucose response in CHD, 669-672  
 hormone replacement therapy effects on CHO metabolism and risk factors for CHD in postmenopausal subjects, 1254-1262
- Carbon dioxide, *see* CO<sub>2</sub>; [<sup>14</sup>CO<sub>2</sub>]
- Cardiac function, troglitazone effects on, 1169-1170
- Cardioprotective effects of troglitazone in STZ-DM, 1168-1173
- Cardiovascular (CV) fitness, effects of body composition, Lp(a) and, on fibrinolysis, 1427-1433
- Cardiovascular (CV) risk factor(s)  
 CT-determined body composition of healthy Indian and Swedish men in relation to, 634-644  
 hormone replacement therapy effects on CHO metabolism and, in postmenopausal subjects, 1254-1262  
 insulin resistance in adolescents as, 908-914  
 multiple, obesity and, 235-240  
 in NIDDM, RBC membrane SLC and, 961-965
- Cardiovascular (CV) system  
 of premenopausal obese women with VAT and SAT, response of, to CRF/AVP and stress tests, 353  
*see also* Heart entries beginning with terms: Cardiovascular, Macrovascular, Myocardial, Vascular *specific arteries and veins*
- Carnitine  
 pivalic acid-induced deficiency in, exercise and, 1501-1507  
*see also* Acetyl-L-carnitine in STZ-DM
- Carnitine palmytoyltransferase-1 (CPT-1), OFS effects on, 1548
- Catalase, activity of, in lungs, 53
- Catecholamines  
 IV  $\gamma$ -glutamyl tyrosine effects on brain tyrosine and concentrations of, in normal subjects, 126-132  
 role of, in regulation of gluconeogenesis, 390-392, 394-395  
*see also* Dopamine; Epinephrine; Norepinephrine
- CBF (cerebral blood flow), regional, effects of acute hypoglycemia on, in IDDM with impaired hypoglycemia awareness, 974-980
- CCK, *see* Cholecystokinin
- Cell differentiation, and GH effects on newly differentiated adipocytes, 34-42
- Cell proliferation, vitamin B<sub>12</sub> effects on cellular alkaline phosphatase activity and, of bone marrow stromal osteoprogenitors and UMR106 osteoblastic cells, 1443-1446
- Cellular alkaline phosphatase, effects of vitamin B<sub>12</sub> on activity of, in bone marrow osteoprogenitor cells and UMR106 osteoblastic cells, 1443-1446
- Central obesity, hyperuricemia, hypertriglyceridemia, DM, and hypertension associated with fasting insulin, overall and, 699-706
- Cephalic-phase insulin response (CPIR) in obese nondiabetic subjects, 168-173
- Cerebral blood flow (CBF), regional, effects of acute hypoglycemia on, in IDDM with impaired hypoglycemia awareness, 974-980
- CETP, *see* Cholesteryl ester transfer protein
- CHD, *see* Coronary heart disease
- Chemistry of peripheral nerves in STZ-DM, effects of ALC and sorbinil on structure, function and, 902-907
- Chemoattractant protein-1 mRNA (messenger ribonucleic acid), monocyte, LPC stimulating expression and production of, in vascular endothelial cells, 559-564
- Children  
 with BBS, empty sellae, impaired testosterone secretion, and defective hypothalamic-pituitary growth and gonadal axes in, 1230-1234  
 dicarboxylic aciduria due to MCTs differentiated from that due to abnormal FA oxidation and fasting in, 162-167  
 with PHPT, decreased cortical and increased cancellous bone in, 76-81  
*see also* Boys; Girl(s); Infancy
- Chinese Mauritians, nondiabetic, relationship of insulin resistance to weight gain in, 627-633
- Chinese men, urinary excretion of T and E<sub>2</sub> by, serum Lp concentrations and, 279-284
- Chloride (Cl), intrarenal glucagon action on urinary excretion of, 385
- CHO(s), *see* Carbohydrates
- Cholecystokinin (CCK)  
 GLP-1, amylin and, in gastric emptying, 1-3  
 release of, stimulated by oral glucose in normal adult subjects and in NIDDM, 196-202
- Cholesterol in sitosterolemia, 675
- Cholesterol (C)  
 in Bardet-Biedel syndrome children, 1231, 1233  
 as CV risk factor in healthy Indian and Swedish men, 640  
 and diet effects on glucose homeostasis and serum lipid levels in exercise, 436  
 in HF diet-induced hyperglycemia and obesity, 1542  
 in hypercholesterolemic thrombophilia, 967  
 in IDDM, *see* Cholesterol in IDDM  
 in NIDDM, *see* Cholesterol in NIDDM  
 OA inhibiting utilization of, for T synthesis in Leydig cells, 293-299  
 plasma, DZ effects on, 336  
 and relationship of plasma TGs, HDL-C, and apo B to postheparin LPL activity, 263; *see also* High-density lipoprotein-cholesterol  
 serum lathosterol-to-cholesterol ratio as index of synthesis of, is not elevated in glomerular proteinuria and not associated with improved hyperlipidemia in response to antiproteinuria therapy, 723-730  
 total, *see* Total cholesterol  
 in uremia, 688, 689  
 and urinary excretion of E<sub>2</sub> and T, 281, 282  
*see also* Hypercholesterolemia; Intermediate-density lipoprotein-cholesterol; Low-density lipoprotein-cholesterol; Very-low-density lipoprotein-cholesterol
- Cholesterol (C) in IDDM  
 blood cell membrane phospholipid composition and, 59  
 progression of microalbuminuria and, 1103, 1104
- Cholesterol (C) in NIDDM  
 blood cell membrane PL composition and, 59  
 with macrovascular disease, 134  
 in normotriglyceridemic NIDDM, 64, 67  
 plasma, role of AT loss in exercise-induced improvement in, 1384
- Cholesteryl ester  
 HDL-, metabolism of, in genetic hypercholesterolemia, 7  
 in normolipidemic men, 1110, 1114-1115  
*see also* Cholesteryl ester transfer protein
- Cholesteryl ester transfer protein (CETP)  
 in CAD, 1377-1378, 1380  
 pancreas transplantation effects on, 859  
 plasma, effects of palmitic and stearic acids on serum lipids, Lps and, in young women, 143-149
- Cholesteryl esterase, OA inhibiting utilization of, for T synthesis in Leydig cells, 293-299

- Cholestyramine, effects of lovastatin and, on plasma sterol levels in homozygous sitosterolemic girl and her sitosterolemic heterozygous father, 673-679
- Choline  
intrapерitoneal insulin effects on LpB-PLs containing, in IDDM, 430-434  
LPC stimulating MCP-1 mRNA expression and production in vascular endothelial cells, 559-564
- Chronic gastrointestinal (GI) disorders, essential fatty acid deficiency in, 12-23
- cICAM-1 (circulating intercellular adhesion molecule-1), level of HbA<sub>1c</sub>, MDA and, in NIDDM, oxidative stress and, 498-501
- Cigarette smoking, *see* Smoking
- Circadian relationships between circulating ANPs, serum phosphate, and serum Ca in healthy subjects, 1021-1028
- Circulating atrial natriuretic peptides (ANPs), circadian relationships between serum Ca, serum phosphate and, in healthy subjects, 1021-1028
- Circulating dehydroepiandrosterone sulfate (DHEAS), effects of moderate protein increase on insulin secretion and, 1483-1486
- Circulating endothelin (ET), ANPs modulating, 315-319
- Circulating intercellular adhesion molecule-1 (cICAM-1), level of HbA<sub>1c</sub>, MDA and, in NIDDM, oxidative stress and, 498-501
- Circulating vitamin E, insulin effects on levels of, 998-1003
- Citrate, PRL regulating oxidation of, in prostate epithelial cells, 442-449
- Citrulline, plasma, effects of *N*-carbamyl glutamate on, in familial leucine-sensitive hypoglycemia, 959
- Cl (chloride), intrarenal glucagon action on urinary excretion of, 385
- Clinical implications of albuterol therapy, 716
- Clinical presentation  
of Bardet-Biedel syndrome, 1231  
*see also specific conditions*
- CL316,243, effects of, on SNS activity, 787-791
- CMAPs (compound muscle action potentials), tolrestat effects on, following nerve crush injury in STZ-DM, 1189-1195
- CO<sub>2</sub> (carbon dioxide), glucose oxidation to, in adipocytes, effects of Mg deficiency on, 839-840
- [<sup>14</sup>CO<sub>2</sub>] (carbon dioxide), splenocyte, MH 7777 effects on metabolism of, 853
- Coenzyme A (CoA), malonyl, in obese salt-sensitive subjects, pioglitazone effects on, 519-525
- Collagen, urinary excretion of pyridinium cross-links of, in infancy, 510-514
- Colonic pH, acarbose effects on, 1179-1187
- Colony-stimulating factor-1 (CSF-1), macrophage response to, in hyperglycemia, 1125-1129
- Compliance with oral albuterol therapy, 713
- Compound muscle action potentials (CMAPs), tolrestat effects on, following nerve crush injury in STZ-DM, 1189-1195
- Computed tomography (CT), body composition of healthy Indian and Swedish men determined by, and relation to CV risk factors, 634-644
- Connecting peptides, *see* C-peptides
- Conscious subjects, 571-586  
effects of decreasing plasma FFAs by ACX on hepatic glucose metabolism in, 1409  
glyburide effects on secretion, tissue uptake, and action of insulin in conscious subjects, 579-586  
role of cortisol in metabolic response to stress hormone in, 571-578
- Constant specific activity (SA) technique, isotope dilution technique versus, in estimation of insulin effects on HGP, 82-91
- Contraceptive steroids, effects of proinsulin and insulin on plasma PAI-1 and t-PA in young women on, 833-838
- Copper (Cu), interactions of lung antioxidant defense system with alcohol, dietary CHOs and, in male and female subjects, 49-56
- Coronary arteries, nandrolone decanoate effects on plasma lipids and, in female subjects on moderately atherogenic diet, 463-468
- Coronary artery disease (CAD), HDL relation to metabolic parameters and severity of, 1375-1382
- Coronary heart disease (CHD)  
and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 876, 877, 879  
*see also* Carbohydrates in CHD
- Cortical bone, decreased, in children with PHPT, 76-81
- Corticotropin (adrenocorticotropin; ACTH)  
effects of CRF/AVP and stress tests on, in premenopausal obese women with VAT and SAT, 351-356  
ET-1 impact on basal and stimulated concentrations of, in men with and without nifedipine pretreatment, 658-661  
serum, in HIV-infected men, 741  
*see also entries beginning with term:* Corticotropin
- Corticotropin-like peptides (ACTH-LPs), pancreatic islet-derived, paracrine action of, on regulation of insulin release, 565-570
- Corticotropin-releasing factor (CRF)  
CRF/AVP test, effects of stress test and, on HPA axis activity and its relationship to AN in premenopausal obese women with SAT and VAT, 351-356  
plasma ACTH level in men before and after stimulation with, nifedipine treatment and, 659
- Cortisol  
arterial, intrarenal glucagon action on, 385  
in Bardet-Biedel syndrome children, 1232, 1233  
effects of CRF/AVP and stress tests on, in premenopausal obese women with VAT and SAT, 351-356  
in multiple trauma, 453  
plasma, protein effects on levels of, 1485  
role of, in metabolic response to stress hormone in conscious subjects, 571-578  
in SCI women, 719, 720  
serum, *see* Serum cortisol  
in stress hormone, *see* Stress hormone
- C-peptides (connecting peptides)  
in Bardet-Biedel syndrome children, 1231, 1233  
and diet effects on glucose homeostasis and serum lipid levels in exercise, 436  
in familial leucine-sensitive hypoglycemia, glucose effects on, 958  
fasting, in  $\beta$ -thalassemia major, 656  
GH effects on, *see* C-peptides, GH effects on  
in IRS, 1535, 1536  
in normotriglyceridemic NIDDM, 64, 67  
pancreas transplantation effects on, 857  
PCT and, 122, 123  
plasma, *see* Plasma C-peptides  
urinary excretion of, in subjects at high risk for IDDM, 873-875
- C-peptides (connecting peptides), GH effects on  
effects of GH administration and resistance exercise in older men, 257  
in GH-deficient men, 366
- CPIR (cephalic-phase insulin response) in obese nondiabetic subjects, 168-173
- CPT-1 (carnitine palmytoyltransferase-1), OFS effects on, 1548
- Creatinine (Cr)  
in Bardet-Biedel syndrome children, 1231  
in FHTG and FDL, omega-FA and fenofibrate effects on, 1306

- Creatinine (Cr) (*Continued*)  
in hospitalized subjects, 1558-1560  
in IDDM, progression of microalbuminuria and, 1102  
in nephrotic syndrome, 823  
in NIDDM with and without renal insufficiency, insulin effects on urinary phosphate excretion in, 783  
pancreas transplantation effects on, 857  
*see also* Serum creatinine; Urinary excretion, creatinine
- Creole Mauritians, nondiabetic, relationship of insulin resistance to weight gain in, 627-633
- CRF, *see* Corticotropin-releasing factor
- Crush injury, tolrestat effects on nerve regeneration in STZ-DM after, 1189-1195
- CSF-1 (colony-stimulating factor-1), macrophage response to, in hyperglycemia, 1125-1129
- CT (computed tomography), body composition of healthy Indian and Swedish men determined by, relation to CV risk factors and, 634-644
- Cu (copper), interactions of lung antioxidant defense system with alcohol, dietary CHOs and, in male and female subjects, 49-56
- Cutaneous glycation, hormonal replacement therapy effects on, in postmenopausal subjects, 1259, 1260
- CV system, *see* Cardiovascular system
- Cyclic adenosine monophosphate, *see* cAMP
- Cyclic cystathionine sulfoxide, *N*-acetylcyclic cystathionine and, in cystathioninuria, LC/APCI-MS in identification of, 1312-1316
- Cystathioninuria, *N*-acetylcyclic cystathionine and cyclic cystathionine sulfoxide identification with LC/APCI-MS in, 1312-1316
- Cytokines  
pentoxifylline and indomethacin effects on production of, in healthy subjects, 1461  
*see also specific cytokines*
- DAG, *see* Diacylglycerol; 1,2-Diacylglycerol
- Dairy products  
relative effects of high SFA levels in meat, tropical oils and, on serum Lps and degradation of LDLs by mononuclear cells in men, 550-558  
VLDLs as poor substrates for milk LPL, 686-690
- Deafferentation, medial basal hypothalamic, effects of, on EtOH-induced PRL release, 1331-1332
- Deafness, maternally inherited diabetes and, insulin resistance associated with, 526-531
- Decanoate, metabolism of, 165-166
- Decarboxylase, ornithine, activity of, in jejunal mucosa after feeding, lingual factors in, 1284-1287
- Defense system, lung antioxidant, of male and female subjects, interactions of, with alcohol, Cu, and dietary CHOs, 49-56
- Dehydroepiandrosterone (DHEA)  
in morbidly obese adolescents, effects of weight, body composition, lipids, and insulin resistance on, 1011-1015  
*see also* Dehydroepiandrosterone in hirsute women
- Dehydroepiandrosterone (DHEA) in hirsute women  
BMD and, 516  
GnRH effects on DHEA in severely hirsute hyperandrogenic women, 25  
in obese hirsute women, 72-75
- Dehydroepiandrosterone sulfate (DHEAS)  
effects of moderate protein increase on insulin secretion and, 1483-1486  
hormone replacement therapy effects on, in postmenopausal subjects, 1258, 1260
- Delayed gastric emptying, GLP-1, amylin, CCK and, 1-3
- Denaturing gradient gel electrophoresis (DGGE), IR gene mutations analysis with, in leprechaunism, 1496
- Denervation, parasympathetic liver and pancreas, effects of, on glucose kinetics, 987-991
- Density, *see* Bone density; Bone mineral density
- Deoxyribonucleic acid, *see* DNA
- Deuterated water ( $^2\text{H}_2\text{O}_2$ ), measurement of plasma C and plasma FA synthesis with, number of incorporated deuterium atoms determined with, 817-821
- Deuterium atoms, number of incorporated, determined with  $^2\text{H}_2\text{O}_2$  measurement of plasma C and plasma FA synthesis, 817-821
- Development, *see* Growth and development
- Dexamethasone (DEX)  
hepatic insulin extraction and beta cell activity following administration of, in healthy subjects, 486-492  
inhibition of FFA oxidation and reversal of skeletal muscle glucose transport impairment induced by, 92-100
- DGGE (denaturing gradient gel electrophoresis), IR gene mutations analysis with, in leprechaunism, 1496
- DHAP (dihydroxyacetone phosphate), effects of xylitol on and, 1357
- DHEA, *see* Dehydroepiandrosterone
- DHEAS, *see* Dehydroepiandrosterone sulfate
- DHT (5  $\alpha$ -dihydrotestosterone), GHBP regulation by, 1521-1526
- Diabetes mellitus (DM), 691-706  
hyperuricemia, hypertriglyceridemia, hypertension and, associated with fasting insulin and central and overall obesity, 699-706  
relationship between AT production of PGI<sub>2</sub>, PGE<sub>2</sub>, and 6-keto-PGF<sub>1 $\alpha$</sub> , plasma insulin level, and BP in DKA, normal adult subjects, and subjects with, 691-698  
relationship between erythrocyte concentrations of glutathione and sorbitol in, 611-613  
*see also* Diabetic ketoacidosis; Diabetic syndrome; Insulin-dependent diabetes mellitus; Maternally inherited diabetes and deafness; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus
- Diabetic ketoacidosis (DKA), relationship between AT production of PGI<sub>2</sub>, PGE<sub>2</sub>, and 6-keto-PGF<sub>1 $\alpha$</sub> , plasma insulin level, and BP in DM, normal adult subjects, and in subjects with, 691-698
- Diabetic syndrome, L-NMMA effects on insulin secretion in, 940-946
- Diacylglycerol (DAG), fecal, acarbose effects on, 1182, 1183
- 1,2-Diacylglycerol (1,2-DAG), insulin effects on myocardial, 774-781
- Diazoxide (DZ), antilipolytic effects of, in obesity, 334-341
- Dicarboxylic aciduria due to MCTs differentiated from that due to abnormal FA oxidation and fasting in children, 162-167
- Diet  
influence of, on glucose homeostasis and serum lipid levels in exercise, 435-441  
moderately atherogenic, nandrolone decanoate effects on plasma lipids and coronary arteries of female subjects on, 463-468  
*see also* Energy intake; Fasting; Food intake; Malnutrition; Nutritional status; Overfeeding; Starvation; Supplementation; Total parenteral nutrition; Weight loss, diet-induced
- entries beginning with terms: Dietary, Postabsorptive, Postprandial specific food groups, substances, and nutrients*
- Diet-induced weight loss, *see* Weight loss, diet-induced
- Dietary carbohydrates, *see* Carbohydrates
- Dietary fat  
effects of CHOs and supplementation with, on CHO metabolism during prolonged exercise, 915-921

Dietary fat (*Continued*)

- exercise effects on concentrations of serum TC and LDL-C related to apo E phenotype in boys and young adults and, 798, 801
- hydrogenated, effects of, on C synthesis and LDL oxidation in moderate hypercholesterolemia, 241-247
- intake of, in glomerular proteinuria, 725
- see also* Fatty acids; Full-fat diet; High-fat diet; High-fat, high-sucrose diet; Low-fat diet *and specific dietary fats*

Dietary protein, *see* Protein

- Digoxin-metabolizing bacteria, fecal, acarbose effects on, 1182, 1183
- 17 $\alpha$  (alpha)-Dihydroequilin, antioxidant effects of, on lipid peroxidation, 411-414

- 5 $\alpha$  (alpha)-Dihydrotestosterone (DHT), GHBP regulation by, 1521-1526

- Dihydroxyacetone phosphate (DHAP), effects of xylitol on and, 1357

- Dipeptidyl peptidase IV (DPIV)-negative subjects, enteroinsular axis in, 1335-1341

- Diphosphate, adenosine, muscle protein synthesis and degradation and, 1281

- 2,3-Diphosphoglyceric acid (2,3-DPG) in whole blood, 52

## Disease states

- serum uric acid concentrations in hospitalized subjects according to concurrent, 1559

*see also* Morbidity *and specific conditions*

- DKA (diabetic ketoacidosis), relationship between AT production of PGI<sub>2</sub>, PGE<sub>2</sub>, and 6-keto-PGF<sub>1 $\alpha$</sub>  in DM, normal adult subjects, and subjects with, 691-698

DM, *see* Diabetes mellitus

## DNA (deoxyribonucleic acid)

- glucose loading inducing fragmentation of proximal tubular cell, 1348-1353
- of insulin-, glucagon-, and somatostatin-secreting cells, IGF-I and IGF-II regulation of, 762, 763
- synthesis of, in leprechaunism, 1495-1496

- Dolichol, serum, effects of anabolic androgenic steroid abuse on serum ubiquinone and, 844-847

- Dominant negative effect of kinase-defective IR on IGF-I-stimulated signaling in fibroblasts, 1474-1482

- Dopamine, effects of, on EtOH-induced PRL release, 1331

## Dose

- AAS, 845
- EtOH, and effects on PRL release, 1331
- mld-STZ, L-NMMA effects on mononuclear splenocytes and NO generation with, 940-946

- 2,3-DPG (2,3-diphosphoglyceric acid) in whole blood, 52

- DPIV (dipeptidyl peptidase IV)-negative subjects, enteroinsular axis in, 1335-1341

- Dysbetalipoproteinemia, familial, effects of omega-FAs and fenofibrate on lipids and hemorrheological parameters in FTG and, 1305-1311

## Dyslipidemia

- voglibose effects on insulin sensitivity and, in nondiabetic hyperinsulinemia, 731-737

*see also* Dyslipidemic syndrome; Hyperlipidemia

- Dyslipidemic syndrome, plasma HDL-C as correlate of visceral obesity-insulin resistance-, in men, 882-888

- DZ (diazoxide), antilipolytic effects of, in obesity, 334-341

E, *see* EpinephrineE<sub>2</sub>, *see* Estradiol

## Education level

- of IDDM subjects, WHR and, 269, 270
- of IRS subjects, 1535

EE, *see* Energy expenditure

- EFA (essential fatty acids), deficiency in, in chronic GI disorder, 12-23

- EGF (epidermal growth factor) receptor, reduced phosphorylation of, by MIS, 190-195

## Elderly subjects

- <sup>31</sup>P magnetic resonance spectroscopy of nutritional status and effects of inflammatory state on liver of, 1059-1061

*see also* Aging; Older men

- Electrophoresis, denaturing gradient gel, IR gene mutations analysis with, in leprechaunism, 1496

- Empty sellae, impaired testosterone secretion, defective hypothalamic-pituitary growth and gonadal axes and, in Bardet-Biedel syndrome children, 1230-1234

- Endogenous opioids, response of, to exercise in IDDM, 137-142

- $\beta$  (beta)-Endorphin, responses of PRL and, to hypoglycemia in well-controlled IDDM, 1434-1440

- Endothelial cells, vascular, LPC stimulating expression and production of MCP-1 mRNA in, 559-564

- Endothelin (ET), circulating, ANPs modulating, 315-319

- Endothelin-1 (ET-1), impact of, on basal and stimulated concentrations of LH, FSH, TSH, GH, ACTH, and PRL in men with and without nifedipine pretreatment, 658-661

- Endotoxemia, effects of, on polyamine metabolism in mucosa of small intestine, 28-33

## Energy expenditure (EE)

- body composition and, 996-997
- CHO ingestion effects on, 1237-1238
- effects of full-fat or reduced-fat diet on substrate oxidation and, in non-obese subjects, 1004-1010
- relationship between glucose metabolism and, in obese NIDDM women with and without prior exercise, 747-752
- resting, impact of low- versus high-nicotine cigarette smoking on, 923-926

## Energy intake

- and exercise effects on concentrations serum TC and LDL-C related to apo E phenotype in boys and young adults, 798, 801
- with high SFA diet, 551
- by malnourished subjects, 1274, 1275
- see also* Diet

- Enteroinsular axis in DPIV-negative subjects, 1335-1341

- Epidermal growth factor (EGF) receptor, reduced phosphorylation of, by MIS, 190-195

## Epinephrine (E)

- lipolysis induced by, in normal, DM, and DKA subjects, 6-keto-PGF<sub>1 $\alpha$</sub>  and PGE<sub>2</sub> production by AT and, 695
- in multiple trauma, 453
- plasma, *see* Plasma epinephrine
- in stress hormone, *see* Stress hormone

- Epithelial cells, prostate, PRL regulating citrate oxidation and m-aconitase in, 442-449

- Ergometric exercise by hypertensive patients with LVH, BNPs during, 1326-1329

## Erythrocyte(s) (red blood cell; RBC)

- in DM, relationship between concentrations of glutathione and sorbitol in, 611-613

- in IDDM and NIDDM, Na<sup>+</sup>/K<sup>+</sup> ATPase turnover and Na<sup>+</sup>/K<sup>+</sup> ATP concentration in, 927-934

- increased Na influx and Ca uptake by, in hyperthyroidism, erythrocyte membrane phospholipid level and, 707-711

*see also* entries beginning with term: Erythrocyte

- Erythrocyte (red blood cell; RBC) adenine nucleotides, effects of xylitol on, 1356, 1357

- Erythrocyte (red blood cell; RBC) folate in NIDDM with macrovascular disease, 134

- Erythrocyte (red blood cell; RBC) membrane(s)  
 in IDDM and NIDDM, changes in PL composition of, 57-62  
 role of phospholipid level of, in increased erythrocyte Na influx and Ca uptake in hyperthyroidism, 707-711  
*see also* Erythrocyte membrane  $\text{Na}^+/\text{K}^+$  ATPase; Erythrocyte membrane sodium-lithium countertransport
- Erythrocyte (red blood cell; RBC) membrane  $\text{Na}^+/\text{K}^+$  (sodium/potassium) ATPase (adenosine triphosphatase), low activity of, in Northeast Thais, 804-810
- Erythrocyte (red blood cell; RBC) membrane sodium-lithium countertransport (SLC)  
 and cardiovascular risk factors in NIDDM, 961-965  
 kinetics of, in nonnephropathic IDDM twins, 1203-1207
- Essential fatty acids (EFAs), deficiency in, in chronic gastrointestinal disorders, 12-23
- Essential hypertension, urapidil effects on plasma Fn in, 1221-1229
- Esterase, cholesteryl, OA inhibiting utilization of, for T synthesis in Leydig cells, 293-299
- Estradiol ( $\text{E}_2$ )  
 and gonadectomy effects on development of hypertension, albuminuria, and STZ-DM, 159  
 nandrolone decanoate effects on concentration of, in female subjects, 465  
 in SCI women, 719, 720  
 urinary excretion of T and, by Chinese men, serum Lp concentrations and, 279-284  
*see also* Estradiol in hirsute women
- Estradiol ( $\text{E}_2$ ) in hirsute women  
 BMD and, 516  
 effects of GnRH in severely hirsute hyperandrogenic women on, 25  
 in obese women, 72-75
- $17\beta$  (beta)-Estradiol ( $\text{E}_2$ ), postprandial HDL-C in postmenopausal women reduced by, 827-832
- Estrogen increasing apo B-independent-catabolism of LDL-C in hyperlipidemia, 889-896
- ET (endothelin), circulating, ANPs modulating, 315-319
- ET-1 (endothelin-1), impact of, on basal and stimulated concentrations of LH, FSH, TSH, GH, ACTH, and PRL in men with and without nifedipine pretreatment, 658-661
- Ethanol (EtOH)  
 action of, inducing PRL release, 1330-1334  
*see also* Alcohol and alcohol consumption
- Ethanolamine phospholipids (PLs) in nephrotic syndrome, 823, 824
- Ethanolamine plasmalogens in nephrotic syndrome, 823-824
- Ethnicity, *see* Race and ethnicity
- EtOH, *see* Ethanol
- Etomoxir, effects of, on pancreatic islet TGs and FA oxidation, 983-984
- Excretion, *see* Fecal excretion; Urinary excretion
- Exercise  
 aerobic, effects of, on body composition and metabolism following diet-induced weight loss, 179-183  
 diet effects on glucose homeostasis and serum lipid levels with, 435-441  
 effects of, on mitochondrial function in skeletal muscle of normal and STZ-DM subjects, 810-816  
 effects of, on serum TC and LDL-C concentrations related to apo E phenotype in boys and young adults, 797-803  
 ergometric, by hypertensive patients with LVH, BNPs during, 1326-1329  
 and hyperinsulinemia, 1554  
 in IDDM, *see* Exercise in IDDM  
 in NIDDM, *see* Exercise in NIDDM  
 and pivalic acid-induced carnitine deficiency, 1501-1507
- Exercise (*Continued*)  
 prolonged, *see* Prolonged exercise, CHOs and  
 and relationship between psychosocial stress and IRS, 1535  
 resistance, *see* Resistance exercise  
 theophylline effects on substrate metabolism during, 1153-1160
- Exercise in IDDM  
 endogenous opioid response to, 137-142  
 strenuous, effects of, on glycerol kinetics, 357-361  
 WHR and, 269, 270
- Exercise in NIDDM  
 inducing improvement in plasma lipids, role of AT loss in, 1383-1395  
 long-term exercise effects on prevention of NIDDM, 475-480  
 relationship between glucose metabolism and thermogenesis in obese NIDDM women with and without prior exercise, 747-752
- FA(s), *see* Fatty acids
- n-3-FA(s) (omega-fatty acids), *see*  $\omega$ -Fatty acids
- Factor VIIc in hypercholesterolemic thrombophilia, 967, 968
- Factor VIIc in hypercholesterolemic thrombophilia, 967, 968
- Familial aggregation of visceral fat level, 378-382
- Familial dysbetalipoproteinemia (FDL), effects of omega-FAs and fenofibrate on lipids and hemorrheological parameters in FHTG and, 1305-1311
- Familial hypercholesterolemia (FH)  
 GH effects on LDL-C and Lp(a) in, 1415-1421  
 sitosterolemia and, 673-679
- Familial hypertriglyceridemia (FHTG), effects of omega-FAs and fenofibrate on lipids and hemorrheological parameters in FDL and, 1305-1311
- Familial hypobetalipoproteinemia (FHLB), apo B-43.7 in, 1296-1304
- Familial leucine-sensitive hypoglycemia with concomitant hyperammonemia, 957-960
- Family history of NIDDM with amino acid polymorphism in HSL, 862
- FAS (fatty acid synthase), OFS effects on, 1548
- Fasting  
 dicarboxylic aciduria due to MCTs differentiated from that due to abnormal FA oxidation and, in children, 162-167  
 PP glucose, PP insulin, and PP lipids and, in IDDM, 1036  
*see also* Starvation and entries beginning with term: Fasting
- Fasting blood glucose  
 in diabetic subjects, glutathione and sorbitol concentrations and, 612  
 in NIDDM with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783  
 in obese and lean subjects, interstitial insulin and, 952
- Fasting C-peptides (connecting peptides) in  $\beta$ -thalassemia major, 656
- Fasting glucagon (G) in obese IGT subjects, 505
- Fasting glucose  
 and abdominal AT distribution, metabolic risk factors and, 1121  
 blood, *see* Fasting blood glucose  
 in CHD, *see* Fasting glucose in CHD  
 and CV risk factors in healthy Indian and Swedish men, 641  
 in hospitalized subjects, 1558, 1559  
 in IRS, 1535  
 in MIDD, 529, 530  
 oral albuterol effects on, 714  
 plasma, *see* Fasting plasma glucose  
 and relationship between weight gain and insulin resistance in nondiabetic subjects, 629, 630  
 smoking and, 1553

- Fasting glucose in CHD  
 effects of high- versus low-glycemic CHOs on, 671  
 and lipid and CHO metabolic risk markers for CHD in non-obese premenopausal women, 330
- Fasting high-density lipoprotein(s) (HDLs), composition of, in IDDM, 1036-1037
- Fasting high-density lipoprotein-cholesterol (HDL-C), 17 $\beta$ -estradiol effects on, in postmenopausal women, 829-830
- Fasting insulin  
 and abdominal AT distribution, metabolic risk factors and, 1121  
 in CHD, *see* Fasting insulin in CHD, CHOs and  
 and CV risk factors in healthy Indian and Swedish men, 641  
 hyperuricemia, hypertriglyceridemia, DM, and hypertension associated with central and overall obesity and, 699-706  
 and intramuscular TG content, 949  
 in MIDD, 529, 530  
 in NIDDM, cardiovascular risk factors and RBC membrane SLC and, 963  
 in obese IGT subjects, 505  
 oral albuterol effects on, 714  
 plasma, *see* Fasting plasma insulin  
 and relationship between weight gain and insulin resistance in nondiabetic subjects, 629-631  
 serum, in  $\beta$ -thalassemia major, 655  
 smoking and, 1553, 1554
- Fasting insulin in CHD, CHOs and  
 high- versus low-glycemic CHO effects, 671  
 and lipid and CHO metabolic risk markers for CHD in non-obese premenopausal women, 330
- Fasting nonesterified fatty acids (FAs), and intramuscular TG content, 949
- Fasting plasma cholesterol (C), overfeeding effects on, 1046
- Fasting plasma C-peptide (connecting peptide), CPIR in obese nondiabetic subjects and, 171
- Fasting plasma fatty acids (FAs) in normolipidemic men, 1110
- Fasting plasma free fatty acids (FFAs), and hyperinsulinemia associated with VPCs, 1250-1252
- Fasting plasma glucose (FPG)  
 and effects of gonadectomy on development of hypertension, albuminuria, and STZ-DM, 159  
 hepatic and peripheral insulin resistance and, 1244  
 and hyperinsulinemia associated with VPCs, 1250, 1252  
 and insulin effects on levels of circulating vitamin E, 999  
 in NIDDM, *see* Fasting plasma glucose in NIDDM  
 in older men, effects of GH administration and resistance exercise on, 257  
 overfeeding effects on, 1046  
 in  $\beta$ -thalassemia major, 655  
 VS effects on, 1132
- Fasting plasma glucose (FPG) in NIDDM  
 cardiovascular risk factors and RBC membrane SLC and, 962  
 and relationship between glucose metabolism and thermogenesis with and without prior exercise in obese NIDDM women, 748
- Fasting plasma high-density lipoprotein-cholesterol (HDL-C), and hyperinsulinemia associated with VPCs, 1250-1252
- Fasting plasma insulin  
 CPIR in obese nondiabetic subjects and, 171, 172  
 and effects of parasympathetic denervation of liver and pancreas on glucose kinetics, 988  
 hepatic and peripheral insulin resistance and, 1244  
 in hyperinsulinemia associated with VPCs, 1248-1253  
 in older men, effects of GH administration and resistance exercise on, 257  
 overfeeding effects on, 1046
- Fasting plasma insulin (*Continued*)  
 and relationship between glucose metabolism and thermogenesis with and without prior exercise in obese NIDDM women, 748
- Fasting plasma K (potassium), and hyperinsulinemia associated with VPCs, 1250-1252
- Fasting plasma low-density lipoprotein-cholesterol (LDL-C), and hyperinsulinemia associated with VPCs, 1250-1252
- Fasting plasma triglycerides (TGs)  
 and hyperinsulinemia associated with VPCs, 1250-1252  
 overfeeding effects on, 1046
- Fasting proinsulin in  $\beta$ -thalassemia major, 656
- Fasting serum high-density lipoprotein-cholesterol (HDL-C) in NIDDM with amino acid polymorphism in HSL, 864
- Fasting serum insulin in  $\beta$ -thalassemia major, 655
- Fasting serum total cholesterol (TC) in NIDDM with amino acid polymorphism in HSL, 864
- Fasting serum triglycerides (TGs)  
 and intramuscular TG content, 949  
 in NIDDM with amino acid polymorphism in HSL, 864
- Fat, *see* Adipose tissue; Dietary fat; Fat-free mass *and entries beginning with element*: Lip-
- Fat-free mass (FFM)  
 age, adiposity, and sex influence on metabolically active component of, 992-997  
 and diet-induced weight loss, *see* Fat-free mass, and diet-induced weight loss  
 exercise and, *see* Fat-free mass, exercise and  
 and glucose processing during FSIGT, 599  
 in NIDDM, 1384  
 of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109  
 oral albuterol effects on, 715  
 of PWS subjects, 1516
- Fat-free mass (FFM), and diet-induced weight loss, 176  
 resistance and aerobic exercise effects on FFM following weight loss, 181
- Fat-free mass (FFM), exercise and  
 in older men, effects of GH administration and resistance exercise on, 256  
 resistance and aerobic exercise effects on FFM following, 181  
 and substrate kinetics during prolonged exercise, 418
- Father, heterozygous sitosterolemic, and his homozygous sitosterolemic girl, cholestyramine and lovastatin effects on plasma sterol levels in, 673-679
- Fatty acid(s) (FAs)  
 AT, size and number of adipocytes and, from birth to 9 years of age in boys, 1395-1401  
 dicarboxylic aciduria due to MCTs, fasting, and abnormal oxidation of, in children, compared, 162-167  
 effects of, on glucose-regulated beta-cell function, pancreatic islet TGs and FA oxidation effects on glucose metabolism associated with, 981-986  
 effects of, on hyperglycemia and obesity, 1540, 1541  
 essential, deficiency in, in chronic GI disorders, 12-23  
 glucose and insulin effects on, 775-776  
 long-chain, metabolism of, 166  
 short-chain, acarbose effects on, 1179-1187  
*see also*  $\omega$ -Fatty acids; Free fatty acids; Monounsaturated fatty acids; Nonesterified fatty acids; Oxidation, FA; Plasma fatty acids; Polyunsaturated fatty acids; Saturated fatty acids
- $\omega$  (omega)-Fatty acid(s) (FAs)  
 effects of fenofibrate and, on lipids and hemorrheological parameters in FDL and FHTG, 1305-1311

- parenteral, effects of, on leukocyte membrane FA composition and leukotriene-synthesizing capacity in postoperative trauma, 1208-1213
  - Fatty acid synthase (FAS), OFS effects on, 1548
  - FBG (finger blood volume), mental stress and, in adolescent boys with IRS, 614-621
  - FDL (familial dysbetalipoproteinemia), effects of omega-FAs and fenofibrate on lipids and hemorrheological parameters in FHTG and, 1305-1311
  - Fecal excretion of acidic and neutral sterols in sitosterolemia, 675
  - Fecal nutrients, acarbose effects on, 1179-1187
  - Female subjects
    - interactions of lung antioxidant defense system with alcohol, Cu, and dietary CHOs in, 49-56
    - on moderately atherogenic diet, nandrolone decanoate effects on plasma lipids and coronary arteries in, 463-468
    - see also* Girl(s); Women
  - Fenofibrate, effects of omega-FAs and, on lipids and hemorrheological parameters in FDL and FHTG, 1305-1311
  - Ferritin in  $\beta$ -thalassemia major, 653
  - FFAs, *see* Free fatty acids
  - FFM, *see* Fat-free mass
  - FH, *see* Familial hypercholesterolemia
  - FHLB (familial hypobetalipoproteinemia), apo B-43.7 in, 1296-1304
  - FHTG (familial hypertriglyceridemia), effects of omega-FAs and fenofibrate on lipids and hemorrheological parameters in FDL and, 1305-1311
  - Fibrinogen (Fn)
    - in FHTG and FDL, 1309
    - in hypercholesterolemic thrombophilia, 967, 968
    - in IDDM and NIDDM, blood cell membrane phospholipid composition and, 59
    - nonenzymatic glycation of, impairing adhesive and proliferative properties of vascular smooth muscle cells, 285-292
    - plasma, in essential hypertension, urapidil effects of, 1221-1229
  - Fibrinolysis, cardiovascular fitness, body composition, and Lp(a) affecting, 1427-1433
  - Fibroblasts
    - dominant negative effects of kinase-defective IRs on IGF-I-stimulated signaling in, 1474-1482
    - insulin binding to, in leprechaunism, 1494-1495
  - Finger blood volume (FBG), mental stress and, in adolescent boys with IRS, 614-621
  - Fish oil, *see*  $\omega$ -Fatty acids
  - Fitness
    - cardiovascular, body composition, Lp(a) and, affecting fibrinolytic potential, 1427-1433
    - physical, *see* Exercise
  - 5-year overfeeding, body weight recovery by identical twins after, 1042-1050
  - Fn, *see* Fibrinogen
  - Folate, erythrocyte, in NIDDM with macrovascular disease, 134
  - Follicle-stimulating hormone (FSH)
    - in Bardet-Biedel syndrome children, 1232, 1233
    - 17 $\beta$ -estradiol effects on, in postmenopausal women, 828
    - ET-1 impact on basal and stimulated concentrations of, in men with and without nifedipine pretreatment, 658-661
    - in SCI women, 718-722
    - see also* Follicle-stimulating hormone in hirsute women
  - Follicle-stimulating hormone (FSH) in hirsute women
    - BMD and, 516
    - GnRH effects on FSH in severely hirsute hyperandrogenic women, 25
    - in obese hirsute women, 72-75
  - Food intake
    - and CL316,243 effects on SNS activity, 788
    - ODC activity in jejunal mucosa after, lingual factors in, 1284-1287
    - see also* Diet
  - Four-compartment model of body composition in aging women, 43-48
  - F6P (fructose-6-phosphate), and glucose cycling by hepatocytes, 104
  - FPG, *see* Fasting plasma glucose
  - Free estradiol (E<sub>2</sub>), and urinary excretion of T and E<sub>2</sub>, 282
  - Free fatty acids (FFAs)
    - in CHD, effects of high- versus low-glycemic CHOs on, 671
    - hyperglycemia effects on, during ischemia, 545-546
    - intrarenal glucagon action on, 385, 386
    - in IRH, 608
    - kinetics of regional, contributing to postabsorptive FFA flux in men and women, 662-666
    - in normolipidemic men, 1110
    - OFS effects on, 1548
    - oxidation of, and reversal of skeletal muscle glucose transport impaired by dexamethasone, 92-100
    - plasma, *see* Plasma free fatty acids
    - serum, *see* Serum free fatty acids
  - Free testosterone (T)
    - and effects of gonadectomy on development of hypertension, albuminuria, and STZ-DM, 159
    - and urinary excretion of T and E<sub>2</sub>, 282
  - Free thyroxine (T<sub>4</sub>) in Bardet-Biedel syndrome children, 1232, 1233
  - Free triiodothyronine (T<sub>3</sub>) in hyperthyroidism, 709
  - Frequently sampled intravenous glucose tolerance test (FSIGT)
    - dexamethasone effects on, 486-492
    - glucose processing during, 598-605
    - in MIDD, 528-529
  - Fructosamine
    - in NIDDM with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783
    - pancreas transplantation effects on, 857
  - Fructose, oligofructose effects on impact of, on hepatic TAG metabolism, 1547-1550
  - Fructose-1,6-biphosphatase [Fru(1,6)Pase], impaired regulation of hepatic, in obese NIDDM subjects, 622-626
  - Fructose-2,6-biphosphatase [Fru(2,6)P<sub>2</sub>], and regulation of hepatic FBPase in obese NIDDM subjects, 622-626
  - Fructose-hypertensive subjects, effects of, on vascular reactivity, 1053-1055
  - Fructose-6-phosphate [Fru(6)P], and glucose cycling by hepatocytes, 104
  - FSH, *see* Follicle-stimulating hormone
  - FSIGT, *see* Frequently sampled intravenous glucose tolerance test
  - L-Fucose, and reduced Na<sup>+</sup>/K<sup>+</sup> ATPase and MNCV, 229-234
  - Full-fat diet, effects of, on EE and substrate oxidation in non-obese subjects, 1004-1010
  - Functional active receptors for IGF-I and IGF-II on insulin-, glucagon-, and somatostatin-producing cells, 759-766
  - Functional liver mass, plasma flow and, in acromegaly before and after long-term octreotide therapy, 109-113
  - G, *see* Glucagon
  - GA3P (glyceraldehyde-3-phosphate), effects of xylitol on and, 1357
  - Gamma ( $\gamma$ )-glutamyl transpeptidase in FHTG and FDL, omega-FA and fenofibrate effects on, 1306
  - Gamma ( $\gamma$ )-glutamyl tyrosine, effects of, on brain tyrosine and catecholamine concentrations in normal subjects, 126-132
  - Gastric emptying
    - of beer in Mexican-Americans and in NHWs, 1174-1178
    - delayed, GLP-1, amylin, CCK and, 1-3



- Gastrointestinal (GI) system  
 chronic disorders of, essential fatty acid deficiency in, 12-23  
 and GI discomfort with CHO and dietary fat ingestion during prolonged exercise, 919, 920  
*see also* Intestine and entries beginning with terms: Gastric, Intestinal
- Gel electrophoresis, denaturing gradient, IR gene mutation analysis with, in leprechaunism, 1496
- Gene(s)  
 of insulin signal-transduction pathway intermediates, effects of beef tallow and safflower oil diets on expression of, 1080-1088  
 IR, severe resistance to insulin and IGF-I due to two mutations of tyrosine kinase domain of, in leprechaunism, 1493-1500  
 LDL receptor, GH normalizing expression of, in hypothyroidism, 680-686  
*see also* Apolipoprotein E polymorphism; DNA; Japanese non-insulin-dependent diabetes mellitus subjects, polymorphism in; Genotype; mRNA and entries beginning with terms: Familial, Genetic, Heterozygous, Homozygous, Inherited
- Genetic factors, 1288-1304  
 in FHLB, 1296-1304  
 in NIDDM, 1288-1295
- Genetic hypercholesterolemia, plasma Lp metabolism in, 4-11
- Genetic obesity, editing of hepatic apo B RNA in, 1056-1058
- Genotype, apo E, in FH, GH and, 1417
- GF, *see* Growth factor
- GFR, *see* Glomerular filtration rate
- GH, *see* Growth hormone
- GHBP, *see* Growth hormone-binding protein
- GHRH, *see* Growth hormone-releasing hormone
- GI system, *see* Gastrointestinal system
- Girl(s)  
 adolescent, *see* Adolescent girls  
 homozygous sitosterolemic, cholestyramine and lovastatin effects on plasma sterol levels in, and her sitosterolemic heterozygous father, 673-679  
 obesity and HDL-C in 10-year-old, race and, 469-474; *see also* Adolescent obesity
- Gliclazide, effects of, on HGP  
 in conscious subjects, 583  
 potentiation of suppression of HGP production in NIDDM as, 1196-1202
- Globulin, *see*  $\beta_2$ -Microglobulin; Sex hormone-binding globulin
- Glomerular filtration rate (GFR)  
 glucose, mannitol, and saline effects on, 1349  
 intrarenal glucagon action on, 385
- Glomerular proteinuria, serum lathosterol-to-cholesterol ratio is not elevated in, and not associated with improved hyperlipidemia in response to antiproteinuria therapy, 723-730
- GLP, *see* entries beginning with terms: Glucagon-like peptide
- Glucagon (G; hyperglycemic factor; hyperglycemic-glycogenolytic factor)  
 action of intrarenal, on renal metabolism, renal hemodynamics, and renal Na handling, 383-388  
 effects of, on xylitol-induced increase in plasma and urinary excretion of purine bases, 1354-1359  
 functional active receptors for IGF-I and IGF-II on cells producing, 759-766  
 glucose and, *see* Glucagon, glucose and  
 in IRH, 608  
 moderate decline in SA and level of, 589  
 in multiple trauma, 453  
 in obese IGT subjects, 505  
 PCT and, 122
- Glucagon (G; hyperglycemic factor; hyperglycemic-glycogenolytic factor) (*Continued*)  
 plasma, *see* Plasma glucagon  
 plasma E and NE effects on concentrations of, 1217  
 RA receptor transcripts and effects of RA and ROH on secretion of, in pancreatic islets and glucagon-secreting cell lines, 300-305  
 role of, in regulation of gluconeogenesis, 390-395  
 in spontaneous NIDDM, 1362, 1363  
 in stress hormone, *see* Stress hormone  
*see also* entries beginning with terms: Glucagon-like
- Glucagon (G), glucose and  
 differential beta cell response to glucose, arginine, and glucagon during progression to IDDM, 306-314  
 hyperglycemia and alteration of glucagon ability to increase hepatic glucose production and activate glycogen phosphorylase in perfused liver, 481-485  
 intrarenal glucagon action on glucose, 385, 386  
 protein kinase A-induced glucagon synthesis and secretion inhibited by glucose, 347-350
- Glucagon-like peptide-1 (GLP-1)  
 glucose dependency on glyburide and, 404-409  
 stimulation of insulin secretion by, but not phosphoinositide hydrolysis from pancreatic islets desensitized by exposure to high glucose or carbachol, 273-278
- Glucagon-like peptide-1 (GLP-1) NH<sub>2</sub>, CCK, amylin and, in gastric emptying, 1-3
- Glucocorticoids  
 role of, in regulation of gluconeogenesis, 397  
*see also* specific glucocorticoids
- Gluconeogenesis (GNG)  
 hepatic, *see* Gluconeogenesis, hepatic  
 role of intracellular Ca<sup>2+</sup> in regulation of, 389-403  
 total, from glycerol with [2-<sup>13</sup>]glycerol, measurement of, 897-901
- Gluconeogenesis (GNG), hepatic  
 effects of decreasing plasma FFAs by ACX on, 1409-1410  
 stress hormone effects on, in conscious subjects, 573-574
- Glucose  
 in adipocytes, Mg deficiency and metabolism of, 838-843  
 in adolescent obesity, 235  
 in Bardet-Biedel syndrome children, 1231, 1233  
 blood, *see* Blood glucose  
 in CAD, 1377-1379  
 and CV risk factors in healthy Indian and Swedish men, 640  
 cycling of, by hepatocytes, effects of thyroid status on, 101-108  
 DNA fragmentation in proximal tubular cells induced by glucose loading, 1348-1353  
 effects of, on fatty acids and heart performance, 775-776  
 FA effects on beta-cell function regulated by, pancreatic islet TGs and FA oxidation effects on glucose metabolism associated with, 981-986  
 fasting, *see* Fasting glucose  
 gastric emptying rate effects on, 1176  
 GH and, *see* Glucose, GH and  
 GLP-1 stimulating insulin secretion but not phosphoinositide hydrolysis from pancreatic islets desensitized by exposure to carbachol or high, 273-278  
 glucagon and, *see* Glucagon, glucose and  
 glyburide and, *see* Glucose, glyburide and  
 hepatic, *see* Hepatic glucose  
 high- versus low-glycemic CHO effects on response of, in CHD, 669-672  
 in hypercholesterolemic thrombophilia, 967  
 in hypertension, *see* Glucose in hypertension  
 in IDDM, *see* Glucose in IDDM

Glucose (*Continued*)

- insulin resistance and, 1405
- insulin secretion induced by, RA status and, 250
- in IRS, 1535, 1536
- kinetics of, *see* Kinetics, glucose
- and lipid and CHO metabolic risk markers for CHD and BP in non-obese premenopausal women, 330
- MIDA of, with [2-<sup>13</sup>]glycerol, 897-901
- M16209 effects on, 1097, 1098
- in NIDDM, *see* Glucose in NIDDM
- oral, CCK release stimulated by, in normal adult subjects, 196-202
- pancreas transplantation effects on, 857
- plasma, *see* Plasma glucose
- plasma E and NE effects on, 1217, 1218
- portal versus peripheral delivery of insulin in handling of portally delivered, 150-154
- posttranscriptional effects of, on proteoglycan mRNA expression in mesangial cells, 1136-1145
- in PWS, 1514-1520
- and relationship between plasma PL SFAs and, 224
- serum, L-NMMA effects on, 941-943
- skeletal muscle, *see* Skeletal muscle glucose
- splenocyte, MH 7777 effects on metabolism of, 851-853
- stress hormone effects on, in conscious subjects, 573
- thermal injury effects on utilization of, by skin, wound, small intestine, and skeletal muscle, 1161-1167
- VS effects on, 1132-1133
- see also* Glucose homeostasis; Glucose intolerance; Glucose-6-phosphate; Glucose tolerance; Glucose transport; Hyperglycemia; Hypoglycemia and entries beginning with elements: Gluc-, Glyc-
- Glucose, GH and
  - effects of GH therapy for GH-deficient men on homeostasis of, 362-369
  - GH effects on glucose uptake, 39
  - GH response to glucose in hyperthyroidism, effects of early changes in plasma glucagon on, 1029-1033
- Glucose, glyburide and
  - glucose dependency on GLP-1 and glyburide, 404-409
  - glyburide effects on hepatic vein and hepatic artery glucose, 580
- Glucose homeostasis
  - diet effects on serum lipids and, in exercise, 435-443
  - effects of GH therapy for GH-deficient men on, 362-369
  - oral albuterol effects on, 715-716
- Glucose in hypertension
  - and changes in activity and phosphorylation of Na<sup>+</sup>/H<sup>+</sup> exchanger in vascular myocytes in spontaneous hypertension, 114-119
  - urinary glucose excretion and effects of gonadectomy on development of hypertension, albuminuria, and STZ-DM, 159
- Glucose in IDDM
  - blood cell membrane phospholipid composition and, 59
  - differential beta cell response to glucose, glucagon, and arginine during progression to IDDM, 306-314
  - octreotide effects on metabolism of, 211-217
  - PP glucose, effects of fasting on, 1036
- Glucose intolerance
  - in  $\beta$ -thalassemia major related to insulin resistance and hepatic dysfunction, 652-657
  - see also* Glucose tolerance
- Glucose in NIDDM
  - blood cell membrane phospholipid composition and, 59
  - CCK release stimulated by oral, 196-202

Glucose in NIDDM (*Continued*)

- effects of starvation in untreated NIDDM on plasma glucose concentrations, 492-497
- in normotriglyceridemic NIDDM, 64, 67
- relationship between glucose metabolism and thermogenesis with and without prior exercise in obese NIDDM women, 747-752
- role of AT loss in exercise-induced plasma lipid improvement and, 1384
- Glucose-6-phosphate (G6P), and glucose cycling by hepatocytes, 103-104
- Glucose tolerance
  - exercise effects on, 477
  - in hyperthyroidism, 1029-1033
  - impaired, obese women with, dysfunctional pancreatic islets in, 501-510
  - see also* Glucose intolerance; Intravenous glucose tolerance test; Oral glucose tolerance test
- Glucose transport
  - basal and insulin-stimulated, in muscle and fat cells, TNF- $\alpha$  effects on, 1089-1094
  - dexamethasone-induced impaired skeletal muscle, not reversed by inhibition of FFA oxidation, 92-100
  - DZ effects on, 336
  - effects of trandolapril alone or in combination with verapamil on, in insulin-resistant skeletal muscle, 535-541
  - see also* GLUT1; GLUT3
- $\alpha$  (alpha)-Glucosidase, L-arabinose effects on, after sucrose ingestion, 1369-1370
- $\alpha$  (alpha)-Glucosidase inhibitor, voglibose as, effects of, on dyslipidemia and insulin sensitivity in nondiabetic hyperinsulinemia, 731-737
- GLUT1, paranodal expression of, in peripheral nerve, 1466-1473
- GLUT3, paranodal expression of, in peripheral nerve, 1466-1473
- Glutamate
  - MH 7777 effects on, 851-853
  - monosodium, ratio of urinary excretion of C-peptide to, in subjects at high risk for IDDM, 874, 875
- Glutamine
  - MH 7777 effects on, 851-853
  - plasma, effects of N-carbamyl glutamate on, in familial leucine-sensitive hypoglycemia, 959
- $\gamma$  (gamma)-Glutamyl transpeptidase in FHTG and FDL, omega-FA and fenofibrate effects on, 1306
- $\gamma$  (gamma)-Glutamyl tyrosine, effects of, on brain tyrosine and catecholamine concentrations in normal subjects, 126-132
- Glutathione, relationship between concentrations of sorbitol and, in erythrocytes of diabetic subjects, 611-613
- Glyburide
  - effects of, on secretion, tissue uptake, and action of insulin in conscious subjects, 579-586
  - glucose and, *see* Glucose, glyburide and
- Glycation
  - aortic and cutaneous, hormonal replacement therapy effects on, in postmenopausal subjects, 1259, 1260
  - nonenzymatic fibronectin, impairing adhesive and proliferative properties of vascular smooth muscle cells, 285-292
- Glycemic carbohydrates (CHOs), high- and low-, effects of, on insulin and glucose response in CHD, 669-672
- Glycemic response
  - L-arabinose inhibiting intestinal sucrase and suppressing, after sucrose ingestion, 1368-1374
  - see also* specific substances
- Glyceraldehyde-3-phosphate (GA3P), effects of xylitol on and, 1357

- Glycerides  
total, in hyperlipidemia, 892  
*see also* Triglycerides
- Glycerol  
gluconeogenesis from, and turnover of, 897-901  
in IRH, 608  
octreotide effects on, in IDDM, 214  
plasma, *see* Plasma glycerol  
strenuous exercise effects on kinetics of, 357-361  
*see also* Diacylglycerol; 1,2-Diacylglycerol; [2-<sup>13</sup>]Glycerol; Glycerol-3-phosphate; Triacylglycerol
- [2-<sup>13</sup>]Glycerol, GNG from glycerol with, 897-901
- Glycerol-3-phosphate, OFS effects on, 1548
- Glycerophospholipids in nephrotic syndrome, 822-826
- Glycine, MH 7777 effects on concentrations of, 851
- Glycogen  
hepatic, stress hormone effects on, in conscious subjects, 574  
in leprechaunism, 1495-1496  
skeletal muscle, *see* Skeletal muscle glycogen  
VS effects on, 1133  
*see also* Glycogen phosphorylase; Glycogen synthase
- Glycogen phosphorylase, hyperglycemia and alteration of glucagon ability to increase hepatic glucose production and activate, in perfused liver, 481-485
- Glycogen synthase (GS)  
octreotide effects on, in IDDM, 214  
skeletal muscle, during FSIGT, 602
- Glycogenolysis, effects of decreasing plasma FFAs by ACX on, 1409-1410
- Glycosylated Hb (hemoglobin) in NIDDM  
gliclazide effects on HGP suppression and, 1197  
in untreated NIDDM, 493, 493
- GNG, *see* Gluconeogenesis
- GnRH (gonadotropin-releasing hormone), long-acting, in severely hyperandrogenic hirsute women, 25-27
- Gonadal axes, defective hypothalamic-pituitary growth and defective, with empty sellae and impaired testosterone secretion in Bardet-Biedel syndrome children, 1230-1234
- Gonadectomy, effects of, on development of STZ-DM, hypertension, and albuminuria, 155-161
- Gonadotropin-releasing hormone (GnRH), long-acting, in severely hirsute hyperandrogenic women, 25-27
- G6P (glucose-6-phosphate), and glucose cycling by hepatocytes, 103-104
- Growth and development  
androgen effects on, 1523  
defective hypothalamic-pituitary, and defective gonadal axes with empty sellae and impaired testosterone secretion in Bardet-Biedel syndrome children, 1230-1234  
relationship between plasma GH, GHBP and rate of, 424-429
- Growth factor (GF)  
reduced phosphorylation of EGF receptor by MIS, 190-195  
*see also* entries *specific growth factors*
- Growth hormone (GH)  
ACX and, *see* Acipimox, effects of, on GH response to GHRH in obesity  
in acromegaly, 109-113  
in Bardet-Biedel syndrome children, 1232  
effects of, on adipocyte precursor cells and newly differentiated adipocytes, 34-42  
ET-1 impact on basal and stimulated concentrations of, in men with and without nifedipine pretreatment, 658-661  
plasma, *see* Plasma growth hormone  
response of, to T and DHT administration, 1523  
serum, *see* Serum growth hormone
- Growth hormone (GH) (*Continued*)  
*see also* Growth hormone, effects of therapy with; Growth hormone, secretion of
- Growth hormone (GH), effects of therapy with  
on LDL-C and Lp(a) in FH, 1415-1421  
in multiple trauma subjects on TPN, effects of, on hyperglycemia, 450-456  
and normalization of LDL receptor gene expression in hypothyroidism, 680-686  
on serum lipids and Lps, increased peripheral conversion of T<sub>4</sub> to T<sub>3</sub> and, 1016-1020  
*see also* Growth hormone, effects of therapy with, for men
- Growth hormone (GH), effects of therapy with, for men  
in older men, effects of resistance exercise and, on insulin sensitivity and secretion during IVGTT, 254-260  
*see also* Growth hormone, effects of therapy of GH-deficient men with
- Growth hormone (GH), effects of therapy of GH-deficient men with, 362-377  
effects of, on serum Lps, LPL, and HL activity, 370-377  
on GH, IGFBP-1, IGFBP-3, and glucose homeostasis, 362-369  
on IGF-I, *see* Insulin-like growth factor-I, GH therapy and
- Growth hormone (GH), secretion of  
cAMP and PKC responses to, in acromegalic pituitary adenomas, 206-210  
effects of early changes in plasma glucagon on, in response to glucose in hyperthyroidism, 1029-1033
- Growth hormone-binding protein (GHBP)  
androgenic steroids regulating, 1521-1526  
relationship between plasma GH, growth rate and, 424-429
- Growth hormone-releasing hormone (GHRH)  
plasma GH level in men before and after stimulation with GHRH following nifedipine and ET-1 treatment, 659  
*see also* Acipimox, effects of, on GH response to GHRH in obesity
- GS, *see* Glycogen synthase
- Hb, *see* Glycosylated Hb in NIDDM and entries beginning with acronym: HbA
- HbA<sub>1</sub> (hemoglobin A<sub>1</sub>)  
in IDDM, *see* HbA<sub>1</sub> in IDDM  
in NIDDM, 1384
- HbA<sub>1</sub> (hemoglobin A<sub>1</sub>) in IDDM  
with hypoglycemia, 975  
progression of microalbuminuria and, 1102
- HbA<sub>1c</sub> (hemoglobin A<sub>1c</sub>)  
and diet effects on glucose homeostasis and serum lipid levels in exercise, 436  
and glucose processing during FSIGT, 599  
in IDDM, *see* HbA<sub>1c</sub> in IDDM  
in NIDDM, *see* HbA<sub>1c</sub> in NIDDM  
in STZ-DM, effects of sorbinil and ALC on, 905  
urapidil effects on, in hypertensive subjects, 1226  
voglibose effects on, in nondiabetic hyperinsulinemia, 734
- HbA<sub>1c</sub> (hemoglobin A<sub>1c</sub>) in IDDM  
autonomic neuropathy and, 1067  
blood cell membrane phospholipid composition and, 59  
intraperitoneal insulin effects on, 432  
Na<sup>+</sup>/K<sup>+</sup> ATPase turnover and Na<sup>+</sup>/K<sup>+</sup> ATP RBC concentration in IDDM and, 928  
in nonnephropathic IDDM, RBC membrane sodium-lithium countertransport kinetics and, 1204  
in well-controlled IDDM, 1435
- HbA<sub>1c</sub> (hemoglobin A<sub>1c</sub>) in NIDDM  
and ACE and AGN gene polymorphism, 220-221  
in adult-onset IDDM subjects, 1510

- HbA<sub>1c</sub> (hemoglobin A<sub>1c</sub>) in NIDDM (*Continued*)  
 with amino acid polymorphism in HSL, 864  
 autonomic neuropathy and, 1067  
 blood cell membrane phospholipid composition and, 59  
 level of cICAM-1, MDA and, and oxidative stress, 498-501  
 with macrovascular disease, 134  
 Na<sup>+</sup>/K<sup>+</sup> ATPase turnover and Na<sup>+</sup>/K<sup>+</sup> ATP erythrocyte concentration in NIDDM and, 928  
 in normotriglyceridemic NIDDM, 64, 67  
 oral glucose and CCK release and, 197  
 with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783  
 sorbitol and glutathione in erythrocytes and, 612
- HCO<sub>3</sub> (bicarbonate) in Bardet-Biedel syndrome children, 1231
- HCV (hepatitis C virus) status of  $\beta$ -thalassemia major subjects, 652-657
- HD (hemodialysis), protein oxidation in, 1319-1322
- HDL(s), *see* High-density lipoprotein(s)
- HDL-C, *see* High-density lipoprotein-cholesterol
- Healthy subjects, *see* Normal adult subjects
- Heart  
 CL316,243 effects on NE turnover in, SNS activity and, 788  
 O<sub>2</sub> consumption in hepatomesenteric bed, brain and, of young and elderly men, sympathetic nervous activity with, 1487-1492  
 troglitazone effects on weight of, in STZ-DM, 1169  
*see also* Coronary heart disease; Heart performance; Heart rate;  
 Organ weight, heart and *entries beginning with terms*: Cardiovascular, Myocardial, Ventricular
- Heart performance, insulin and glucose effects on, 775
- Heart rate (HR)  
 and endogenous opioid response to exercise in IDDM, 139  
 in exercise with pivalic acid-induced carnitine deficiency, 1504  
 hyperglycemia effects on, during ischemia, 544  
 of hypertensive subjects with LVH, 1327  
 intrarenal glucagon effects on, 385  
 mental stress and, in adolescent boys with IRS, 614-621  
 and O<sub>2</sub> consumption in heart, hepatomesenteric bed, and brain, 1488  
 theophylline effects on, during exercise and, 1156
- Height  
 of aging women, 44, 45  
 and androgen regulation of GHBP, 1522  
 and body composition of healthy Indian and Swedish men, 635  
 of cancer patients, response to radiation therapy and, 768  
 of CHD subjects, 670  
 and circadian relationships between serum Ca, serum phosphate, and circulating ANPs, 1022  
 exercise and, *see* Height, exercise and  
 of FHLB subjects, 1297  
 of FHTG and FDL subjects, 1308  
 and fibrinolytic potential, 1429  
 of hypertensive subjects with LVH, 1327  
 and insulin effects on HGP, 83  
 of insulin-resistant adolescents, 909  
 of Laron syndrome subjects, 1264  
 of NIDDM subjects, *see* Height of NIDDM subjects  
 of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109  
 and O<sub>2</sub> consumption in heart, hepatomesenteric bed, and brain, 1488  
 of obese subjects, *see* Height of obese subjects  
 of PWS subjects, 1515, 1516  
 and regional FFA kinetics, 663  
 of smokers, and smoking effects on REE, 924
- Height, exercise and  
 and diet effects on glucose homeostasis and serum lipid levels, 436  
 and effects of GH administration and resistance exercise in older men, 256  
 of IDDM subjects, and endogenous opioid response to exercise, 139  
 and influence of age, sex and adiposity on metabolically active component of FFM, 993  
 relationship between glucose metabolism and thermogenesis with and without prior exercise in obese NIDDM women, 748  
 and strenuous exercise effects on glycerol kinetics, 358
- Height of NIDDM subjects  
 and effects of vanadyl sulfate on CHO and lipid metabolism, 1131  
 and relationship between glucose metabolism and thermogenesis with and without prior exercise in obese NIDDM women, 748  
 of untreated NIDDM subjects, 493
- Height of obese subjects  
 of obese adolescents, cardiovascular risk factors and, 235  
 of obese NIDDM women, relationship between glucose metabolism and thermogenesis with and without prior exercise and, 748  
 of obese 10-year-old girls, 471
- Hematocrit, intrarenal glucagon action on, 385
- Hemodialysis (HD), protein oxidation in, 1319-1322
- Hemodynamics  
 renal, intrarenal glucagon action on, 383-388  
*see also* Blood flow; Blood pressure; Heart rate; Plasma flow
- Hemoglobin, *see entries beginning with acronym*: Hb
- Hemorheological parameters, effects of omega-FAs and fenofibrate on lipids and, in FDL and FHTG, 1305-1311
- Hepatic apolipoprotein B (apo B) RNA (ribonucleic acid) editing in genetic obesity, 1056-1058
- Hepatic artery glucose in conscious subjects, glyburide effects on, 580
- Hepatic blood flow, glyburide effects on, in conscious subjects, 580
- Hepatic dysfunction, glucose intolerance in  $\beta$ -TM related to insulin resistance and, 652-657
- Hepatic fructose-1,6-bisphosphatase (FBPase), impaired regulation of, in obese NIDDM subjects, 622-626
- Hepatic gluconeogenesis, stress hormone effects on, in conscious subjects, 573-574
- Hepatic glucose  
 effects of decreasing plasma FFAs by ACX on metabolism of, in normal subjects, 1408-1414  
*see also* Hepatic glucose production
- Hepatic glucose production (HGP)  
 gliclazide effects on, *see* Gliclazide, effects of, on HGP  
 glyburide effects on, in conscious subjects, 583  
 hyperglycemia and alteration of glucagon ability to activate glycogen phosphorylase and increase, 481-485  
 indomethacin and pentoxifylline modulating, in healthy subjects, 1458-1465  
 insulin effects on turnover of, constant SA technique versus isotope dilution technique in estimation of, 82-91  
 and MIDA glucose with [2-<sup>13</sup>]glycerol, 897-901  
 moderate decline in SA and, 587-593
- Hepatic glycogen, stress hormone effects on, in conscious subjects, 574
- Hepatic insulin  
 extraction of, and beta cell activity following dexamethasone administration in healthy subjects, 486-492  
 glyburide effects on, in conscious subjects, 581-583

- Hepatic insulin resistance, relationship of, with PAI-1 in Pima Indians, 1243-1247
- Hepatic lipase (HL) activity, effects of GH therapy of GH-deficient men on, 370-377
- Hepatic low-density lipoprotein (LDL) receptor, GH effects on, in hypothyroidism, 683
- Hepatic mRNA (messenger ribonucleic acid)  
of HDL and LDL receptor, GH effects on, in hypothyroidism, 683  
protein and TNF, determinants of concentrations of, in malnourished subjects, 1273-1276
- Hepatic nuclear protein, total, starvation effects on, 971
- Hepatic portal blood flow, differential effects of pathophysiological versus physiological concentrations of plasma E and NE on KB metabolism and, 1214-1220
- Hepatic triacylglycerol (TAG), OFS effects on fructose impact on metabolism of, 1547-1550
- Hepatic vein alanine, stress hormone effects on, in conscious subjects, 576
- Hepatic vein glucose in conscious subjects, glyburide effects on, 580
- Hepatic vein lactate, stress hormone effects on, in conscious subjects, 576
- Hepatitis C virus (HCV) status of beta-thalassemia major subjects, 652-657
- Hepatocytes, glucose cycling by, effects of thyroid status on, 101-108
- Hepatoma 7777, Morris, reduced immune function and reduced splenocyte metabolism in subjects implanted with, 848-855
- Hepatomesenteric bed, O<sub>2</sub> consumption in heart, brain and, of young and elderly men, sympathetic nervous activity with, 1487-1492
- Heterozygous father, sitosterolemic, cholestyramine and lovastatin effects on plasma sterol levels in, and in his sitosterolemic homozygous girl, 673-679
- HF, *see* High-fat diet
- HFHS (high-fat, high-sucrose) diet, effects of, on malonyl coenzyme A in obese salt-sensitive subjects, 519-525
- HGP, *see* Hepatic glucose production
- High-density lipoprotein(s) (HDLs;  $\alpha$ -lipoproteins)  
and adenoviral delivery of LDL receptors in hyperlipidemic subjects, 1447-1457  
low-fat diet effects on, in sitosterolemia, 674  
of normolipidemic men, myristate, palmitate, and stearate metabolism and, 1109  
relation of, to metabolic parameters and severity of CAD, 1375-1382  
*see also* High-density lipoprotein(s) in IDDM; High-density lipoprotein<sub>2</sub>; High-density lipoprotein<sub>3</sub>; High-density lipoprotein-cholesterol; High-density lipoprotein-cholesteryl ester; High-density lipoprotein-cholesteryl ester; Lipoprotein(a)
- High-density lipoprotein(s) in IDDM  
PP changes in composition and subfraction distribution of, 1034-1041  
progression of microalbuminuria and, 1103, 1104
- High-density lipoprotein<sub>2</sub> (HDL<sub>2</sub>)  
in NIDDM, 1384  
PP changes in composition and subfraction distribution of, in IDDM, 1034-1041  
*see also* High-density lipoprotein<sub>2</sub>-cholesterol
- High-density lipoprotein<sub>3</sub> (HDL<sub>3</sub>)  
in NIDDM, 1384  
PP changes in composition and subfraction distribution of, in IDDM, 1034-1041  
*see also* High-density lipoprotein<sub>3</sub>-cholesterol
- High-density lipoprotein-cholesterol (HDL-C)  
AAS abuse effects on, 845  
and abdominal AT distribution, metabolic risk factors and, 1121  
in adolescents with insulin resistance, 909-911  
in CAD, 1378-1380  
in CHD, *see* High-density lipoprotein-cholesterol in CHD  
exercise and, *see* High-density lipoprotein-cholesterol, exercise and  
in FH, GH and, 1417, 1418  
in FHLB, 1297, 1302  
in FHTG and FDL, 1308  
fibrinolytic potential and, 1429  
GH therapy effects on, 372, 1017  
in glomerular proteinuria, 726  
in high SFA diet, 553, 555, 556  
hydrogenated fat diet effects on, 244  
in hyperuricemia, hypertriglyceridemia, DM, and hypertension, 700-703  
in IDDM, *see* High-density lipoprotein-cholesterol in IDDM  
and insulin effects on levels of circulating vitamin E, 999, 1000  
in IRS, 1535, 1536  
in morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA and, 1013  
nandrolone decanoate effects on, 465  
in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM  
in obesity, *see* High-density lipoprotein-cholesterol in obesity  
oral albuterol effects on, 714  
overfeeding effects on, 1046  
palmitic and stearic acid effects on, 146  
plasma, *see* Plasma high-density lipoprotein-cholesterol  
postprandial, 17 $\beta$ -estradiol reducing, in postmenopausal women, 827-832  
and relationship of plasma TGs, apo B and, to postheparin LPL activity, 263  
serum, *see* Serum high-density lipoprotein-cholesterol  
in uremia, 688, 689  
and urinary excretion of E<sub>2</sub> and T, 281-283  
voglibose effects on, in nondiabetic hyperinsulinemia, 734  
*see also* High-density lipoprotein<sub>2</sub>-cholesterol; High-density lipoprotein<sub>3</sub>-cholesterol
- High-density lipoprotein-cholesterol (HDL-C), exercise and exercise and diet effects on, 436  
exercise effects on HDL-C concentrations related to apo E phenotype in boys and young adults, 798
- High-density lipoprotein-cholesterol (HDL-C) in CHD  
high- versus low-glycemic CHO effects, 671  
lipid and CHO metabolic risk markers for CHD and BP in non-obese premenopausal women, 330
- High-density lipoprotein-cholesterol (HDL-C) in IDDM  
intraperitoneal insulin effects on, 432  
Lp, apo, and LDL size and, 1268, 1269  
in nonnephropathic IDDM, RBC membrane SLC kinetics and, 1204
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM  
cardiovascular risk factors and RBC membrane SLC and, 962, 963  
Lp, apo, and LDL size and, 1268, 1269  
in normotriglyceridemic NIDDM, 64, 67  
plasma, role of AT loss in exercise-induced improvement in, 1384
- High-density lipoprotein-cholesterol (HDL-C) in obesity  
in obese adolescents, 235  
in obese 10-year-old girls, race and, 469-474
- High-density lipoprotein<sub>2</sub>-cholesterol (HDL<sub>2</sub>-C)  
in FHTG and FDL, 1308  
in high SFA diets, 553

- High-density lipoprotein<sub>2</sub>-cholesterol (HDL<sub>2</sub>-C) (*Continued*)  
and lipid and CHO metabolic risk markers for CHD in non-obese premenopausal women, 330  
pancreas transplantation effects on, 858  
and relationship of plasma TGs, HDL-C, and apo B to postheparin LPL activity, 263  
and urinary excretion of E<sub>2</sub> and T, 281-283  
in visceral obesity-insulin resistance-dyslipidemic syndrome, 885, 886
- High-density lipoprotein<sub>3</sub>-cholesterol (HDL<sub>3</sub>-C)  
in FHTG and FDL, 1308  
in high SFA diet, 553  
and lipid and CHO metabolic risk markers for CHD in non-obese premenopausal women, 330  
pancreas transplantation effects on, 858  
and urinary excretion of E<sub>2</sub> and T, 281-283  
in visceral obesity-insulin resistance-dyslipidemic syndrome, 885, 886
- High-density lipoprotein (HDL)-cholesteryl ester, metabolism of, in genetic hypercholesterolemia, 7
- High-fat (HF) diet  
decreased fat oxidation following meal, in weight-reduced subjects, 174-178  
hyperglycemia and obesity induced by, effects of different oils on, 1539-1546
- High-fat,high-sucrose (HFHS) diet, effects of, in obese subjects, 519-525
- High-glycemic carbohydrates (CHOs), effects of low-glycemic CHOs versus, on insulin and glucose response in CHD, 669-672
- High-nicotine cigarette smoking, low- versus, impact of, on REE, 923-926
- Hirsute women  
hyperandrogenic severely, long-acting GnRH in, 25-27  
obese, hormonal parameters in, 72-75  
young, menstrual history and BMD in, 515-518
- Histidine, MH 7777 effects on concentrations of, 851
- HIV (human immunodeficiency virus) infection, anterior pituitary- and pituitary-dependent target organ function in men with, 738-746
- HL (hepatic lipase) activity, effects of GH therapy for GH-deficient men on, 370-377
- <sup>2</sup>H<sub>2</sub>O<sub>2</sub> (deuterated water), plasma C and FA synthesis measurement with, number of incorporated deuterium atoms determined with, 817-821
- Homeostasis, glucose, *see* Glucose homeostasis
- Homocysteine, hyperhomocysteinemia following methionine load in NIDDM with vascular disease, 133-135
- Homovanillic acid (HVA), brain, IV  $\gamma$ -glutamyl tyrosine effects on, 130
- Homozygous sitosterolemic girl, cholestyramine and lovastatin effects on plasma sterol levels in heterozygous sitosterolemic father and his, 673-679
- Hormone replacement therapy, effects of, on CHO metabolism and cardiovascular risk factors in postmenopausal subjects, 1254-1262
- Hormone-sensitive lipase (HSL), amino acid polymorphism in, in Japanese NIDDM subjects, 862-864
- Hospitalized subjects, serum uric acid in, 1557-1561
- HPA (hypothalamus-pituitary-adrenal) axis, activity of, and its relationship to AN in premenopausal obese women with VAT and SAT, effects of CRF/AVP and stress tests on, 351-356
- HPO, *see* Hypothalamus-pituitary-ovary axis
- HPT (hypothalamus-pituitary-thyroid) axis in SCI women, 718-722
- HR, *see* Heart rate
- HS (hunger sensation) in obesity with NIDDM, 24-hour pattern of, 1342-1347
- HSL (hormone-sensitive lipase), amino acid polymorphism in, in Japanese NIDDM subjects, 862-864
- Human immunodeficiency virus (HIV) infection, anterior pituitary- and pituitary-dependent target organ function in men with, 738-746
- Hunger sensation (HS) in obesity with NIDDM, 24-hour pattern of, 1342-1347
- HVA (homovanillic acid), brain, IV  $\gamma$ -glutamyl tyrosine effects on, 130
- Hydrogen, breath, acarbose effects on, 1182-1183
- Hydrogenated dietary fat, effects of, on C synthesis and LDL oxidation in moderate hypercholesterolemia, 241-247
- Hydrolysis, phosphoinositide, GLP-1 stimulating insulin secretion but not, from pancreatic islets desensitized by exposure to high glucose or carbachol, 273-278
- 3-Hydroxybutyrate (3-OHB), octreotide effects on, in IDDM, 214
- $\beta$ -Hydroxybutyric acid ( $\beta$ -OHB)  
effects of exercise on, in normal and STZ-DM subjects, 811  
in familial leucine-sensitive hypoglycemia, glucose effects on, 958
- 5-Hydroxycarboic acid, urinary excretion of, in dicarboxylic aciduria, 163-164
- 4-Hydroxyestrone, antioxidant effects of, on lipid peroxidation, 411-414
- 5-Hydroxyhexanoic acid, urinary excretion of, in dicarboxylic aciduria, 163-164
- 7-Hydroxyoctanoic acid, urinary excretion of, in dicarboxylic aciduria, 163-164
- 17-Hydroxyprogesterone, *see* 17-OHP
- Hyperammonemia, familial leucine-sensitive hypoglycemia with concomitant, 957-960
- Hyperandrogenic women, severely hirsute, long-acting GnRH in, 25-27
- Hypercholesterolemia  
familial, *see* Familial hypercholesterolemia  
genetic, plasma Lp metabolism in, 4-11  
moderate, hydrogenated dietary fat effects on C synthesis and LDL oxidation in, 241-247  
with thrombophilia, 966-969
- Hyperglycemia  
and alteration of glucagon ability to increase hepatic glucose production and activate glycogen phosphorylase, 481-485  
effects of, on myocardial interstitial glucose and glucose uptake during ischemia, 542-549  
GH effects on, in multiple trauma subjects on TPN, 450-456  
HF diet-induced obesity and, effects of different oils on, 1539-1546  
macrophage response to CSF-1 in, 1125-1129
- Hyperglycemic factor, *see* Glucagon
- Hyperhomocysteinemia following methionine load in NIDDM and macrovascular disease, 133-135
- Hyperinsulinemia  
associated with ventricular premature complexes, 1248-1253  
effects of, on PAI-1, 1245  
HFHS diet effects on, in obese subjects, 519-525  
insulin resistance and, with portal-caval transposition, 120-125  
lack of association between smoking and, 1551-1556  
nondiabetic, voglibose effects on dyslipidemia and insulin sensitivity in, 731-737  
relationship between plasma PL SFAs and, 223-228
- Hyperlipidemia  
estrogen increasing apo B-independent catabolism of LDL receptor in, 889-896

Hyperlipidemia (*Continued*)

- LDL receptors in, *see* Low-density lipoprotein receptor(s) in hyperlipidemia
- serum lathosterol-to-cholesterol ratio is not elevated in glomerular proteinuria and not associated with improved, in response to antiproteinuria therapy, 723-730

*see also specific hyperlipidemic conditions*

- Hyperparathyroidism, primary, decreased cortical and cancellous bone in, 76-81

## Hypertension

- CAD and, 1377
- essential, urapidil effects on plasma F<sub>n</sub> in, 1221-1229
- glucose in, *see* Glucose in hypertension
- hyperuricemia, hypertriglyceridemia, DM and, associated with fasting insulin and central and overall obesity, 699-706
- in IDDM, blood cell membrane phospholipid composition and, 59
- with LVH, BNPs during ergometric exercise by patients with, 1326-1329
- metformin effects on vascular reactivity in fructose-hypertensive subjects, 1053-1055
- in obese adolescents, 235
- in STZ-DM, *see* Hypertension, and STZ-DM

## Hypertension, and NIDDM

- blood cell membrane phospholipid composition and, 59
- cardiovascular risk factors and RBC membrane SLC and, 963

## Hypertension, and STZ-DM

- effects of gonadectomy on development of albuminuria, hypertension, and STZ-DM, 155-161
- insulin resistance with hypertension in STZ-DM, alacepril effects on, 457-462

## Hyperthyroidism

- GH response to glucose in, effects of early changes in plasma glucagon on, 1029-1033
- increased erythrocyte Na influx and Ca uptake in, erythrocyte membrane phospholipid level and, 707-711
- T<sub>3</sub> in, *see* Triiodothyronine in hyperthyroidism
- T<sub>4</sub> in, *see* Thyroxine in hyperthyroidism

## Hypertriglyceridemia

- familial, effects of omega-FAs and fenofibrate on lipids and hemorrheological parameters in FDL and, 1305-1311
- hyperuricemia, DM, and hypertension with, associated with fasting insulin and central and overall obesity, 699-706
- Hypertrophy, left ventricular, hypertension with, BNPs during ergometric exercise by patients with, 1326-1329
- Hyperuricemia, hypertriglyceridemia, DM, and hypertension with, associated with fasting insulin and central and overall obesity, 699-706

## Hypobetalipoproteinemia, familial, apo B-43.7 in, 1296-1304

## Hypoglycemia

- familial leucine-sensitive, with concomitant hyperammonemia, 957-960
- in IDDM, *see* Hypoglycemia in IDDM
- idiopathic reactive, nonoxidative metabolism of postprandial glucose in, 606-610

## Hypoglycemia in IDDM

- with impaired hypoglycemia awareness, acute hypoglycemia effects on rCBF in, 974-980
- time course of defective alpha cell response to, 1422-1426
- in well-controlled IDDM, responses of PRL and  $\beta$ -endorphin to, 1434-1440

## Hypothalamic ablation, medial basal, effects of, on EtOH-induced PRL release, 1332

## Hypothalamic deafferentation, medial basal, on EtOH-induced PRL release, 1331-1332

- Hypothalamic-pituitary growth, defective gonadal axes and, with empty sellae, and impaired testosterone secretion in Bardet-Biedel syndrome children, 1230-1234

- Hypothalamus-pituitary-adrenal (HPA) axis, activity of, and its relationship to AN in premenopausal obese women with VAT and SAT, effects of CRF/AVP and stress tests on, 351-356

## Hypothalamus-pituitary-ovary (HPO) axis

- in SCI women, 718-722
- in severely hyperandrogenic hirsute women, GnRH therapy effects on, 25-27

## Hypothalamus-pituitary-thyroid (HPT) axis in SCI women, 718-722

- Hypothyroidism, normalization of LDL gene receptor expression in, with GH, 680-686

Hypoxanthine, *see* Purine bases

- IBAT (intercapsular brown adipose tissue), and CL316,243 effects on SNS activity, 788

- ICAM-1 (intercellular adhesion molecule-1), circulating, level of HbA<sub>1c</sub>, MDA and, in NIDDM, oxidative stress and, 498-501

IDDM, *see* Insulin-dependent diabetes mellitus

- Identical twins, body weight recovery by, after 5-year overfeeding, 1042-1050

- Idiopathic reactive hypoglycemia (IRH), nonoxidative metabolism of postprandial glucose in, 606-610

IDL, *see* Intermediate-density lipoprotein

- IDL-C (intermediate-density lipoprotein-cholesterol), pancreas transplantation effects on, 858

- IGF, *see* Insulin-like growth factor-I; Insulin-like growth factor-II
- IGFBP, *see* Insulin-like growth factor binding protein-1; Insulin-like growth factor binding protein-2 mRNA; Insulin-like growth factor binding protein-3

- IGT (impaired glucose tolerance), obese women with, dysfunctional pancreatic islets in, 502-510

- Immune function, reduced, and reduced splenocyte metabolism in subjects implanted with MH 7777, 848-855

- Immunocytochemical localization of GLUT1 and GLUT3 polypeptides in peripheral nerve, 1468-1470

## Immunoreactive insulin (IRI)

- and long-term sucrose-rich diet, 1528-1529
- PCT and, 122, 123
- serum, and effects of gonadectomy on development of hypertension, albuminuria, and STZ-DM, 159

- Impaired glucose tolerance (IGT), obese women with, dysfunctional pancreatic islets in, 502-510

## Income of IDDM subjects, WHR and, 269

- Indian Mauritians, nondiabetic, relationship of insulin resistance to weight loss in, 627-633

- Indian men, CT-determined body composition of healthy Swedish and, in relation to CV risk factors, 634-644

- Indirect calorimetry in measurement of octreotide effects in IDDM, 214

- Indomethacin, pentoxifylline and, modulating HGP, in healthy subjects, 1458-1465

## Infancy

- urinary excretion of pyridinium cross-links of collagen in, 510-514
- see also* Children

## Infection

- effects of, on polyamine metabolism in small intestine mucosa, 28-33

- HIV, anterior pituitary- and pituitary-dependent target organ function in men with, 738-746

- Inflammatory state, effects of nutritional state and, on liver of elderly subjects, <sup>31</sup>P magnetic resonance spectroscopy in assessment of, 1059-1061

- Inherited diabetes and deafness, maternally, insulin resistance associated with, 526-531
- Injury, *see* Trauma and injury
- Inorganic plasma phosphate, effects of xylitol on, 1356-1357
- Inositol, *see: myo*-inositol
- Insulin
- arterial, intrarenal glucagon action on, 385
  - in CAD, 1377-1379
  - cells producing, functional active receptors for IGF-I and IGF-II on, 759-766; *see also* Beta cells
  - and CV risk factors in healthy Indian and Swedish men, 640, 641
  - and diet effects on glucose homeostasis and serum lipid levels in exercise, 436
  - effects of, on circulating vitamin E levels, 998-1003
  - effects of, on HGP, constant SA technique versus isotope dilution technique in estimation of, 82-91
  - effects of, on intracellular Ca concentrations, 1402-1407
  - effects of, on plasma PAI-1 and t-PA in young women on contraceptive steroids, 833-838
  - effects of gastric emptying rate on, 1176
  - in familial leucine-sensitive hypoglycemia, glucose effects on, 958
  - fasting, *see* Fasting insulin
  - gene of signal-transduction pathway intermediates of, effects of beef tallow and safflower oil diets on expression of, 1080-1088
  - GH therapy effects on GH-deficient men and, 366
  - glucose transport in muscle and fat cells stimulated by, TNF- $\alpha$  effects on, 1089-1094
  - hepatic, *see* Hepatic insulin
  - in HF diet-induced hyperglycemia and obesity, 1541, 1542
  - in hypercholesterolemic thrombophilia, 967
  - immunoreactive, *see* Immunoreactive insulin
  - in IRH, 608
  - myocardial 1,2-DAG increased by, 774-781
  - in NIDDM, *see* Insulin in NIDDM
  - in obesity, *see* Insulin in obesity
  - during OGTT, 599
  - pancreas transplantation effects on, 857
  - plasma, *see* Plasma insulin
  - plasma E and NE effects on, 1217, 1218
  - portal versus peripheral delivery of, in handling of portally delivered glucose, 150-154
  - in PWS, 1514-1520
  - stress hormone effects on, in conscious subjects, 573
  - see also* Hyperinsulinemia; Insulin-dependent diabetes mellitus; Insulin receptor gene; Insulin release and secretion; Insulin resistance; Insulin resistance syndrome; Insulin sensitivity; Insulinitis; Non-insulin-dependent diabetes mellitus; Proinsulin; des 31,32 Proinsulin *and entries beginning with terms:* Insulin-like growth factor
- Insulin in CHD
- effects of high- versus low-glycemic CHOs on response of, 669-672
  - and lipid and CHO metabolic risk markers for CHD in non-obese premenopausal women, 330
- Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus)
- adult-onset, effects of intensive therapy of, on insulin sensitivity and insulin reserve, 1508-1513
  - beta cells in, *see* Beta cells in IDDM
  - changes in PL composition of PMN leukocyte, erythrocyte, and platelet membranes in, 57-62
  - exercise in, *see* Exercise in IDDM
  - glucose, *see* Glucose in IDDM
  - Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus) (*Continued*)
  - hypoglycemia in, *see* Hypoglycemia in IDDM
  - intraperitoneal insulin effects on choline-containing LpB-PLs in, 430-434
  - Lp, apo, and LDL size in, 1267-1272
  - octreotide effects on glucose metabolism and insulin sensitivity in, 211-217
  - plasma met-enkephalin in, autonomic neuropathy and, 1065-1068
  - PP changes in HDL composition and subfraction distribution in, 1034-1041
  - progression in microalbuminuria in, apo B as predictor of, 1101-1107
  - psychosocial factors and WHR in, 268-272
  - RA status, and development of, 248-254
  - RBC Na<sup>+</sup>/K<sup>+</sup> ATPase turnover and Na<sup>+</sup>/K<sup>+</sup> ATP concentration in, 927-934
  - twins with nonnephropathic, erythrocyte membrane SLC kinetics in 1203-1207
  - well-controlled, responses of PRL and  $\beta$ -endorphin to, 1434-1440
- Insulin-like growth factor-I (IGF-I)
- in Bardet-Biedel syndrome children, 1232
  - dominant negative effects of kinase-defective IRs on signaling in fibroblasts stimulated by, 1474-1482
  - effects of long-term treatment with, on serum Lp(a) in Laron syndrome, 1263-1266
  - functional active receptors for, on insulin-, glucagon-, and somatostatin-producing cells, 759-766
  - GH therapy and, *see* Insulin-like growth factor-I, GH therapy and
  - hormone replacement therapy effects on, in postmenopausal subjects, 1258
  - in multiple trauma, 453
  - plasma, *see* Plasma insulin-like growth factor-I
  - response of, to T and DHT, 1523
  - severe resistance to, in leprechaunism, due to two mutations of tyrosine kinase domain of insulin receptor gene, 1493-1500
- Insulin-like growth factor-I (IGF-I), GH therapy and
- effects of resistance exercise and, in older men on, 256
  - for GH-deficient men, effects of, on IGF-I, GH, IGFBP-3, and glucose homeostasis, 362-369
- Insulin-like growth factor-II (IGF-II), functional active receptors for, on insulin-, glucagon-, and somatostatin-producing cells, 759-766
- Insulin-like growth factor binding protein-1 (IGFBP-1), effects of GH therapy for GH-deficient men on IGF-I, GH, IGFBP-3, and glucose homeostasis, 362-369
- Insulin-like growth factor binding protein-2 (IGFBP-2) mRNA (messenger ribonucleic acid) in malnourished subjects, 1275
- Insulin-like growth factor binding protein-3 (IGFBP-3), effects of GH therapy for GH-deficient men on IGF-I, GH, IGFBP-1, and glucose homeostasis, 362-369
- Insulin in NIDDM
- effects of starvation in untreated NIDDM on plasma insulin concentrations, 492-497
  - in normotriglyceridemic NIDDM, 64, 67
  - with and without renal insufficiency, insulin effects on urinary excretion of phosphate in, 782-786
- Insulin in obesity
- cephalic-phase insulin response in nondiabetic obese subjects, 168-173
  - hyperuricemia, hypertriglyceridemia, DM, and hypertension associated with fasting plasma insulin level and central and overall obesity, 699-706
  - with IGT, 504, 505



- Insulin in obesity (*Continued*)  
 interstitial insulin in obese and lean subjects, 951-956  
 in obese adolescents, 235
- Insulin receptor(s) (IRs)  
 autophosphorylation of, *see* Autophosphorylation, IR  
 dominant negative effect of kinase-defective, on IGF-I-stimulated signaling in fibroblasts, 1474-1482
- Insulin receptor (IR) gene, severe resistance to insulin and IGF-I due to two mutations of tyrosine kinase domain of, in leprechaunism, 1493-1500
- Insulin release and secretion  
 due to A-4166, 184-189  
 effects of GH administration and resistance exercise in older men on, during IVGTT, 254-260  
 effects of moderate protein increase on, 1483-1486  
 GLP-1 stimulating, but not phosphoinositide hydrolysis from pancreatic islets desensitized by exposure to high glucose or carbachol, 273-278  
 glucose-induced, RA status and, 250  
 glyburide effects on tissue uptake, action and, in conscious subjects, 579-586  
 L-NMMA effects on, in diabetic syndrome, 940-946  
 paracrine action of pancreatic islet-derived corticotropin-like peptides on regulation of, 565-570
- Insulin resistance  
 alacepril effects on hypertension and, in STZ-DM, 476-462  
 effects of, on DHEA in morbidly obese adolescents, 1011-1015  
 effects of trandolapril alone or in combination with verapamil on glucose transport in insulin-resistant skeletal muscle, 535-541  
 glucose intolerance in  $\beta$ -TM related to hepatic dysfunction and, 652-657  
 hepatic and peripheral, relationship of, with PAI-1 in Pima Indians, 1243-1247  
 hyperinsulinemia and, with portal-caval transposition, 120-125  
 and insulin effects on intracellular Ca concentrations, 1402-1407  
 and Mg deficiency effects on glucose oxidation to CO<sub>2</sub> in adipocytes, 838-843  
 MIDD-associated, 526-531  
 in NIDDM, lack of relationship between urinary albumin excretion and, 1062-1064  
 plasma HDL-C as correlate of visceral obesity-insulin resistance-dyslipidemic syndrome in men, 882-888  
 relationship of, to weight gain in nondiabetic Creole, Chinese, and Indian Mauritians, 627-633  
 severe, in leprechaunism, due to two mutations of tyrosine kinase domain of insulin receptor gene, 1493-1500  
 smoking and, 1551-1556  
 in Swedish adolescents, 908-914  
*see also* Insulin resistance syndrome; Insulin sensitivity
- Insulin resistance syndrome (IRS), stress and  
 and autonomically mediated physiological responses to experimentally induced mental stress in adolescent boys, 614-621  
 psychological stress and, 1533-1538
- Insulin sensitivity  
 effects of GH administration and resistance exercise in older men on, during IVGTT, 254-260  
 effects of intensive therapy of adult-onset IDDM on insulin reserve and, 1508-1513  
 and insulin effects on levels of circulating vitamin E, 999  
 M16209 effects on, 1095-1100  
 muscle, intramuscular TGs and, in nondiabetic subjects, 947-950  
 octreotide effects on glucose metabolism and, in IDDM, 211-217  
 voglibose effects on dyslipidemia and, in nondiabetic hyperinsulinemia, 731-737  
*see also* Insulin resistance
- Insulinitis, RA status, and development of, 248-254
- Intensive therapy of adult-onset insulin-dependent diabetes mellitus (IDDM), insulin sensitivity and insulin reserve with, 1508-1513
- Intercapsular brown adipose tissue (IBAT), and CL316,243 effects on SNS activity, 788
- Intercellular adhesion molecule-1 (ICAM-1), level of HbA<sub>1c</sub>, MDA and, in NIDDM, oxidative stress and, 498-501
- Intermediate-density lipoprotein (IDL)  
 in FHLB, 1302  
 of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109
- Intermediate-density lipoprotein-cholesterol (IDL-C), pancreas transplantation effects on, 858
- Interstitial glucose, myocardial, hyperglycemia effects on glucose uptake and, during ischemia, 542-549
- Interstitial insulin in obese and lean subjects, 951-956
- Intestinal sucrase, L-arabinose inhibiting, after sucrose ingestion, 1368-1374
- Intestine  
 small, *see* Small intestine  
 substrate balance in, stress hormone effects on, in conscious subjects, 575-576  
*see also* Mucosa, intestinal
- Intracellular Ca (calcium), insulin effects on concentrations of, 1402-1407
- Intracellular Ca<sup>2+</sup> (calcium ion), role of, in regulation of gluconeogenesis, 389-403
- Intracellular glucose, VS effects on, 1132
- Intramuscular triglycerides (TGs), and muscle insulin sensitivity in nondiabetic subjects, 947-950
- Intraperitoneal (IP) insulin, effects of, on choline-containing LpB-PLs in IDDM, 430-434
- Intrarenal glucagon, action of, on renal hemodynamics, renal metabolism, and renal Na handling, 383-388
- Intravenous (IV) glucose tolerance test (IVGTT)  
 in conscious subjects, glyburide effects on, 579-586  
 effects of resistance exercise and GH administration in older men on insulin secretion and insulin sensitivity during, 254-260  
 and long-term sucrose-rich diet, 1529-1530  
 oral albuterol effects on, 714  
 in PWS, 1514-1520  
 in  $\beta$ -thalassemia major, 652-657  
 of young women on contraceptive steroids, 835-836  
*see also* Frequently sampled intravenous glucose tolerance test
- Intravenous (IV)  $\gamma$  (gamma)-glutamyl tyrosine, effects of, on brain tyrosine and catecholamine concentrations in normal subjects, 126-132
- IP (intraperitoneal) insulin, effects of, on choline-containing LpB-PLs in IDDM, 430-434
- IR(s), *see* Insulin receptor(s); Insulin receptor gene
- IRH (idiopathic reactive hypoglycemia), nonoxidative metabolism of postprandial glucose in, 606-610
- IRI, *see* Immunoreactive insulin
- IRS, *see* Insulin resistance syndrome, stress and
- Ischemia, hyperglycemia effects on myocardial interstitial glucose and glucose uptake during, 542-549
- Islets, *see* Pancreatic islet(s); Pancreatic islet cell antibodies
- Isoleucine, MH 7777 effects on concentrations of, 851
- N[(*trans*-4-Isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), somatostatin and insulin secretion due to, 184-189
- Isotope dilution technique, constant SA technique versus, in estimation of insulin effects on HGP, 82-91
- IV, *see* entries beginning with term: Intravenous

- Japanese non-insulin-dependent diabetes mellitus (NIDDM) subjects, polymorphism in  
 amino acid polymorphism in HSL, 862-864  
 polymorphism of ACE and AGN genes in nephropathic NIDDM subjects, 218-222
- Jejunal mucosa, ODC activity in, after food intake, lingual factors in, 1284-1287
- K (potassium)  
 erythrocyte, in hyperthyroidism, 709  
 intrarenal glucagon action on arterial, 385  
 plasma, *see* Plasma K  
 serum, oral albuterol effects on, 714, 716  
 total body, *see* Total body K  
*see also*  $K_g$ ;  $K^+$  channel opener;  $Na^+/K^+$  ATP;  $Na^+/K^+$  ATPase; Urinary excretion, K
- $K_g$  in beta-thalassemia major, 655
- $K^+$  (potassium) channel opener, ATP-sensitive to, inhibition of A-4166-induced insulin and somatostatin release and, 185-186
- KBs, *see* Ketone bodies
- Ketoacidosis, diabetic, relationship between AT production of  $PGI_2$ ,  $PGE_2$ , and 6-keto- $PGF_{1\alpha}$ , plasma insulin level, and BP in DM, normal adult subjects, and in subjects with, 691-698
- Ketone(s), total, relationship between plasma insulin, BP, and levels of, in normal, DM, and DKA subjects, 693
- Ketone bodies (KBs)  
 differential effects of pathophysiological versus physiological concentrations of plasma E and NE on hepatic portal blood flow and metabolism of, 1214-1220  
 effects of CHO and dietary fat ingestion during prolonged exercise on, 919
- 6-Keto-prostaglandin  $F_{1\alpha}$  ( $PGF_{1\alpha}$ ), relationship between AT production of  $PGI_2$ ,  $PGE_2$  and, BP in normal, diabetic, and DKA subjects, and plasma insulin level, 691-698
- Kidney, *see* Nonnephropathic insulin-dependent diabetes mellitus; Organ weight, kidney *entries beginning with terms*: Intrarenal, Renal and *element*: Nephro-
- Kinase  
 dominant negative effect of kinase-defective IR on IGF-I-stimulated signaling in fibroblasts, 1474-1482  
*see also* Protein kinase; Tyrosine kinase
- Kinetics  
 glucose, *see* Kinetics, glucose  
 glycerol, effects of strenuous exercise on, 357-361  
 insulin, during FSIGT, 600  
 lactate, during short exercise by pregnant women, 753-758  
 of RBC membrane SLC in nonnephropathic IDDM twins, 1203-1207  
 rectal proliferative, acarbose effects on, 1183, 1184  
 regional FFA, contributing to postabsorptive FFA flux in men and women, 662-666  
 substrate, of CHO ingestion and CHO loading during prolonged exercise, compared, 415-423  
 of sucrase inhibition by L-arabinose, 1370  
 tracer, muscle protein synthesis and degradation in anesthesia measured with, 1279-1283
- Kinetics, glucose  
 effects of parasympathetic denervation of liver and pancreas on, 987-991  
 during FSIGT, 600  
 in multiple trauma, 454  
 in NIDDM, gliclazide effects on, 1197  
 during short exercise by pregnant women, 753-758
- Lactate  
 arterial, *see* Arterial lactate  
 blood, and exercise with pivalic acid-induced carnitine deficiency, 1504  
 in familial leucine-sensitive hypoglycemia, glucose effects on, 958  
 and glucose cycling by hepatocytes, 104  
 hepatic and portal vein, stress hormone effects on, in conscious subjects, 580  
 hyperglycemia effects on, during ischemia, 545-546  
 intrarenal glucagon action on, 385, 386  
 kinetics of, during short exercise by pregnant women, 753-758  
 octreotide effects on, in IDDM, 214  
 plasma, and plasma C and FA synthesis measurement with deuterated water, 819, 820  
 splenocyte, MH 7777 effects on metabolism of, 852
- Lactic acid, blood, xylitol effects on, 1358
- LANPs (long-acting natriuretic peptides), circadian relationships between serum Ca, serum phosphate, and circulating, 1021-1028
- Lard, effects of, in hyperglycemia and obesity, 1540, 1541
- Laron syndrome, long-term IGF-I therapy effects on serum Lp(a) in, 1263-1266
- Lathosterol, serum lathosterol-to-cholesterol ratio is not elevated in glomerular proteinuria and not associated with improved hyperlipidemia in response to antiproteinuria therapy, 723-730
- LC/APCI-MS (liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization interface system), N-acetylcyclic cystathionine and cyclic cystathionine sulfoxide in cystathioninuria identified with, 1312-1316
- LDL(s), *see* Low-density lipoprotein(s)
- LDL-C, *see* Low-density lipoprotein-cholesterol
- Lean body mass, *see* Fat-free mass
- Lean subjects, *see* Non-obese subjects
- Left ventricular hypertrophy (LVH), hypertension with, BNPs during ergometric exercise by patients with, 1326-1329
- Leprechaunism, severe resistance to insulin and IGF-I in, due to two mutations of tyrosine kinase domain of insulin receptor gene, 1493-1500
- Leucine  
 familial hypoglycemia sensitive to, with concomitant hyperammonemia, 957-960  
 MH 7777 effects on concentrations of, 851
- Leukemia, T-cell, cachexia induced by, 645-651
- Leukocyte membrane fatty acids (FAs), effects of parenteral fish oil on leukotriene-synthesizing capacity and composition of, in postoperative trauma, 1208-1213
- Leukotriene (LT), effects of parenteral fish oil on leukotriene-synthesizing capacity in postoperative trauma, 1208-1213
- Leydig cells, OA inhibiting cholesteryl esterase and cholesterol utilization for T synthesis in, 293-299
- LH, *see* Luteinizing hormone
- LHRH (D-Trp-6-luteinizing hormone-releasing hormone; Triptorelin) for severely hirsute hyperandrogenic women, 25-27
- Lingual factors, effects of, on ODC activity in jejunal mucosa after feeding, 1284-1287
- Linoleic acid, *see* Safflower oil
- Lipase, *see* Hepatic lipase activity; Hormone-sensitive lipase; Lipoprotein lipase
- Lipid(s)  
 effects of, on DHEA in morbidly obese adolescents, 1011-1015  
 effects of omega-FAs and fenofibrate on hemorrheological parameters and, in FDL and FHTG, 1305-1311

Lipid(s) (*Continued*)

- lipid metabolic risk markers for CHD and blood pressure in non-obese premenopausal women of different racial origins, 328-333
- in NIDDM, vanadyl sulfate effects on metabolism of, 1130-1136
- oxidation of, effects of CHO ingestion on, 1239
- plasma, *see* Plasma lipids
- PP, effects of fasting on, in IDDM, 1036
- serum, *see* Serum lipids
- see also* Dietary fat; Dyslipidemia; Fatty acids; Hyperlipidemia; Lipid peroxidation; Normolipidemic men; Phospholipid(s) *entries beginning with elements: Adip-, Lip- and specific lipids*
- Lipid peroxidation
  - antioxidant effects of 4-hydroxystosterone and 17 $\alpha$ -dihydroequilin on, 411-414
  - in NIDDM Mexican-Americans and non-Hispanic whites, 876-881
- Lipogenesis, GH effects on uptake of, 39
- Lipolysis
  - in DM, DKA, and normal subjects, relationship between 6-keto-PGF<sub>1 $\alpha$</sub>  and PGE<sub>2</sub> production and, 694-695
  - GH effects on, 39
  - VS effects on, 1133
  - see also* Antilipolytic effects
- Lipolytic enzymes in CAD, 1377-1378
- Lipoprotein (Lp)
  - estrogen effects on concentrations of, 891-892
  - of myristate, palmitate, and stearate Lp in normolipidemic men, comparative metabolism of, 1109-1118
  - plasma, *see* Plasma lipoprotein
  - serum, *see* Serum lipoprotein(s)
  - size of, in IDDM, 1267-1272
  - see also* Apolipoprotein(s); High-density lipoprotein(s); Intermediate-density lipoprotein; Intermediate-density lipoprotein-cholesterol; Lipoprotein(a); Lipoprotein B-phospholipids; Lipoprotein lipase activity; Low-density lipoprotein(s)
- Lipoprotein (Lp) in NIDDM
  - postprandial Lp metabolism in normotriglyceridemic NIDDM, apo E polymorphism influence on, 63-71
  - size of, 1267-1272
- Lipoprotein(a) [Lp(a); high-density lipoprotein<sub>1</sub>]
  - cardiovascular fitness, body composition and, affecting fibrinolysis, 1427-1433
  - GH therapy effects on, *see* Lipoprotein(a), GH therapy effects on
  - in glomerular proteinuria, 726
  - in IDDM, *see* Lipoprotein(a) in IDDM
  - in morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA in, 1013
  - serum, long-term IGF-I therapy effects on, in Laron syndrome, 1263-1266
  - size of, in NIDDM, 1269
  - and urinary excretion of E<sub>2</sub> and T, 281, 282
- Lipoprotein(a) [Lp(a); high-density lipoprotein<sub>1</sub>], GH therapy effects on, 1017
  - in FH, 1415-1421
- Lipoprotein(a) [Lp(a); high-density lipoprotein<sub>1</sub>] in IDDM
  - progression of microalbuminuria and, 1103, 1104
  - size of, 1269
- Lipoprotein B (LpB)-phospholipids (PLs), choline-containing, intraperitoneal insulin effects on, in IDDM, 430-434
- Lipoprotein lipase (LPL)
  - in CAD, 1378
  - milk, VLDLs in uremia as poor substrates for, 686-690
  - see also* Lipoprotein lipase activity

- Lipoprotein lipase (LPL) activity
  - effects of GH therapy for GH-deficient men on, 370-377
  - postheparin, relationship of plasma TGs, HDL-C, and apo B to, dependent on apo E polymorphism, 261-267
- Liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization interface system (LC/APCI-MS), *N*-acetylcyclic cystathionine and cyclic cystathionine sulfoxide in cystathioninuria identified with, 1312-1316
- Lithium, *see* Erythrocyte membrane sodium-lithium countertransport
- Liver
  - effects of parasympathetic denervation of, on glucose kinetics, 987-991
  - in elderly subjects, <sup>31</sup>P magnetic resonance spectroscopy to assess effects of nutritional status and inflammatory state of, 1059-1061
  - functional mass of, plasma flow and, in acromegaly before and after long-term octreotide therapy, 109-113
  - weight of, in nephrotic syndrome, 823, 824
  - see also entries beginning with element: Hepat-*
- Long-acting natriuretic peptides (LANPs), circadian relationships between serum Ca, serum phosphate, and circulating, 1021-1028
- Long-chain fatty acids (FAs), metabolism of, 166
- Long-term effects
  - of 5-year overfeeding in identical twins, 1042-1050
  - of full-fat or reduced-fat diet, on EE and substrate oxidation in non-obese subjects, 1004-1010
  - of GnRH in severely hirsute hyperandrogenic women, 25-27
- Long-term exercise, effects of, on prevention of NIDDM, 475-480
- Long-term sucrose (S)-rich diet, effects of, on endocrine pancreas in normal subjects, 1527-1532
- Long-term therapy
  - with ACX potentiating GH response to GHRH by decreasing serum FFAs in obese men, 594-597
  - with IGF-I, effects of, on serum Lp(a) in Laron syndrome, 1263-1266
  - with octreotide, functional liver mass and plasma flow in acromegaly before and after, 109-113
  - with trandolapril and verapamil, 537-539
- Lovastatin, effects of cholestyramine and, on plasma sterol levels in sitosterolemic homozygous girl and her sitosterolemic heterozygous father, 673-679
- Low-density lipoprotein(s) (LDLs;  $\beta$ -lipoproteins)
  - in hyperlipidemia, 894
  - low-fat diet effects on, in sitosterolemia, 674
  - of normolipidemic men, myristate, palmitate, and stearate metabolism and, 1109
  - oxidation of, *see* Oxidation, LDL
  - peroxidation of, antioxidant effects of 4-hydroxystosterone and 17 $\alpha$ -dihydroequilin on, 411-414
  - relative effects of high SFA levels in meat, dairy products, and tropical oils on serum Lps and degradation of, by mononuclear cells in men, 550-558
  - size of, in NIDDM, 1267-1272
  - see also* Familial dysbetalipoproteinemia; Familial hypobetalipoproteinemia; Low-density lipoprotein-cholesterol; Low-density lipoprotein receptor(s) in hyperlipidemia; Low-density lipoprotein receptor gene; Very-low-density lipoprotein(s)
- Low-density lipoprotein(s) (LDLs;  $\beta$ -lipoproteins) in IDDM
  - progression of microalbuminuria and, 1103, 1104
  - size of, 1267-1272

- Low-density lipoprotein-cholesterol (LDL-C)  
 AAS abuse effects on, 845  
 in CAD, 1378-1380  
 in CHD, *see* Low-density lipoprotein-cholesterol in CHD  
 exercise and, *see* Low-density lipoprotein-cholesterol, exercise and  
 and  
 fasting plasma, and hyperinsulinemia associated with VPCs, 1250-1252  
 in FHLB, 1297, 1302  
 in FHTG and FDL, 1308  
 fibrinolytic potential and, 1429  
 GH therapy effects on, *see* Low-density lipoprotein-cholesterol, GH therapy effects on  
 in glomerular proteinuria, 726  
 in high SFA diet, 553, 555  
 hydrogenated fat diet effects on, 244  
 in hyperlipidemia, 892  
 in IDDM, *see* Low-density lipoprotein-cholesterol in IDDM  
 and insulin effects on levels of circulating vitamin E, 999, 1000  
 nandrolone decanoate effects on concentration of, 465  
 in NIDDM, *see* Low-density lipoprotein-cholesterol in NIDDM  
 in obese adolescents, *see* Low-density lipoprotein-cholesterol in obese adolescents  
 oral albuterol effects on, 714  
 palmitic and stearic acid effects on, 146  
 pancreas transplantation effects on, 858  
 plasma, *see* Plasma low-density lipoprotein-cholesterol  
 and relationship of plasma TGs, HDL-C, and apo B to postheparin LPL activity, 263  
 serum, *see* Serum low-density lipoprotein-cholesterol  
 in uremia, 688, 689  
 and urinary excretion of E<sub>2</sub> and T, 281-283  
 in visceral obesity-insulin resistance-dyslipidemic syndrome, 885, 886  
*see also* Very-low-density lipoprotein-cholesterol
- Low-density lipoprotein-cholesterol (LDL-C), exercise and diet effects on glucose homeostasis and serum lipid levels with exercise, 436  
 exercise effects on concentrations of serum TC and LDL-C related to apo E phenotype in boys and young adults, 797-803
- Low-density lipoprotein-cholesterol (LDL-C), GH therapy effects on  
 in FH, 1415-1421  
 in GH-deficient men, 372  
 and peripheral conversion of T<sub>4</sub> to T<sub>3</sub>, 1017
- Low-density lipoprotein-cholesterol (LDL-C) in CHD  
 effects of high- versus low-glycemic CHO on, 671  
 metabolic risk markers for CHD, BP, and LDL-C in non-obese premenopausal women, 330
- Low-density lipoprotein-cholesterol (LDL-C) in IDDM  
 intraperitoneal insulin effects on, 432  
 Lp, apo, and LDL size and, 1268, 1269  
 in nonnephropathic IDDM, RBC membrane SLC kinetics and, 1204
- Low-density lipoprotein-cholesterol (LDL-C) in NIDDM  
 Lp, apo, and LDL size and, 1268, 1269  
 in normotriglyceridemic NIDDM, 64, 67  
 plasma, role of AT loss in exercise-induced improvement in, 1384
- Low-density lipoprotein-cholesterol (LDL-C) in obese adolescents, 235  
 insulin-resistant, 909-911  
 in morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA in, 1013
- Low-density lipoprotein (LDL) receptor(s) in hyperlipidemia  
 adenoviral delivery of, HDLs and, 1447-1457  
 estrogen increasing apo B-independent catabolism of, 889-896
- Low-density lipoprotein (LDL) receptor gene, GH and normalization of expression of, in hypothyroidism, 680-686
- Low-fat diet  
 effects of, on EE and substrate oxidation in healthy non-obese subjects, 1004-1010  
 effects of, on plasma sterol level in sitosterolemia, 674
- Low-glycemic carbohydrates (CHOs), effects of high- versus, on insulin and glucose response in CHD, 669-672
- Low-nicotine cigarette smoking, high- versus, impact of, on REE, 923-926
- Loxiglumide, effects of, on CCK, 198
- Lp, *see* Lipoprotein
- Lp(a), *see* Lipoprotein(a)
- LpB (lipoprotein B)-PLs (phospholipids), choline-containing, intraperitoneal insulin effects on, in IDDM, 430-434
- LPC (lysophosphatidylcholine), expression and production of MCP-1 mRNA stimulated by, in vascular endothelial cells, 559-564
- LPL, *see* Lipoprotein lipase
- LT (leukotriene), effects of parenteral fish oil on leukotriene-synthesizing capacity in postoperative trauma, 1208-1213
- Lungs  
 of male and female subjects, interaction of antioxidant defense system of, with alcohol, Cu, and dietary CHOs, 49-56  
 pulmonary effects of oral albuterol, 713-714
- Luteinizing hormone (LH)  
 in Bardet-Biedel syndrome children, 1232, 1233  
 ET-1 impact on basal and stimulated concentrations of, in men with and without nifedipine pretreatment, 658-661  
 in SCI women, 718-722  
 serum, *see* Serum luteinizing hormone  
*see also* Luteinizing hormone in hirsute women
- Luteinizing hormone (LH) in hirsute women  
 BMD and, 516  
 GnRH effects on, in severely hirsute hyperandrogenic women, 25  
 in obese hirsute women, 72-75
- Luteinizing hormone-releasing hormone (LHRH) for severely hirsute hyperandrogenic women, 25-27
- LVH (left ventricular hypertrophy), hypertension with, BNPs during ergometric exercise by patients with, 1326-1329
- Lymphocytes, stress hormone effects on protein synthesis in, in normal adult subjects, 1388-1394
- Lysine, MH 7777 effects on concentrations of, 851
- Lysophosphatidylcholine (LPC), expression and production of MCP-1 mRNA stimulated by, in vascular endothelial cells, 559-564
- β (beta)<sub>2</sub>-M, *see* β<sub>2</sub>-Microglobulin
- Macrophages  
 activation of NADPH oxidase in LDL oxidation mediated by, 1069-1079  
 response of, to CSF-1 in hyperglycemia, 1125-1129
- Macrovascular disease, hyperhomocysteinemia following methionine load in NIDDM and, 133-135
- Magnesium (Mg)  
 glucose metabolism in adipocytes and deficiency in, 838-843  
 serum, oral albuterol effects on, 714, 716
- <sup>31</sup>P Magnetic resonance spectroscopy to assess nutritional status and inflammatory state effects on liver of elderly subjects, 1059-1061

## Male subjects

- interactions of lung antioxidant defense system with alcohol, Cu, and dietary CHOs, 49-56
- pubertal, androgen regulation of GHBP in, 1521-1526  
*see also* Boys; Men
- Malnutrition, protein and TNF as determinants of plasma concentrations of IGF-1, albumin, and their hepatic mRNAs in, 1273-1276
- Malondialdehyde (MDA), level of cICAM-1, HbA<sub>1c</sub> and, in NIDDM, oxidative stress and, 498-501
- Malonyl coenzyme A (CoA) in obese salt-sensitive subjects, pioglitazone effects on, 519-525
- Mannitol, effects of, on GFR, 1349
- MAP (mitogen-activated protein) kinase, IGF-I-stimulated activity of, 1479
- Mass isotopomer distribution analysis (MIDA) of glucose with [2-<sup>13</sup>]glycerol, 897-901
- Mass spectrometry with atmospheric pressure chemical ionization interface system, liquid chromatography-, *N*-acetylcystathionine and cyclic cystathionine sulfoxide in cystathioninuria identified with, 1312-1316
- Maternally inherited diabetes and deafness (MIDD), insulin resistance associated with, 526-531
- Mauritian subjects, nondiabetic Indian, Creole, and Chinese, relationship of insulin resistance to weight gain in, 627-633
- Maximal exercise, and pivalic acid-induced carnitine deficiency, 1502
- MBHA (medial basal hypothalamic ablation), effects of, on EtOH-induced PRL release, 1332
- MBHD (medial basal hypothalamic deafferentation), effects of, on EtOH-induced PRL release, 1331-1332
- MCP-1 (monocyte chemoattractant protein-1) mRNA (messenger ribonucleic acid), LPC stimulating expression and production of, in vascular endothelial cells, 559-564
- MCTs, *see* Medium-chain triglycerides
- MDA (malondialdehyde), level of cICAM-1, HbA<sub>1c</sub> and, in NIDDM, oxidative stress and, 498-501
- Meat, relative effects of high SFA levels in dairy products, tropical oils and, on serum Lps and degradation of LDLs by mononuclear cells in men, 550-558
- Medial basal hypothalamic ablation (MBHA), effects of, on EtOH-induced PRL release, 1332
- Medial basal hypothalamic deafferentation (MBHD), effects of, on EtOH-induced PRL release, 1331-1332
- Medium-chain triglycerides (MCTs)  
dicarboxylic aciduria due to, differentiated from that due to abnormal FA oxidation and fasting in children, 162-167  
effects of CHOs and supplementation with, on CHO metabolism during prolonged exercise, 915-921
- Men  
Chinese, urinary excretion of T and E<sub>2</sub> in, serum Lp concentrations and, 279-284  
ET-1 impact on basal and stimulated concentrations of LH, FSH, TSH, GH, ACTH, and PRL in, with and without nifedipine pretreatment, 658-661  
exercising, *see* Exercise; Older exercising men  
GH therapy for, *see* Growth hormone, effects of therapy with, for men  
healthy Swedish and Indian, CT-determined body composition of, in relation to CV risk factors in, 634-644  
HIV-infected, anterior pituitary-and pituitary-dependent target organ function in, 738-746  
normolipidemic, Lp metabolism of myristate, palmitate, and stearate in, 1109-1118  
obese, *see* Men, obese  
older, *see* Older men

Men (*Continued*)

- oral albuterol effects on serum lipids and CHO metabolism in, 712-717
- plasma HDL-C as correlate of visceral obesity-insulin resistance-dyslipidemic syndrome in, 882-888
- regional FFA kinetics contributing to postabsorptive FFA flux in, 662-666
- relative effects of high SFA levels in meat, dairy products, and tropical oils on serum Lps and LDL degradation by mononuclear cells in, 550-558
- young, *see* Young adults; Young men  
*see also* Father; Sex and specific conditions
- Men, obese  
ACX potentiating GH response to GHRH by decreasing serum FFAs in, 594-597  
nondiabetic, CPIR in, 168-173  
*see also* Obesity
- Menstrual history  
of young hirsute women, current bone mineral density and, 515-518  
*see also* Postmenopausal subjects; Premenopausal women
- Mental stress, experimentally induced, autonomically mediated physiological responses to, in adolescent boys, IRS and, 614-621
- Mesangial cells, posttranscriptional effects of glucose on proteoglycan mRNA expression in, 1136-1145
- Messenger ribonucleic acid, *see* mRNA
- Metabolic parameters  
HDL relation to, and severity of CAD, 1375-1382  
*see also* specific metabolic parameters
- Metabolic rate, *see* Resting metabolic rate
- Metabolic risk factors  
abdominal AT, race and, 1119-1124  
for CHD, and blood pressure in non-obese premenopausal women of different racial origins, lipid and CHO as markers for, 328-333  
*see also* specific risk factors
- Met-enkephalin, plasma, in IDDM and NIDDM, autonomic neuropathy and, 1065-1068
- Metformin for fructose-hypertensive subjects, effects of, on vascular reactivity, 1053-1055
- Methionine  
hyperhomocysteinemia following load with, in NIDDM and macrovascular disease, 133-135  
MH 7777 effects on concentrations of, 851
- Mexican-Americans, NHWs compared with  
on gastric emptying of beer, 1174-1178  
on plasma oxidizability, 876-881
- Mg, *see* Magnesium
- MH 7777 (Morris hepatoma 7777), reduced immune function and reduced splenocyte metabolism in subjects implanted with, 848-855
- MI (myocardial infarction) in NIDDM Mexican-Americans and non-Hispanic whites, 878-879
- Microalbuminuria  
in IDDM, apo B as predictor of progression of, 1101-1107  
in NIDDM, cardiovascular risk factors and RBC membrane SLC and, 963
- β<sub>2</sub> (βa<sub>2</sub>)-Microglobulin (β<sub>2</sub>M)  
serum, in NIDDM with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783  
urinary excretion of, in infancy, 510-514
- MIDA (mass isotopomer distribution analysis) of glucose with [2-<sup>13</sup>]glycerol, 897-901

- MIDD (maternally inherited diabetes and deafness), insulin resistance associated with, 526-531
- Milk lipoprotein lipase (LPL), VLDLs in uremia as poor substrates for, 686-690
- MIS (Mullerian inhibiting substance), reduced EGF receptor phosphorylation by, 190-195
- Mitochondria  
function of, in skeletal muscle of normal and STZ-DM subjects, effects of exercise on, 810-816  
liver and kidney, in nephrotic syndrome, 823, 824
- Mitogen-activated protein (MAP) kinase, IGF-I-stimulated activity of, 1479
- Mitogen responses to MH 7777, 851, 852
- Mld-STZ (multiple low-dose streptozotocin), L-NMMA effects on mononuclear splenocytes and NO generation with, 940-946
- MNCV, *see* Motor nerve conduction velocity
- Moderate hypercholesterolemia, dietary hydrogenated fat effects on C synthesis and LDL oxidation in, 241-247
- Moderately atherogenic diet, nandrolone decanoate effects on plasma lipids and coronary arteries of female subjects on, 463-468
- Monocyte chemoattractant protein-1 (MCP-1) mRNA (messenger ribonucleic acid), LPC stimulating expression and production of, in vascular endothelial cells, 559-564
- L-N<sup>G</sup>-Monomethyl-arginine (L-NMMA), effects of, on mononuclear splenocytes and NO generation with mld-STZ, 940-946
- Mononuclear cells, relative effects of high SFA levels in meat, dairy products, and tropical oils on serum Lps and LDL degradation by, in men, 550-558
- Mononuclear splenocytes (MSs), L-NMMA effects on NO generation and, with mld-STZ, 940-946
- Monophosphate, *see* AMP
- Monosodium glutamate (MSG), ratio of urinary excretion of C-peptides to, in subjects at high risk for IDDM, 874, 875
- Monounsaturated fatty acids (MUFAs)  
in hydrogenated fat diet, 242  
and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 877  
relationship between hyperinsulinemia and, 224-226
- Morbid obesity  
adolescents with, effects of weight, body composition, lipids, and insulin resistance on DHEA in, 1011-1015  
in PWS, 1514-1520
- Morphology, changes in endocrine pancreas, due to long-term sucrose-rich diet in normal subjects, 1527-1532
- Morphometry  
of nerves, tolrestat effects on, following crush injury in STZ-DM, 1191, 1193  
of pancreas, long-term sucrose-rich diet and, 1530
- Morris hepatoma 7777 (MH 7777), reduced immune function and reduced splenocyte metabolism in subjects implanted with, 848-855
- Motor nerve conduction velocity (MNCV)  
Na<sup>+</sup>/K<sup>+</sup> ATPase and, *see* Na<sup>+</sup>/K<sup>+</sup> ATPase, MNCV and  
of peripheral nerves in STZ-DM, sorbinil and ALC effects on, 902-907  
tolrestat effects on, following crush injury in STZ-DM, 1189-1192
- mRNA (messenger ribonucleic acid)  
FBPase, in obese NIDDM subjects, 624, 625  
GLUT1 and GLUT3, in peripheral nerve, 1468  
hepatic, *see* Hepatic mRNA  
MCP-1 monocyte, LPC stimulating expression and production of, in vascular endothelial cells, 559-564  
mRNA (messenger ribonucleic acid) (*Continued*)  
proteoglycan, posttranscriptional effects of glucose on expression of, in mesangial cells, 1136-1145  
RA receptor, 302-303  
MS(s) (mononuclear splenocytes), L-NMMA effects on NO generation and, with mld-STZ, 940-946  
MSG (monosodium glutamate), ratio of urinary excretion of C-peptides to, in subjects at high risk for IDDM, 874, 875  
M16209 [1-(bromobenzo[b]furan-2-ylsulfonil)hydantoin], effects of, on insulin sensitivity, 1095-1100  
Mucosa, intestinal  
jejunal, ODC activity in, after food intake, lingual factors in, 1284-1287  
of small intestine, endotoxemia and sepsis effects on polyamine metabolism in, 28-33  
MUFAs, *see* Monounsaturated fatty acids  
Mullerian inhibiting substance (MIS), reduced EGF receptor phosphorylation by, 190-195  
Multiple cardiovascular (CV) risk factors, adolescent obesity associated with adult obesity and, 235-240  
Multiple low-dose streptozotocin (mld-STZ) subjects, L-NMMA effects on mononuclear splenocytes and NO generation in, 940-946  
Multiple trauma subjects on TPN, effects of GH therapy on hyperglycemia in, 450-456  
Muscarinic receptor antagonist, effects of, on CCK, 198  
Muscle  
cells of vascular smooth, nonenzymatic glycation of fibronectin impairing adhesive and proliferative properties of, 285-292  
effects of exercising with pivalic acid-induced deficiency in muscle carnitine, 1502  
effects of GH administration and resistance exercise by older men on strength of, 256  
skeletal, *see* Skeletal muscle  
*see also* Muscle action potentials; Muscle cells; Muscle protein; Myocytes and entries beginning with terms: Intramuscular, Myocardial  
Muscle action potentials, compound, tolrestat effects on, following nerve crush injury in STZ-DM, 1189-1195  
Muscle cells, basal and insulin-stimulated glucose transport in, TNF- $\alpha$  effects on, 1089-1094  
Muscle protein  
skeletal, stress hormone effects on synthesis of, in albuminuria, 1388-1394  
synthesis and degradation of, in anesthesia, tracer kinetics in measurement of, 1279-1283  
Mutations of tyrosine kinase domain of insulin receptor gene, severe resistance to insulin and IGF-I due to two, in leprechaunism, 1493-1500  
Myocardial 1,2-diacylglycerol (1,2-DAG), insulin effects on 774-781  
Myocardial infarction (MI), and plasma oxidizability in NIDDM Mexican-Americans and NHWs, 878, 879  
Myocardial interstitial glucose, hyperglycemia effects on glucose uptake and, during ischemia, 542-549  
Myocytes, vascular, activity and phosphorylation of Na<sup>+</sup>/H<sup>+</sup> exchanger in, in spontaneous hypertension, glucose effects on, 114-119  
*myo*-inositol  
L-fucose effects on, 231-232  
in STZ-DM, *see: myo*-inositol in STZ-DM  
*myo*-inositol in STZ-DM  
ALC deficiency and altered Na<sup>+</sup>/K<sup>+</sup> ATPase activity, MNCV, and nerve content of, 865-871

- myo*-inositol in STZ-DM (*Continued*)  
 effects of supplementation with sorbinil and, on polyphosphoinositide turnover in peripheral nerves of STZ-DM subjects, 320-327
- Myristate, Lp metabolism of, in normolipidemic men, 1109-1118
- N (nitrogen)  
 balance of, in multiple trauma, 453  
*see also* Urea nitrogen in NIDDM
- Na (sodium)  
 increased erythrocyte Ca uptake and influx of, in hyperthyroidism, erythrocyte membrane phospholipid level and, 707-711  
 obese subjects sensitive to, effects of pioglitazone on malonyl coenzyme A in, 519-525  
 renal handling of, intrarenal glucagon action on, 383-388  
*see also* Erythrocyte membrane sodium-lithium countertransport;  $\text{Na}^+/\text{H}^+$  exchanger;  $\text{Na}^+/\text{K}^+$  ATP;  $\text{Na}^+/\text{K}^+$  ATPase; Natriuretic peptides; Urinary excretion, Na
- $\text{Na}^+/\text{H}^+$  exchanger (NHE), glucose effects on activity and phosphorylation of, in vascular myocytes, 114-119
- $\text{Na}^+/\text{K}^+$  (sodium/potassium) ATP (adenosine triphosphate), concentration of, in erythrocytes of IDDM and NIDDM subjects, 927-934
- $\text{Na}^+/\text{K}^+$  (sodium/potassium) ATPase (adenosine triphosphatase) erythrocyte membrane, low activity of, in Northeast Thais, 804-810  
 turnover of erythrocyte, in IDDM and NIDDM, 927-934  
*see also*  $\text{Na}^+/\text{K}^+$  ATPase, MNVC and
- $\text{Na}^+/\text{K}^+$  (sodium/potassium) ATPase (adenosine triphosphatase), MNVC and  
 ALC deficiency and altered nerve *myo*-inositol content, MNCV, and activity of, in STZ-DM, 865-871  
 L-fucose and reduced MNCV, 229-234
- Na/Li (sodium-lithium) countertransport, *see* Erythrocyte membrane sodium-lithium countertransport
- NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, activation of, in macrophage-mediated oxidation of LDL, 1069-1079
- Nandrolone decanoate, effects of, on plasma lipids and coronary arteries in female subjects on moderately atherogenic diet, 463-468
- Natriuretic peptides  
 brain, during ergometric exercise by hypertensive patients with LVH, 1326-1329  
*see also* Atrial natriuretic peptides
- Natural killer (NK) cells, activity of, in MH 7777, 850-851
- NE, *see* Norepinephrine
- NEFAs, *see* Nonesterified fatty acids
- Negative effect, dominant, of kinase-defective IR on IGF-I-stimulated signaling in fibroblasts, 1474-1482
- Nephropathy in Japanese NIDDM subjects, polymorphism of ACE and AGN genes with, 218-222
- Nephrotic syndrome, glycerophospholipids in, 822-826
- Nerve(s)  
 ALC deficiency in altered  $\text{Na}^+/\text{K}^+$  ATPase activity, MNCV, and *myo*-inositol content of, 865-871  
 tolrestat effects on regeneration of, in STZ-DM after crush injury, 1189-1195  
*see also* Peripheral nerves in STZ-DM, sorbinil effects on
- Nerve conduction velocity, *see* Motor nerve conduction velocity
- Nervous system, *see* Autonomic nervous system; Autonomically mediated physiological responses; Denervation; Motor nerve conduction velocity; Nerve(s); Neuropathy; Neurovascular effects; Peripheral nerves; Sympathetic nervous system
- Neuropathy, autonomic, plasma met-enkephalin in IDDM and NIDDM and, 1065-1068
- Neurovascular effects of STZ-DM, rapid reversal of, with aminoguanidine, 1147-1152
- Neutral sterols, fecal excretion of, in sitosterolemia, 675
- $\text{NH}_3$  (ammonia), splenocyte, MH 7777 effects on metabolism of, 853
- $\text{NH}_4$  (ammonium), familial leucine-sensitive hypoglycemia with concomitant hyperammonemia, 957-960
- NHE ( $\text{Na}^+/\text{H}^+$  exchanger), glucose effects on activity and phosphorylation of, in vascular myocytes, 114-119
- NHWs, *see* Mexican-Americans, NHWs compared with
- Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, activation of, in macrophage-mediated oxidation of LDL, 1069-1079
- Nicotine, *see* Smoking
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nifedipine, ET-1 impact on basal and stimulated concentrations of LH, FSH, TSH, GH, ACTH, and PRL in men with and without pretreatment with, 658-661
- Nitric oxide (NO), L-NMMA effects on mononuclear splenocytes and on generation of, with mld-STZ, 940-946
- Nitric oxide (NO) synthase, inhibition of, with aminoguanidine in rapid reversal of neurovascular effects of STZ-DM, 1147-1152
- Nitrogen, *see* N
- NK (natural killer) cells, activity of, in MH 7777, 850-851
- L-NMMA (L- $N^G$ -monomethyl-arginine), effects of, on mononuclear splenocytes and NO generation with mld-STZ, 940-946
- NO, *see* Nitric oxide; Nitric oxide synthase
- Nondiabetic subjects  
 Creole, Indian, and Chinese Mauritian, relationship of insulin resistance to weight gain in, 627-633  
 hyperinsulinemic, voglibose effects on dyslipidemia and insulin sensitivity in, 731-737  
 intramuscular TGs and muscle insulin sensitivity in, 947-950  
 $\text{Na}^+/\text{K}^+$  ATPase turnover and  $\text{Na}^+/\text{K}^+$  ATP concentration in erythrocytes of, 927-934  
 obese, cephalic-phase insulin response in, 168-173  
 PP changes in HDL composition and subfraction distribution in, 1034-1041  
 relationship between plasma PL SFAs and hyperinsulinemia in, 223-228
- Nonenzymatic glycation of fibronectin impairing adhesive and proliferative properties of vascular smooth muscle cells, 285-292
- Nonesterified fatty acids (NEFAs)  
 CHO ingestion effects on, 1236-1238  
 effects of plasma E and NE concentrations on, 1216-1218  
 fasting, and intramuscular TG content, 949  
 octreotide effects on, in IDDM, 214
- Nonhirsute women  
 impact of obesity on hormonal parameters in, 72-75  
 young, current bone mineral density and menstrual history of, 515-518
- Non-Hispanic whites, *see* Mexican-Americans, NHWs compared with
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus)  
 changes in PL composition of PMN leukocyte, erythrocyte, and platelet membranes in, 57-62  
 exercise and, *see* Exercise in NIDDM  
 glizalide potentiating suppression of HGP in, 1196-1202  
 glucose in, *see* Glucose in NIDDM

- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus) (*Continued*)
- HbA<sub>1c</sub> in, *see* HbA<sub>1c</sub> in NIDDM
  - hyperhomocysteinemia following methionine load in macrovascular disease and, 133-135
  - insulin in, *see* Insulin in NIDDM
  - in Japanese subjects, *see* Japanese non-insulin-dependent diabetes mellitus subjects, polymorphism in
  - lack of relationship between urinary albumin excretion and insulin resistance in, 1062-1064
  - Lp, apo, and LDL size in, 1267-1272
  - normotriglyceridemic, influence of apo E polymorphism on postprandial Lp metabolism in, 63-71
  - obesity with, *see* Non-insulin-dependent diabetes mellitus, obesity and
  - plasma met-enkephalin in, autonomic neuropathy and, 1065-1068
  - plasma oxidizability in Mexican-Americans and non-Hispanic whites with, 876-881
  - PWS and, 1514-1520
  - RBC membrane SLC and cardiovascular risk factors in, 961-965
  - RBC Na<sup>+</sup>/K<sup>+</sup> ATPase turnover and Na<sup>+</sup>/K<sup>+</sup> ATP concentration in, 927-934
  - spontaneous, function of alpha cells with partial pancreatectomy as model of, 1360-1367
  - urinary excretion in, *see* Urinary excretion in NIDDM
  - vanadyl sulfate effects of CHO metabolism in, 1130-1136
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes), obesity and
- CPIR in, 168-173
  - genetic factors and, 1288-1295
  - impaired regulation of hepatic FBPase in, 622-626
  - 24-hour pattern of HS in, 1342-1347
  - in women, relationship between glucose metabolism and thermogenesis with and without prior exercise in, 747-752
- Nonnephropathic insulin-dependent diabetes mellitus (IDDM) twins, erythrocyte membrane Na/Li countertransport kinetics in 1203-1207
- Non-obese subjects
- DZ effects in, 334-341
  - effects of full-fat or reduced-fat diet on EE and substrate oxidation in, 1004-1010
  - IGT and pancreatic islet cell function in, 502-510
  - interstitial insulin in obese and, 951-956
  - urate changes in pubertal non-obese adolescent boys, 203-210
  - women, *see* Non-obese women
- Non-obese women
- ACX effects on GH response to GHRH alone or combined with arginine in, 342-350
  - premenopausal, of different racial origins, lipid and CHO metabolic risk markers for CHD and BP in, 328-333
- Nonoxidative metabolism, postprandial glucose, in idiopathic reactive hypoglycemia, 606-610
- Norepinephrine (NE)
- in multiple trauma, 453
  - and O<sub>2</sub> consumption in heart, hepatomesenteric bed, and bed of young and elderly men, 1487-1492
  - plasma, *see* Plasma norepinephrine
  - in stress hormone, *see* Stress hormone
  - turnover of, and SNS activity, 787-791
- Normal adult subjects
- ANPs in, *see* Normal adult subjects, ANPs in
  - CCK release stimulated by oral glucose in, 196-202
  - changes in PL composition of erythrocyte membrane, platelet membrane, and polymorphonuclear leukocyte membrane in, 57-62
- Normal adult subjects (*Continued*)
- effects of decreasing plasma FFAs by ACX on hepatic glucose metabolism in, 1408-1414
  - effects of long-term sucrose-rich diet on endocrine pancreas in, 1527-1532
  - exercise effects on mitochondrial function on skeletal muscle of, 810-816
  - hepatic insulin extraction and beta cell activity following dexamethasone administration in, 486-492
  - HSL polymorphism in, 862-864
  - insulin effects on glucose turnover in, 82-91
  - IV  $\gamma$ -glutamyl tyrosine effects on brain tyrosine and catecholamine concentrations in, 126-132
  - level of MDA, cICAM-1, and HbA<sub>1c</sub> in, oxidative stress and, 498-501
  - non-obese, effects of full-fat or reduced-fat diet on EE and substrate oxidation in, 1004-1010
  - nonoxidative metabolism of postprandial glucose in, 606-610
  - pentoxifylline and indomethacin modulating HGP in, 1458-1465
  - relationship between AT production of PGI<sub>2</sub>, PGE<sub>2</sub>, and 6-keto-PGF<sub>1 $\alpha$</sub> , plasma insulin level, and BP in DM, DKA and, 691-698
  - relationship between plasma PLs, apo B, and HDL-C to postheparin lipase activity dependent on apo E polymorphism in, 261-267
  - stress hormone effects on protein synthesis in skeletal muscle, albumin, and lymphocytes in, 1388-1394
  - see also* Men; Women
- Normal adult subjects, ANPs in
- circadian relationships between serum Ca, serum phosphate, and circulating ANPs in, 1021-1028
  - modulating circulating ET in, 315-319
- Normolipidemic men, Lp metabolism of myristate, palmitate, and stearate in, 1109-1118
- Normotension in NIDDM, cardiovascular risk factors and RBC membrane SLC and, 963
- Normotriglyceridemia, NIDDM with, influence of apo E polymorphism on postprandial Lp metabolism in, 63-71
- Northeast Thais, low activity of erythrocyte membrane Na<sup>+</sup>/K<sup>+</sup> ATPase in, 804-810
- Nuclear protein, total hepatic, starvation effects on, 971
- Nutrition, *see* Diet; Nutritional status
- Nutritional status, effects of inflammatory state and, on liver of elderly subjects, <sup>31</sup>P magnetic resonance spectroscopy to assess, 1059-1061
- O<sub>2</sub> (oxygen)
- consumption of, in heart, hepatomesenteric bed, and brain in young and elderly men, sympathetic nervous activity with, 1487-1492; *see also* VO<sub>2</sub>; VO<sub>2</sub>max, exercise and
  - intrarenal glucagon action on uptake of, 386-387
- OA (oleic acid; *cis*-9-octadecenoic acid), cholesteryl esterase and cholesterol utilization for T synthesis in Leydig cells inhibited by, 293-299
- Obesity
- antilipolytic effects of DZ in, 334-341
  - in Bardet-Biedel syndrome children, 1230-1234
  - genetic, editing of hepatic apo B RNA in, 1056-1058
  - GH response to GHRH in, *see* Acipimox, effects of, on GH response to GHRH in obesity
  - HDL-C and, in 10-year-old girls, race and, 469-474
  - HF diet-induced hyperglycemia and, effects of different oils on, 1539-1546
  - insulin in, *see* Insulin in obesity
  - morbid, *see* Morbid obesity



Obesity (*Continued*)

- NIDDM and, *see* Non-insulin-dependent diabetes mellitus, obesity and
- pioglitazone effects on malonyl coenzyme A in obese salt-sensitive subjects, 519-525
- visceral, *see* Visceral obesity
- see also* Adipose tissue; Adolescent obesity; Men, obese; Women, obese
- cis*-9-Octadecenoic acid (oleic acid), cholesteryl esterase and cholesterol utilization for T synthesis in Leydig cells inhibited by, 293-299
- Octanoate
- effects of, on pancreatic islet TGs and FA oxidation, 984, 985
- metabolism of, 165-166
- Octreotide therapy
- effects of, on glucose metabolism and insulin sensitivity in IDDM, 211-217
- long-term, functional liver mass and plasma flow in acromegaly before and after, 109-113
- ODC (ornithine decarboxylase), activity of, in jejunal mucosa after feeding, lingual factors in, 1284-1287
- OFS (oligofructose), effects of, on fructose impact on hepatic TAG metabolism, 1547-1550
- OGTT, *see* Oral glucose tolerance test
- $\beta$ -OHB, *see*  $\beta$ -Hydroxybutyric acid
- 3-OHB (3-hydroxybutyrate), octreotide effects on, in IDDM, 214
- 17-OHP (17-hydroxyprogesterone)
- GnRH effects in severely hirsute hyperandrogenic women on, 25
- in young hirsute women, 516
- Oil(s)
- effects of different, on HF diet-induced hyperglycemia and obesity, 1539-1546
- fish, *see*  $\omega$ -Fatty acids
- safflower, *see* Safflower oil
- tropical, relative effects of high SFA levels in meat, dairy products and, on serum Lps and degradation of LDLs by mononuclear cells in men, 550-558
- Older exercising men
- effects of GH administration and resistance exercise on insulin sensitivity and secretion during IVGTT in, 254-260
- serum T and SHBG level increased by exercise in older men, 935-939
- Older men
- exercising, *see* Older exercising men
- O<sub>2</sub> consumption in heart, hepatomesenteric bed, and brain of, sympathetic nervous activity with, 1487-1492
- Oleic acid (OA; *cis*-9-octadecenoic acid), cholesteryl esterase and cholesterol utilization for T synthesis in Leydig cells inhibited by, 293-299
- Oligofructose (OFS), effects of, on fructose impact on hepatic TAG metabolism, 1547-1550
- Omega ( $\omega$ )-fatty acids, *see*  $\omega$ -Fatty acids
- Opioids, response of endogenous, to exercise in IDDM, 137-142
- Oral albuterol, effects of, on serum lipids and carbohydrate metabolism in men, 712-717
- Oral glucose, CCK release stimulated by, in normal adult subjects and in NIDDM, 196-202
- Oral glucose tolerance test (OGTT)
- in CHD, effects of high- versus low-glycemic CHOs on, 669-672
- dexamethasone effects on, 486-492
- of DPIV-negative subjects, 1336
- effects of parasympathetic denervation of liver and pancreas on, 987-991
- in GH-deficient men, effects of GH therapy on, 365-366
- glucose processing during, 598-605

Oral glucose tolerance test (OGTT) (*Continued*)

- in healthy Indian and Swedish men, 640
- in PWS, 1514-1520
- of subjects with hepatic and peripheral insulin resistance, 1243-1247
- in  $\beta$ -thalassemia major, 652-657
- urapidil effects on, in hypertension, 1226
- voglibose effects on, in nondiabetic hyperinsulinemia, 731-737
- of young women on contraceptive steroids, 834-835
- Organ function, anterior pituitary- and pituitary-dependent target, in HIV-infected men, 738-746
- Organ weight
- heart, *see* Organ weight, heart
- IBAT and spleen, and CL316,243 effects on SNS activity, 788
- kidney, *see* Organ weight, kidney
- liver, in nephrotic syndrome, 823, 824
- Organ weight, heart
- and CL316,243 effects on SNS activity, 788
- pioglitazone effects on, 521, 523
- in STZ-DM, troglitazone effects and, 1169
- Organ weight, kidney
- and effects of gonadectomy on development of hypertension, albuminuria, and STZ-DM, 159
- in nephrotic syndrome, 823
- Ornithine, MH 7777 effects on concentrations of, 851
- Ornithine decarboxylase (ODC), activity of, in jejunal mucosa after feeding, lingual factors in, 1284-1287
- Orotic acid, effects of *N*-carbamyl glutamate on urinary excretion of, in familial leucine-sensitive hypoglycemia, 959
- Osteoblastic cells, UMR106, effects of vitamin B<sub>12</sub> on alkaline phosphatase activity in, and proliferation of, 1443-1446
- Osteoprogenitor cells, bone marrow, effects of vitamin B<sub>12</sub> on alkaline phosphatase activity in, and proliferation of, 1443-1446
- Overall obesity, *see* Obesity
- Overfeeding, 5-year, body weight recovery by identical twins after, 1042-1050
- Overweight, *see* Obesity
- Oxidase, activation of NADPH, in macrophage-mediated oxidation of LDL, 1069-1079
- Oxidation
- CHO, *see* Oxidation, CHO
- citrate, in prostate epithelial cells, PRL regulating, 442-449
- decreased PP dietary fat, following high-fat meal in weight-reduced subjects, 174-178
- glucose, to CO<sub>2</sub> in adipocytes, effects of Mg deficiency on, 839-840
- LDL, *see* Oxidation, LDL
- lipid, *see* Oxidation, lipid
- protein, *see* Oxidation, protein
- substrate, effects of full- or reduced-fat diet on, in nonobese subjects, 1004-1010
- see also* Oxidation, FA; Oxidative stress; Oxidizability
- Oxidation, CHO
- CHO ingestion and, 1238-1239
- theophylline effects during exercise and, 1156
- Oxidation, FA
- abnormal, dicarboxylic aciduria due to MCTs differentiated from that due to fasting and, in children, 162-167
- effects of, on glucose metabolism associated with FA effects on glucose-related beta-cell function, 981-986
- FFA, and reversal of skeletal muscle glucose transport impaired by dexamethasone, 92-100
- theophylline effects on, during exercise and, 1156

- Oxidation, LDL  
 dietary hydrogenated fat effects on, in moderate hypercholesterolemia, 241-247  
 macrophage-mediated, NADPH oxidase activation in, 1069-1079
- Oxidation, lipid  
 CHO ingestion and, 1239  
*see also* Lipid peroxidation
- Oxidation, protein  
 in HD and renal transplantation, 1319-1322  
 in IRH, 608
- Oxidative stress, effects of, on level of MDA, HbA<sub>1c</sub>, and cICAM-1 in NIDDM, 498-501
- Oxidizability  
 plasma, in NIDDM Mexican-Americans and non-Hispanic whites, 876-881  
*see also* Oxidation
- Oxygen, *see* O<sub>2</sub>
- P<sub>2</sub> (biphosphate), fructose-2,6-, and regulation of hepatic FBPase in obese NIDDM subjects, 622-626
- PAF-AH (platelet-activating factor-acetylhydrolase) in nephrotic syndrome, 823, 825-826
- PAI (plasminogen activator inhibitor), urapidil effects on, in hypertension, 1223
- PAI-1, *see* Plasminogen activator inhibitor-1
- Palmitate  
 effects of, on pancreatic islet TGs and FA oxidation, 984, 985  
 metabolism of Lp of, in normolipidemic men, 1109-1118  
 plasma, and plasma C and plasma FA synthesis measurement with <sup>2</sup>H<sub>2</sub>O<sub>2</sub> to determine number of incorporated deuterium atoms, 818, 820  
 retinyl, 17 $\beta$ -estradiol effects on, in postmenopausal women, 829
- Palmitic acid, effects of stearic acid and, on serum lipids, Lps, and plasma CETP activity in young women, 143-149
- Palmitoyltransferase-1, carnitine, OFS effects on, 1548
- Pancreas  
 effects of long-term sucrose-rich diet on endocrine, in normal adult subjects, 1527-1532  
 effects of parasympathetic denervation of, on glucose kinetics, 987-991  
 effects of transplantation of, on plasma Lp distribution and composition, 856-861  
*see also* entries beginning with element: Pancreat-
- Pancreatectomy, partial, alpha cell function with, as model of spontaneous NIDDM, 1360-1367
- Pancreatic islet(s)  
 desensitized by exposure to high glucose or carbachol, GLP-1 stimulating insulin secretion but not phosphoinositide hydrolysis from, 273-278  
 dysfunctional, in obese women with IGT, 502-510  
 paracrine action of corticotropin-like peptides derived from, on regulation of insulin release, 565-570  
 RA receptor transcripts and effects of RA and ROH on glucagon secretion in glucagon-secreting cell lines and, 300-305  
*see also* Alpha cells; Beta cells; Pancreatic islet cell antibodies
- Pancreatic islet cell antibodies (Abs), characteristics of subjects positive for, who progressed to IDDM, 310
- PAP (phosphatidate phosphohydrolase), OFS effects on, 1548
- Paracrine action of pancreatic islet-derived corticotropin-like peptides on regulation of insulin release, 565-570
- Paranodal expression of GLUT1 and GLUT3 in peripheral nerve, 1466-1473
- Parasympathetic denervation of liver and pancreas, effects of, on glucose kinetics, 987-991
- Parenteral nutrition, *see* Total parenteral nutrition
- Partial pancreatectomy, function of pancreatic alpha cells in, as model of spontaneous NIDDM, 1360-1367
- Partial thromboplastin time (PTT), activated, in hypercholesterolemic thrombophilia, 967, 968
- Pase (biphosphatase), fructose-1,6-, impaired regulation of hepatic, in obese NIDDM subjects, 622-626
- Pathophysiological concentrations of plasma E and NE, differential effects of physiological versus, on ketone body metabolism and hepatic portal blood flow, 1214-1220
- PCOS (polycystic ovarian syndrome), hormonal parameters in, 72-75
- PCT (portal-caval transposition), hyperinsulinemia and insulin resistance with, 120-125
- Pentoxifylline, indomethacin and, modulating HGP in healthy subjects, 1458-1465
- Peptidase, enteroinsular axis in DPIV-negative subjects, 1335-1341
- Peptides  
 paracrine action of pancreatic islet-derived corticotropin-like, on regulation of insulin release, 565-570  
*see also* C-peptides; Natriuretic peptides; Polypeptides *entries beginning with terms: Glucagon-like peptide and specific peptides*
- Peripheral blood lymphocytes, stress hormone infusion on, 1393
- Peripheral conversion of T<sub>4</sub> to T<sub>3</sub>, GH effects on serum lipids and Lps and increased, 1016-1020
- Peripheral insulin delivery, portal delivery compared with, in handling of portally delivered glucose, 150-154
- Peripheral insulin resistance, relationship between hepatic, and PAI-1 in Pima Indians, 1243-1247
- Peripheral nerves  
 paranodal expression of GLUT1 and GLUT3 in, 1466-1473  
*see also* Peripheral nerves in STZ-DM, sorbinil effects on
- Peripheral nerves in STZ-DM, sorbinil effects on  
 sorbinil and ALC effects on structure, chemistry, and function of, 902-907  
 sorbinil and *myo*-inositol supplementation effects on turnover of polyphosphoinositide in, 320-327
- Peroxidation, *see* Lipid peroxidation
- PG, *see* 6-Keto-prostaglandin F<sub>1 $\alpha$</sub> ; Prostacyclin; Prostaglandin E<sub>2</sub>; Prostaglandin F<sub>1</sub>
- pH  
 blood, effects of intrarenal glucagon action on, 385  
 colonic, acarbose effects on, 1179-1187
- Phenotype  
 apo E, varying effects of exercise on serum TC and LDL-C concentrations related to, in boys and young adults, 797-803  
 splenocyte, MH 7777 effects on progression of, 850
- Phenylalanine (Phe)  
 N[(*trans*-4-isopropylcyclohexyl)-carbonyl]-D-, somatostatin and insulin secretion due to, 184-189  
 MH 7777 effects on concentrations of, 851
- Phosphatase, cellular alkaline, vitamin B<sub>12</sub> effects on activity of, and on proliferation of bone marrow osteoprogenitor cells and UMR106 osteoblastic cells, 1443-1446
- Phosphate  
 serum, circadian relationships between circulating ANPs, serum Ca and, in healthy subjects, 1021-1028  
 urinary excretion of, in NIDDM with and without renal insufficiency, 782-786  
 xylitol effects on DHAP, GA3P, and inorganic plasma, 1356-1357

- Phosphate (*Continued*)  
*see also* ADP; AMP; ATP; Fructose-2,6-biphosphate; Fructose-6-phosphate; Glucose-6-phosphate; Glycerol-3-phosphate; NADPH oxidase
- Phosphohydrolase, phosphotidate, OFS effects on, 1548
- Phosphoinositide  
 effects of supplementation with sorbinil and *myo*-inositol on polyphosphoinositide turnover in peripheral nerves of STZ-DM subjects, 320-327  
 GLP-1 stimulating insulin secretion but not hydrolysis of, from pancreatic islets desensitized by exposure to high glucose or carbachol, 273-278
- Phospholipid(s) (PLs)  
 ethanolamine, in nephrotic syndrome, 823, 824  
 in IDDM, *see* Phospholipid(s) in IDDM  
 in NIDDM, and changes in composition of erythrocyte, platelet, and polymorphonuclear cell membrane, 57-62  
 in normolipidemic men, 1110, 1114  
 OFS effects on, 1548  
 pancreas transplantation effects on, 859  
 in postoperative trauma, effects of parenteral fish oil on, 1210-1211  
 role of erythrocyte membrane level of, in increased erythrocyte Na influx and Ca uptake in hyperthyroidism, 707-711  
 in uremia, 688, 689  
*see also* Glycerophospholipids; Phospholipid saturated fatty acids
- Phospholipid(s) (PLs) in IDDM  
 and changes in composition in erythrocyte, platelet, and polymorphonuclear cell membrane, 57-62  
 choline-containing LpB-, intraperitoneal insulin effects on, 430-434
- Phospholipid (PL) saturated fatty acids (SFAs), plasma, relationship between hyperinsulinemia and, 223-228
- Phosphorylase, glycogen, hyperglycemia and alteration of glucagon ability to increase hepatic glucose production and activate, 481-485
- Phosphorylation  
 activity and, of  $\text{Na}^+/\text{H}^+$  exchanger in vascular myocytes in spontaneous hypertension, glucose effects on, 114-119  
 reduced EGF receptor, by MIS, 190-195  
*see also* Autophosphorylation, IR
- Phosphotidate phosphohydrolase (PAP), OFS effects on, 1548
- PHPT (primary hyperparathyroidism), decreased cortical and increased cancellous bone in, 76-81
- Physical activity, *see* Exercise
- Physical training, *see* Exercise
- Physiological concentrations of plasma E and NE, differential effects of pathophysiological versus, on ketone body metabolism and hepatic portal blood flow, 1214-1220
- Physiological responses, autonomically mediated, to experimentally induced mental stress in adolescent boys, IRS and, 614-621
- Pima Indians, relationship between hepatic and peripheral insulin resistance and PAI-1 in, 1243-1247
- Pioglitazone, effects of, on malonyl coenzyme A in obese salt-sensitive subjects, 519-525
- Pituitary  
 acromegalic adenomas of, PKC and cAMP responses, to GH secretion in, 206-210  
 target organ function dependent on, in HIV-infected men, 738-746  
*see also* Pituitary-ovarian-adrenal axis and entries beginning with terms: Hypothalamus-pituitary
- Pituitary-ovarian-adrenal axis in severely hirsute hyperandrogenic women, GnRH therapy effects on, 25-27
- Pivalic acid, carnitine deficiency induced by, exercise and, 1501-1507
- PK, *see* Protein kinase
- PKA (protein kinase A), glucagon synthesis and secretion induced by, inhibited by glucose, 347-350
- PKC, *see* Protein kinase C
- PL(s), *see* Phospholipid(s)
- Plasma, oxidizability of, in NIDDM Mexican-Americans and non-Hispanic whites, 876-881
- Plasma adrenomedullin (AM) in acute asthma, 1323-1325
- Plasma alanine, effects of *N*-carbamyl glutamate on, in familial leucine-sensitive hypoglycemia, 959
- Plasma albumin  
 in multiple trauma, 451  
 in nephrotic syndrome, 823  
 protein and TNF as determinants of concentrations of plasma IGF-1 and, and their hepatic mRNAs in malnourished subjects, 1273-1276
- Plasma amino acids  
 IV  $\gamma$ -glutamyl tyrosine effects on, 129, 130  
 MH 7777 effects on, 850, 851  
 radiation therapy effects on, 769
- Plasma apolipoprotein A-I (apo A-I)  
 17 $\beta$ -estradiol effects on, in postmenopausal women, 828  
 role of AT loss in exercise-induced improvement in, in NIDDM, 1384
- Plasma apolipoprotein B (apo B) in NIDDM, role of AT loss in exercise-induced improvement in, 1384
- Plasma cholesterol (C)  
 in CAD, 1378-1380  
 DZ effects on, 336  
 fasting plasma, overfeeding effects on, 1046  
 measurement of synthesis of, with deuterated water, incorporation of deuterium atoms determined with, 817-821  
 in nephrotic syndrome, 823  
 in NIDDM, role of AT loss in exercise-induced improvement in, 1384  
 total, exercise effects on, 1384
- Plasma cholesteryl ester transfer protein (CETP), effects of palmitic and stearic acids on serum lipids, Lps and, in young women, 143-149
- Plasma citrulline, effects of *N*-carbamyl glutamate on, in familial leucine-sensitive hypoglycemia, 959
- Plasma corticotropin (ACTH; adrenocorticotropin), level of, in men before and after stimulation with CRF following nifedipine and ET-1 treatment, 659
- Plasma cortisol, protein effects on levels of, 1485
- Plasma C-peptides (connecting peptide)  
 fasting, CPIR in obese nondiabetic subjects and, 171  
 gliclazide effects on, in NIDDM, 1197-1198  
 protein effects on levels of, 1485
- Plasma creatinine (Cr) in nephrotic syndrome, 823
- Plasma dehydroepiandrosterone sulfate (DHEAS), protein effects on levels of, 1485
- Plasma epinephrine (E)  
 differential effects of physiological versus pathophysiological concentrations of, on ketone body metabolism and hepatic portal blood flow, 1214-1220  
 radiation therapy effects on, 769  
 theophylline effects on, during exercise on, 1159
- Plasma fatty acids (FAs)  
 in chronic gastrointestinal disorders, 15, 16  
 deuterated water measuring synthesis of, determination of incorporated deuterium atoms with, 817-821

# Plasma fatty acids (FAs) (*Continued*)

- effects of CHOs and dietary fat supplementation on, during prolonged exercise, 915-921
- fasting, in normolipidemic men, 1110
- see also* Plasma free fatty acids

# Plasma fibrinogen (Fn) in essential hypertension, urapidil effects of, 1221-1229

## Plasma flow

- functional liver mass and, in acromegaly before and after long-term octreotide therapy, 109-113
- renal intrarenal glucagon action on, 385

## Plasma free fatty acids (FFAs)

- DZ effects on, 336
- effects of decreasing, by ACX, on hepatic glucose metabolism in normal subjects, 1408-1414
- fasting, and hyperinsulinemia associated with VPCs, 1250-1252
- gliclazide effects on HGP in, NIDDM and, 1197-1198
- pioglitazone effects on, 523
- radiation therapy effects on, 769
- VS effects on, 1133

## Plasma glucagon (G)

- in conscious subjects, *see* Plasma glucagon in conscious subjects
- effects of early changes in, on GH response to glucose in hyperthyroidism, 1029-1033
- gliclazide effects on HGP in, NIDDM and, 1197-1198
- and renal extraction of glucagon, 386
- theophylline effects on, during exercise on, 1159
- xylitol effects on, 1356

## Plasma glucagon (G) in conscious subjects

- glyburide effects on, 583
- stress hormone effects on arterial, 573

## Plasma glucose

- L-arabinose effects on, after sucrose ingestion, 1371
- arterial, hyperglycemia effects on, during ischemia, 546
- body weight and, in STZ-DM, 321
- CHO ingestion effects on, 1236-1238
- dependency of, on glyburide and GLP-1, 407
- DZ effects on, 336
- effects of xylitol on, 1356
- fasting, *see* Fasting plasma glucose
- gliclazide effects on HGP in, NIDDM and, 1197
- glyburide effects on, in conscious subjects, 581
- hormone replacement therapy effects on, 1257
- and hyperinsulinemia associated with VPCs, 1250, 1252
- in IDDM, progression of microalbuminuria and, 1102
- and intramuscular TG content, 949
- long-term sucrose-rich diet effects on, 1529
- moderate decline in SA and level of, 587-593
- in multiple trauma, 451
- in obesity, *see* Plasma glucose in obesity
- PCT and, 122
- and plasma C and FA synthesis measurement with deuterated water, 820
- radiation therapy of cancer effects on, 769
- smoking and, 1553
- in STZ-DM, *see* Plasma glucose in STZ-DM
- in  $\beta$ -thalassemia major, 655
- thermal injury effects on level of, 1162-1163
- trandolapril and verapamil effects on, 537
- in untreated NIDDM, starvation effects on concentrations of, 492-497
- voglibose effects on, in nondiabetic hyperinsulinemia, 734

## Plasma glucose in obesity

- CPIR in obese nondiabetic subjects and, 171, 172
- pioglitazone effects on, 520-521

## Plasma glucose in STZ-DM

- ALC replacement effects on, 867
- and normal subjects, exercise effects on, 811
- tolrestat effects on nerve crush injury and, 1191
- troglitazone effects on, 1169

## Plasma glutamine, effects of *N*-carbonyl glutamate on, in familial leucine-sensitive hypoglycemia, 959

## Plasma glycerol

- effects of CHO and dietary fat ingestion during prolonged exercise on, 919
- radiation therapy effects on, 769

## Plasma growth hormone (GH)

- level of, in men before and after stimulation with GHRH following nifedipine and ET-1 treatment, 659
- relationship between GHBP, growth rate and, 424-429

## Plasma growth hormone-binding protein (GHBP), effects of T and DHT on, 1523

## Plasma high-density lipoprotein-cholesterol (HDL-C)

- as correlate of visceral obesity-insulin resistance-dyslipidemic syndrome in men, 882-888
- fasting, and hyperinsulinemia associated with VPCs, 1250-1252
- in NIDDM, role of AT loss in exercise-induced improvement in, 1384

## Plasma 3-hydroxybutyrate (3-OHB), exercise effects on, in normal and STZ-DM subjects, 811

## Plasma insulin

- L-arabinose effects on, after sucrose ingestion, 1371
- CHO ingestion effects on, 1236-1238
- DZ effects on, 336
- exercise and, *see* Plasma insulin, exercise and
- fasting, *see* Fasting plasma insulin
- glyburide and, *see* Plasma insulin, glyburide and
- hormone replacement therapy effects on, 1257, 1260
- hyperglycemia effects on, during ischemia, 546
- and hyperinsulinemia associated with VPCs, 1250
- moderate decline in SA and level of, 589
- in NIDDM, *see* Plasma insulin in NIDDM
- pioglitazone effects on, in obese subjects, 520-521
- radiation therapy of cancer effects on, 769
- relationship between AT production of PGE<sub>2</sub>, PGI<sub>2</sub>, 6-keto-PGF<sub>1 $\alpha$</sub>  and, BP in normal, diabetic, and DKA subjects and, 691-698
- smoking and, 1553
- thermal injury effects on level of, 1162-1163
- trandolapril and verapamil effects on, 537

## Plasma insulin, exercise and

- exercise effects on, in STZ-DM and normal subjects, 811
- theophylline effects during exercise, 1159

## Plasma insulin, glyburide and

- glyburide effects on insulin in conscious subjects, 581
- glyburide- and GLP-1-dependent plasma insulin, 407

## Plasma insulin-like growth factor-1 (IGF-1)

- protein effects on levels of, 1485
- protein and TNF role in concentrations of albumin and, and their hepatic mRNAs in malnutrition, 1273-1278

## Plasma insulin in NIDDM

- gliclazide effects on HGP and, 1197-1198
- in spontaneous NIDDM, response of, to arginine, 1361-1363, 1365
- starvation effects in untreated NIDDM on concentrations of, 492-497

## Plasma K (potassium)

- fasting, and hyperinsulinemia associated with VPCs, 1250-1252
- and low activity of erythrocyte membrane Na<sup>+</sup>/K<sup>+</sup> ATPase, 806

- Plasma lactate, and plasma C and FA synthesis measurement with deuterated water, 819, 820
- Plasma lipids  
exercise effects on, *see* Plasma lipids, exercise effects on  
hydrogenated fat diet effects on, 244  
nandrolone decanoate effects on coronary arteries and, in female subjects on moderately atherogenic diet, 463-468  
in obesity, pioglitazone effects on, 521
- Plasma lipids, exercise effects on, 477  
in NIDDM, role of AT loss in exercise-induced improvement in, 1383-1395
- Plasma lipoprotein (Lp)  
metabolism of, in genetic hypercholesterolemia, 4-11  
pancreas transplantation on distribution and composition of, 856-861
- Plasma low-density lipoprotein-cholesterol (LDL-C)  
fasting, and hyperinsulinemia associated with VPCs, 1250-1252  
in NIDDM, role of AT loss in exercise-induced improvement in, 1384
- Plasma met-enkephalin in IDDM and NIDDM, autonomic neuropathy and, 1065-1068
- Plasma Na (sodium), and low activity of erythrocyte membrane  $\text{Na}^+/\text{K}^+$  ATPase, 806
- Plasma norepinephrine (NE)  
cancer radiation therapy effects on, 769  
differential effects of physiological versus pathophysiological concentrations of, on ketone body metabolism and hepatic portal blood flow, 1214-1220  
in hypertensive patients with LVH during ergometric exercise, 1328  
theophylline effects on, during exercise on, 1159
- Plasma palmitate, and plasma C and FA synthesis measurement with deuterated water, 819, 820
- Plasma phosphate, inorganic, effects of xylitol on, 1356-1357
- Plasma phospholipid (PL) saturated fatty acids (SFAs), relationship between hyperinsulinemia and, 223-228
- Plasma plasminogen activator inhibitor type 1 (PAI-1), effects of proinsulin and insulin on, in young women on contraceptive steroids, 833-838
- Plasma platelet-activating factor-acetylhydrolase (PAF-AH) in nephrotic syndrome, 825-826
- Plasma prolactin (PRL), level of, in men before and after stimulation with TRH following nifedipine and ET-1 treatment, 660
- Plasma purine bases, glucagon effects on xylitol-induced increase in, 1354-1359
- Plasma pyruvate, and plasma C and FA synthesis measurement with deuterated water, 819, 820
- Plasma renin activity (PRA) in hypertensive patients with LVH during ergometric exercise, 1328
- Plasma sterols, cholestyramine and lovastatin effects on levels of, in sitosterolemic homozygous girl and her heterozygous father, 673-679
- Plasma testosterone (T), protein effects on levels of, 1485
- Plasma thyroxine ( $\text{T}_4$ ) in hyperthyroidism, 709
- Plasma  $\alpha$  (alpha)-tocopherol (vitamin E), hydrogenated dietary fat effects on, 245
- Plasma total cholesterol (TC), exercise effects on, 477
- Plasma triglycerides (TGs)  
in CAD, 1378-1380  
DZ effects on, 336  
exercise effects on, 477  
fasting, *see* Fasting plasma triglycerides  
in NIDDM, role of AT loss in exercise-induced improvement in, 1384
- Plasma triglycerides (TGs) (*Continued*)  
pioglitazone effects on, 523  
relation of apo B, HDL-C and, to postheparin LPL activity is dependent on apo E polymorphism, 261-267
- Plasma xylitol, effects of xylitol on, 1356
- Plasmalogens, ethanolamine, in nephrotic syndrome, 823-824
- Plasminogen, levels of, hypercholesterolemic thrombophilia, 967, 968
- Plasminogen activator, tissue, effects of proinsulin and insulin on, in young women on contraceptive steroids, 833-838
- Plasminogen activator inhibitor (PAI), urapidil effects on, in hypertension, 1223
- Plasminogen activator inhibitor-1 (PAI-1)  
and fibrinolytic potential, 1429  
in IRS, 1535, 1536  
plasma, effects of proinsulin and insulin on, in young women on contraceptive steroids, 833-838  
relationship between hepatic and peripheral insulin resistance and, in Pima Indians, 1243-1247
- Platelet-activating factor-acetylhydrolase (PAF-AH) in nephrotic syndrome, 823, 825-826
- Platelet aggregation, effects of high SFA diet on, 554, 556-557
- Platelet buffering capacity in NIDDM, cardiovascular risk factors and RBC membrane SLC and, 962, 963
- Platelet membranes, changes in PL composition of, in IDDM and NIDDM, 57-62
- PMN (polymorphonuclear) leukocyte membranes, changes in PL composition of, in IDDM and NIDDM, 57-62
- Polyamine, endotoxemia and sepsis effects on metabolism of, in mucosa of small intestine, 28-33
- Polycystic ovarian syndrome (PCOS), hormonal parameters in, 72-75
- Polymorphism, *see* Apolipoprotein E polymorphism; Japanese non-insulin-dependent diabetes mellitus subjects, polymorphism in
- Polymorphonuclear (PMN) leukocyte membranes, changes in PL composition of, in IDDM and NIDDM, 57-62
- Polypeptides, characterization of GLUT1 and GLUT3, in peripheral nerve, 1468-1470
- Polyphosphoinositide, turnover of, in peripheral nerves of STZ-DM subjects, effects of sorbinil and *myo*-inositol supplementation on, 320-327
- Polyunsaturated fatty acids (PUFAs)  
in hydrogenated dietary fat, 242  
and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 877  
relationship between hyperinsulinemia and, 224-226
- Portal blood flow, hepatic, differential effects of pathophysiological versus physiological concentrations of plasma E and NE on KB metabolism and, 1214-1220
- Portal-caval transposition (PCT), hyperinsulinemia and insulin resistance with, 120-125
- Portal insulin delivery, peripheral delivery compared with, in handling of portally delivered glucose, 150-154
- Portal vein alanine, stress hormone effects on, in conscious subjects, 576
- Portal vein glucose in conscious subjects, glyburide effects on, 580
- Portal vein lactate, stress hormone effects on, in conscious subjects, 576
- Postabsorptive flux of FFAs in men and women, kinetics of regional FFAs contributing to, 662-666
- Postheparin lipoprotein lipase (LPL) activity, relationship of plasma TGs, HDL-C, and apo B to, dependent on apo E polymorphism, 261-267

- Postmenopausal subjects  
 17 $\beta$ -estradiol reducing postprandial HDL-C in, 827-832  
 hormone replacement therapy effects on cardiovascular risk factors and CHO metabolism in, 1254-1262
- Postoperative trauma, effects of parenteral fish oil on leukotriene-synthesizing capacity and leukocyte membrane FAs in, 1208-1213
- Postprandial (PP) changes in HDL composition and subfraction distribution in IDDM, 1034-1041
- Postprandial (PP) dietary fat oxidation following high-fat meal, diet-induced weight loss and, 174-178
- Postprandial (PP) glucose, nonoxidative metabolism of, in idiopathic reactive hypoglycemia, 606-610
- Postprandial (PP) high-density lipoprotein-cholesterol (HDL-C), 17 $\beta$ -estradiol reducing, in postmenopausal women, 827-832
- Postprandial (PP) metabolism  
 effects of aerobic and resistance exercise on, in weight-reduced subjects, 182  
 Lp, in normotriglyceridemic NIDDM, apo E polymorphism influence on, 63-71
- Postprandial (PP) thermogenesis, substrate utilization and, after different CHO ingestion, 1235-1242
- Potassium, *see* K
- PP, *see* entries beginning with term: Postprandial
- PRA (plasma renin activity) in hypertensive patients with LVH during ergometric exercise, 1328
- Prader-Willi syndrome (PWS), glucose and insulin metabolism in, 1514-1520
- Pregnancy, glucose and lactate kinetics during short exercise in, 753-758
- Premature complexes, ventricular, hyperinsulinemia associated with, 1248-1253
- Premenopausal women  
 non-obese, of different racial origins, lipid and CHO metabolic risk markers for CHD and BP in, 328-333  
 obese, with VAT and SAT, HPA activity and its relationship to AN in, and effects of AVP/CRF stress tests in, 351-356
- Prevention of NIDDM, long-term effects of exercise on, 475-480
- Primary hyperparathyroidism (PHPT), decreased cortical and increased cancellous bone in, 76-81
- PRL, *see* Prolactin
- 17-OH-Progesterone, *see* 17-OHP
- Progression to IDDM, differential beta cell response to glucose, glucagon, and arginine during, 306-314
- Proinsulin  
 in CAD, 1379  
 effects of, on plasma PAI-1 and t-PA levels in young women on contraceptive steroids, 833-838  
 fasting, in  $\beta$ -thalassemia major, 656
- des 31,32 Proinsulin in  $\beta$ -thalassemia major, 656
- Prolactin (PRL)  
 in Bardet-Biedel syndrome children, 1232, 1233  
 citrate oxidation and m-aconitase in prostate epithelial cells regulated by, 442-449  
 ET-1 impact on basal and stimulated concentrations of, in men, with and without nifedipine pretreatment, 658-661  
 ethanol action inducing release of, 1330-1334  
 GnRH effects on, in severely hirsute hyperandrogenic women on, 25  
 in hirsute women, BMD and, 516  
 responses of  $\beta$ -endorphin and, to hypoglycemia in well-controlled IDDM, 1434-1440  
 in SCI women, 718-722  
 serum, *see* Serum prolactin
- Proliferative (and adhesive) properties of VSMCs impaired by nonenzymatic glycation of Fn, 285-292
- Prolonged exercise, CHOs and  
 effects of dietary fat supplementation and CHOs on CHO metabolism during prolonged exercise, 915-921  
 substrate kinetics of CHO ingestion and CHO loading during prolonged exercise, compared, 415-423
- Prostacyclin (PGI<sub>2</sub>), relationship between AT production of PGE<sub>2</sub>, 6-keto-PGF<sub>1 $\alpha$</sub>  and, BP in normal, diabetic, and DKA subjects, and plasma insulin level, 691-698
- Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), relationship between AT production of PGI<sub>2</sub> 6-keto-PGF<sub>1 $\alpha$</sub>  and, BP in normal, diabetic, and DKA subjects, and plasma insulin level, 691-698
- Prostaglandin F<sub>1</sub> (PGF<sub>1</sub>), 6-keto-, relationship between AT production of PGI<sub>2</sub>, PGE<sub>2</sub> and, BP in normal, diabetic, and DKA subjects, and plasma insulin level, 691-698
- Prostate epithelial cells, PRL regulating citrate oxidation and m-aconitase in, 442-449
- Protein, 1273-1283  
 binding, *see* Growth hormone-binding protein; Insulin-like growth factor binding protein-1; Insulin-like growth factor binding protein-2 mRNA; Insulin-like growth factor binding protein-3  
 cholesteryl ester transfer, *see* Cholesteryl ester transfer protein  
 effects of moderate increase in, on insulin secretion and DHEAS, 1483-1486  
 in glomerular proteinuria, 725  
 muscle, *see* Muscle protein  
 in NIDDM, *see* Protein in NIDDM  
 oxidation of, *see* Oxidation, protein  
 receptor, and effects of starvation on T<sub>3</sub> maximal binding capacity for T<sub>3</sub> receptor, 970-973  
 TNF and, as determinants of plasma IGF-1 and albumin concentrations and their hepatic mRNAs in malnourished subjects, 1273-1278  
 total, in IDDM, blood cell membrane phospholipid composition and, 59  
 in uremia, 688, 689  
*see also* Apolipoprotein(s); Lipoprotein; Protein kinase; Protein-1 mRNA; Proteinuria
- Protein kinase (PK)  
 mitogen-activated, IGF-I-stimulated activity of, 1479  
*see also* Protein kinase A; Protein kinase C
- Protein kinase A (PKA), glucagon synthesis and secretion induced by, inhibited by glucose, 347-350
- Protein kinase C (PKC)  
 effects of inhibitor of, on LPC-induced MCP-1 mRNA expression, 560  
 responses of cAMP and, to GH secretion in acromegalic pituitary adenomas, 206-210  
 role of, in glucose effects on proteoglycan mRNA expression, 1141-1142
- Protein in NIDDM  
 with obesity, level of, and FBPase activity, 624, 625  
 total, blood cell membrane PL composition and, 59
- Protein-1 mRNA (messenger ribonucleic acid), monocyte chemoattractant, LPC stimulating expression and production of, in vascular endothelial cells, 559-564
- Proteinuria  
 glomerular, serum lathosterol-to-cholesterol ratio is not elevated in, and not associated with improved hyperlipidemia in response to antiproteinuria therapy, 723-730  
 in NIDDM with macrovascular disease, 134  
*see also* Albuminuria

- Proteoglycan mRNA (messenger ribonucleic acid), posttranscriptional effects of glucose on expression of, in mesangial cells, 1136-1145
- Prothrombin in FHTG and FDL, omega-FA and fenofibrate effects on, 1306
- Prothrombin time (PT), activated partial, in hypercholesterolemic thrombophilia, 967, 968
- Proximal tubular cell apoptosis induced by glucose loading, 1348-1353
- Psychological stress, IRS and, 1533-1538
- Psychosocial factors  
WHR and, in IDDM subjects, 268-272  
*see also* Education level; Income; Race and ethnicity
- PT (prothrombin time), activated partial, in hypercholesterolemic thrombophilia, 967, 968
- PTT (partial thromboplastin time), activated, in hypercholesterolemic thrombophilia, 967, 968
- Puberty  
male, androgen regulation of GHBP in, 1521-1526  
*see entries beginning with term:* Adolescent
- PUFAs, *see* Polyunsaturated fatty acids
- Pulmonary function, oral albuterol effects on, 713-714
- Purine bases  
glucagon effects on xylitol-induced increase in plasma and urinary excretion of, 1354-1359  
*see also* Uric acid
- PWS (Prader-Willi syndrome), glucose and insulin metabolism in, 1514-1520
- Pyridinium cross-links of collagen, urinary excretion of, in infancy, 510-514
- Pyruvate  
in familial leucine-sensitive hypoglycemia, glucose effects on, 958  
and glucose cycling by hepatocytes, 104  
plasma, and plasma C and FA synthesis measurement with deuterated water, 819, 820  
splenocyte, MH 7777 effects on metabolism of, 852
- Pyruvic acid, blood, xylitol effects on, 1358
- RA, *see entries beginning with terms:* Retinoic acid
- Race and ethnicity  
abdominal AT distribution, metabolic risk factors and, 1119-1124  
CT-determined body composition in relation to CV risk factors in Indian and Swedish men, 634-644  
and HDL-C in obese 10-year-old girls, 469-474  
insulin resistance in Swedish adolescents, 908-914  
lipid and CHO metabolic risk markers for CHD and BP in non-obese premenopausal women of different racial origins, 328-333  
low activity of erythrocyte membrane Na<sup>+</sup>/K<sup>+</sup> ATPase in Northeast Thais, 804-810  
of morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA in, 1012  
relationship between hepatic and peripheral insulin resistance and PAI-1 in Pima Indians, 1243-1247  
relationship of insulin resistance and weight gain in nondiabetic Creole, Chinese, and Indian Mauritians, 627-633  
urinary excretion of T and E<sub>2</sub> in Chinese men, serum Lp concentrations and, 279-284  
*see also* Japanese non-insulin-dependent diabetes mellitus subjects, polymorphism in; Mexican-Americans, NHWs compared with
- Radiation therapy of cancer, metabolic response to, 767-773
- RBCs (red blood cells), *see* Erythrocyte(s)
- rCBF (regional cerebral blood flow), effects of acute hypoglycemia on, in IDDM with impaired hypoglycemia awareness, 974-980
- Reactive hypoglycemia, idiopathic, nonoxidative metabolism of postprandial glucose in, 606-610
- Recombinant growth hormone, *see* Growth hormone, effects of therapy with
- Recovery of BW by identical twins after 5 years of overfeeding, 1042-1050
- Rectal proliferative indices, acarbose effects on, 1179-1187
- Red blood cells, *see* Erythrocyte(s)
- Reduced-fat diet, *see* Low-fat diet
- Reductase inhibitor, *see* Aldose reductase inhibitor(s)
- REE (resting energy expenditure), impact of low- versus high-nicotine cigarette smoking on, 923-926
- Regeneration of nerves, tolrestat effects, after crush injury in STZ-DM, 1189-1195
- Regional cerebral blood flow (rCBF), effects of acute hypoglycemia on, in IDDM with impaired hypoglycemia awareness, 974-980
- Regional free fatty acids (FFAs), kinetics of, contributing to postabsorptive FFA flux in men and women, 662-666
- Renal failure, VLDLs as poor substrates for milk LPL in uremia, 686-690
- Renal function, pancreas transplantation effects on, 857
- Renal hemodynamics, intrarenal glucagon action on, 383-388
- Renal insufficiency, NIDDM with and without, insulin effects on urinary excretion of phosphate in, 782-786
- Renal metabolism, intrarenal glucagon action on, 383-388
- Renal Na (sodium) handling, intrarenal glucagon action on, 383-388
- Renal plasma flow (RPF), intrarenal glucagon action on, 385
- Renal substrate balance, stress hormone effects on, in conscious subjects, 574-575
- Renal transplantation, protein oxidation in, 1319-1322
- Renal vascular resistance, intrarenal glucagon action on, 385
- Renin, PRA in hypertensive patients with LVH during ergometric exercise, 1328
- RER (respiratory exchange ratio), theophylline effects on, during exercise and, 1156
- Resistance exercise  
effects of aerobic exercise and, on body composition and metabolism following diet-induced weight loss, 179-183  
and GH administration in older men, effects of, on insulin sensitivity and secretion during IVGTT, 254-260
- Respiratory exchange ratio (RER), theophylline effects on, during exercise, 1156
- Resting energy expenditure (REE), impact of low- versus high-nicotine cigarette smoking on, 923-926
- Resting metabolic rate (RMR)  
of morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA in, 1013  
*see also* Resting metabolic rate in weight-reduced subjects
- Resting metabolic rate (RMR) in weight-reduced subjects  
effects of aerobic exercise and resistance training on, 182  
following high-fat meal, 176
- Retinoic acid (RA) receptor transcripts, and effects of ROH and RA on glucagon secretion in pancreatic islets and glucagon-secreting cell lines, 300-305
- Retinoic acid (RA) status, IDDM and insulinitis development and, 248-254
- Retinol (ROH; vitamin A<sub>1</sub>), RA receptor transcripts and effects of RA and, on glucagon secretion in pancreatic islets and glucagon-secreting cell lines, 300-305

- Retinyl palmitate (RP), 17 $\beta$ -estradiol effects on, in postmenopausal women, 829
- Reversal  
   rapid, of neurovascular effects of STZ-DM with aminoguanidine, 1147-1152  
   of reduced Na<sup>+</sup>/K<sup>+</sup> ATPase and MNCV due to L-fucose, 229-234
- Ribonucleic acid, *see* RNA
- Risk and risk factors  
   insulin effects on beta cell function in subjects at high risk for IDDM, 873-875  
   metabolic, *see* Metabolic risk factors  
   *see also* Cardiovascular risk factor(s) and specific risk factors
- RMR, *see* Resting metabolic rate
- RNA (ribonucleic acid)  
   editing of hepatic apo B, in genetic obesity, 1056-1058  
   *see also* mRNA
- ROH (retinol), RA receptor transcripts and effects of RA and, on glucagon secretion in pancreatic islets and glucagon-secreting cell lines, 300-305
- RP (retinyl palmitate), 17 $\beta$ -estradiol effects on, in postmenopausal women, 829
- RPF (renal plasma flow), intrarenal glucagon action on, 385
- S, *see* Sucrose
- SA, *see* Specific activity
- Safflower oil (linoleic acid)  
   effects of, on expression of insulin signal-transduction pathway intermediates gene, 1080-1088  
   effects of, on hyperglycemia and obesity, 1540, 1541  
   in STZ-DM, effects of sorbinil and ALC on, 905
- Saline, effects of, on GFR, 1349
- SAT, *see* Subcutaneous adipose tissue
- Saturated fatty acids (SFAs)  
   effects of high levels of, in meat, dairy products, and tropical oils on serum Lps and LDL degradation by mononuclear cells in men, 550-558  
   exercise effects on concentrations of serum TC and LDL-C related to apo E phenotype in boys and young adults, 798, 801  
   in hydrogenated fat diet, 242  
   and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 877  
   plasma PL, relationship between hyperinsulinemia and, 223-228
- SCFAs (short-chain fatty acids), acarbose effects on, 1179-1187
- SCI (spinal-cord injury), women with, HPO and HPT axes in, 718-722
- SCL (skin conductance level), mental stress and, in adolescent boys with IRS, 614-621
- Sellae, empty, with impaired testosterone secretion, and defective hypothalamic-pituitary growth and gonadal axes in Bardet-Biedel syndrome children, 1230-1234
- Sepsis, *see* Infection
- Serine, MH 7777 effects on concentrations of, 851
- Serum albumin  
   in glomerular proteinuria, 725  
   in IDDM, progression of microalbuminuria and, 1102  
   in  $\beta$ -thalassemia major, 653  
   and urinary excretion of T and E<sub>2</sub>, 281
- Serum Ca (calcium), circadian relationships between circulating ANPs, serum phosphate and, in healthy subjects, 1021-1028
- Serum carnitine, pivalic acid-induced deficiency in, 1502
- Serum cholesterol (C)  
   urapidil effects on, in hypertension, 1223  
   in uremia, 689
- Serum corticotropin (ACTH) in HIV-infected men, 741
- Serum cortisol  
   in HIV-infected men, 741  
   in SCI women, 719
- Serum creatinine (Cr)  
   in glomerular proteinuria, 725  
   of hypertensive subjects with LVH, 1327  
   in IDDM, *see* Serum creatinine in IDDM  
   in NIDDM, *see* Serum creatinine in NIDDM
- Serum creatinine (Cr) in IDDM  
   in nonnephropathic IDDM, RBC membrane Na/lithium countertransport kinetics and, 1204  
   progression of microalbuminuria and, 1102
- Serum creatinine (Cr) in NIDDM  
   and ACE and AGN gene polymorphism, 220  
   with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783
- Serum dolichol, effects of anabolic androgenic steroid abuse on serum ubiquinone and, 844-847
- Serum estradiol (E<sub>2</sub>) in SCI women, 719
- Serum ferritin in  $\beta$ -thalassemia major, 653
- Serum follicle-stimulating hormone (FSH) in SCI women, 719
- Serum free fatty acids (FFAs)  
   in GH-deficient men, effects of GH therapy on, 365-366  
   in obesity, *see* Serum free-fatty acids in obesity
- Serum free fatty acids (FFAs) in obesity  
   ACX potentiating GH response to GHRH by decreasing, in obese men, 594-597  
   CPIR in obese nondiabetic subjects and, 171
- Serum L-fucose, dietary L-fucose effects on, 232
- Serum glucose, L-NMMA effects on, 941-943
- Serum growth hormone (GH)  
   in GH-deficient men, 363, 364, 371  
   in HIV-infected men, 741  
   in SCI women, 719
- Serum high-density lipoprotein-cholesterol (HDL-C)  
   fasting, in NIDDM, with amino acid polymorphism in HSL, 864  
   in uremia, 689
- Serum insulin  
   in adolescents with insulin resistance, 909, 911-912  
   fasting, in  $\beta$ -thalassemia major, 655  
   in STZ-DM, *see* Serum insulin in STZ-DM
- Serum insulin-like growth factor-I (IGF-I)  
   effects of GH therapy for GH-deficient men on, 363-364, 371  
   effects of long-term therapy with IGF-I on levels of, 1264
- Serum insulin-like growth factor binding protein-3 (IGFBP-3), effects of GH therapy in GH-deficient men on, 363-364
- Serum insulin in STZ-DM  
   immunoreactive, and effects of gonadectomy on development of hypertension, albuminuria, and STZ-DM, 159  
   troglitazone effects on, 1169
- Serum K (potassium), oral albuterol effects on, 714, 716
- Serum lathosterol-to-cholesterol ratio is not elevated in glomerular proteinuria and not associated with improved hyperlipidemia in response to antiproteinuria therapy, 723-730
- Serum lipids  
   diet effects on glucose homeostasis and levels of, in exercise, 435-441  
   effects of palmitic and stearic acids on serum Lps, plasma CETP activity and, in young women, 143-149  
   GH effects on serum Lps and, increased peripheral conversion of T<sub>4</sub> to T<sub>3</sub> and, 1016-1020  
   oral albuterol effects on carbohydrate metabolism and, in men, 712-717



- Serum lipoprotein(s) (Lps)  
 effects of GH therapy for GH-deficient men on, 370-377  
 effects of palmitic and stearic acids on serum lipids, plasma CETP activity and, in young women, 143-149  
 GH effects on serum lipids and, increased peripheral conversion of T<sub>4</sub> to T<sub>3</sub> and, 1016-1020  
 relative effects of high SFA levels in meat, dairy products, and tropical oils on, and on degradation of LDLs by mononuclear cells in men, 550-558  
 urinary excretion of T and E<sub>2</sub> in Chinese men, and concentrations of, 279-284
- Serum lipoprotein(a) [Lp(a)], long-term IGF-I therapy effects on, in Laron syndrome, 1263-1266
- Serum low-density lipoprotein-cholesterol (LDL-C)  
 exercise effects on concentrations of serum TC and, related to apo E phenotype in boys and young adults, 797-803  
 in uremia, 689
- Serum luteinizing hormone (LH)  
 in HIV-infected men, 741  
 in SCI women, 719
- Serum Mg (magnesium), oral albuterol effects on, 714, 716
- Serum  $\beta_2$  (beta<sub>2</sub>)-Microglobulin ( $\beta_2$ M) in NIDDM with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783
- Serum phosphate, circadian relationships between circulating ANPs, serum Ca and, in healthy subjects, 1021-1028
- Serum prolactin (PRL)  
 in HIV-infected men, 741  
 in SCI women, 719
- Serum sex hormone-binding globulin (SHBG)  
 effects of GH therapy in GH-deficient men on, 363-364  
 level of serum T and, increased by exercise in older men, 935-939
- Serum sialic acid in IDDM, progression of microalbuminuria and, 1102
- Serum testosterone (T)  
 effects of GH therapy for GH-deficient men on, 363-364  
 in HIV-infected men, 741  
 level of serum SHBG and, increased by exercise in older men, 935-939
- Serum thyrotropin (TSH)  
 effects of GH therapy of GH-deficient men on, 363-364  
 in HIV-infected men, 741  
 in SCI women, 718-722
- Serum thyroxine (T<sub>4</sub>)  
 effects of GH therapy for GH-deficient men on, 363-364  
 in HIV-infected men, 741  
 in SCI women, 719
- Serum total cholesterol (TC)  
 exercise effects on concentrations of LDL-C and, related to apo E phenotype in boys and young adults, 797-803  
 fasting, in NIDDM with amino acid polymorphism in HSL, 864  
 in glomerular proteinuria, 726  
 in nonnephropathic IDDM, RBC membrane Na/lithium countertransport kinetics and, 1204
- Serum triglycerides (TGs)  
 fasting, *see* Fasting serum triglycerides  
 in glomerular proteinuria, 726  
 in NIDDM with amino acid polymorphism, 864  
 urapidil effects on, in hypertension, 1223
- Serum triiodothyronine (T<sub>3</sub>)  
 effects of GH therapy of GH-deficient men on, 363-364  
 in SCI women, 719
- Serum ubiquinone, effects of anabolic androgenic steroid abuse on serum dolichol and, 844-847
- Serum urate in pubertal lean and obese boys, 204
- Serum uric acid  
 in hospitalized subjects, 1557-1561  
 oral albuterol effects on, 714
- Serum very-low-density lipoprotein (VLDL), urapidil effects on, in hypertension, 1223
- Severe insulin resistance in leprechaunism due to two mutations of tyrosine kinase domain of insulin receptor gene, 1493-1500
- Severely hyperandrogenic hirsute women, long-acting GnRH in, 25-27
- Severity of CAD, HDL relation to metabolic parameters and, 1375-1382
- Sex  
 of acromegalic subjects, *see* Sex of acromegalic subjects  
 of cancer patients, response to radiation therapy and, 768  
 of CHD subjects, 670  
 effects of full-fat or reduced-fat diet on EE and substrate oxidation of non-obese subjects, 1005  
 and EtOH effects on PRL release, 1331  
 exercise and, *see* Sex, exercise and  
 of FHLB subjects, 1297  
 and glucose processing during FSIGT, 599  
 of hypercholesterolemic thrombophilia patients, 968  
 and hyperinsulinemia associated with VPCs, 1250-1252  
 of hypertensive subjects, *see* Sex of hypertensive subjects  
 of IDDM subjects, 269  
 influence of adiposity, age and, on metabolically active component of FFM, 992-997  
 insulin and, *see* Sex, insulin and  
 of morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA in, 1012  
 of multiple trauma subjects, 451  
 of NIDDM subjects, *see* Sex of NIDDM subjects  
 of non-obese subjects, effects of full- or reduced-fat diet on EE and substrate oxidation in, 1005  
 of PWS subjects, 1515, 1516  
 and relationship between hepatic and peripheral insulin resistance and PAI-1, 1244  
 and relationship between plasma PL SFAs, 224  
 of smokers, 1552-1554  
 of  $\beta$ -thalassemia major subjects, 653  
 and urinary excretion of pyridinium cross-links of collagen, 511  
*see also* Female subjects; Male subjects
- Sex, exercise and  
 and strenuous exercise effects on glycerol kinetics, 358  
 varying effects of exercise on concentrations serum TC and LDL-C related to apo E phenotype in boys and young adults, 798
- Sex, insulin and  
 and insulin effects on intracellular Ca concentrations, insulin resistance and, 1403, 1405  
 and insulin effects on levels of circulating vitamin E, 999
- Sex of acromegalic subjects, 110
- Sex of acromegalic pituitary adenoma subjects, 207
- Sex hormone-binding globulin (SHBG)  
 in hirsute women, *see* Sex hormone-binding globulin in hirsute women  
 serum, *see* Serum sex hormone-binding globulin  
 and urinary excretion of T and E<sub>2</sub>, 282
- Sex hormone-binding globulin (SHBG) in hirsute women  
 BMD and, 516  
 GnRH effects on, in severely hirsute hyperandrogenic women on, 25
- Sex of hypertensive subjects  
 with LVH, 1327  
 urapidil effects on plasma Fn and, 1222, 1223

- Sex of IDDM subjects  
 apo, Lp, and LDL size and, 1269  
 autonomic neuropathy and, 1066  
 with hypoglycemia, 975  
 with nonnephropathic IDDM, RBC membrane SLC kinetics and, 1204  
 progression of microalbuminuria and, 1102, 1104  
 with well-controlled IDDM, 1435
- Sex of NIDDM subjects  
 and ACE and AGN gene polymorphism, 220  
 of adult-onset IDDM subjects, 1510  
 apo, Lp, and LDL size and, 1269  
 autonomic neuropathy and, 1066  
 and effects of vanadyl sulfate on CHO and lipid metabolism, 1131  
 and gliclazide effects on HGP suppression, 1197  
 of NIDDM Mexican-Americans and non-Hispanic whites, 877-879  
 normotriglyceridemic, 64  
 oral glucose and CCK release in, 197  
 with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783
- SFAs, *see* Saturated fatty acids
- SHBG, *see* Sex hormone-binding globulin
- Short-chain fatty acids (SCFAs), acarbose effects on, 1179-1187
- Short-term therapy with trandolapril, 536-537
- Sialic acid, serum, in IDDM, progression of microalbuminuria and, 1102
- Side effects  
 of ACX, 344  
 of octreotide, 214-215  
 of oral albuterol, 713
- Signal-transduction pathway intermediates, insulin, effects of beef tallow and safflower oil diets on expression of gene of, 1080-1088
- Sitostanol in sitosterolemia, 675
- Sitosterolemia, cholestyramine and lovastatin effects on plasma sterol levels in homozygous girl and her heterozygous father with, 673-679
- Skeletal muscle  
 in body composition of healthy Indian and Swedish men, 637-638  
 insulin-resistant, effects of trandolapril alone or in combination with verapamil on glucose transport in, 535-541  
 in MIDD, 528  
 of normal and STZ-DM subjects, effects of exercise on mitochondrial function in, 810-816  
 stress hormone infusion effects on protein synthesis in, in normal adult subjects, 1388-1394  
 thermal injury effects on glucose utilization by, 1161-1167  
*see also* Skeletal muscle glucose; Skeletal muscle glycogen; Skeletal muscle glycogen synthase
- Skeletal muscle glucose  
 dexamethasone-induced impaired transport of, not reversed by inhibition of FFA oxidation, 92-100  
 during FSIGT, 601-602
- Skeletal muscle glycogen  
 effects of CHOs and dietary fat supplementation on, during prolonged exercise, 919-920  
 during FSIGT, 602
- Skeletal muscle glycogen synthase (GS) during FSIGT, 602
- Skeleton  
 in body composition of healthy Indian and Swedish men in relation to CV risk factors, 637, 638  
*see also* entries beginning with term: Skeletal
- Skin  
 thermal injury effects on glucose utilization by, 1161-1167  
*see also* entries beginning with terms: Cutaneous, Epidermal, Skin
- Skin conductance level (SCL), mental stress and, in adolescent boys with IRS, 614-621
- Skin glycation, hormonal replacement therapy effects on, in postmenopausal subjects, 1259, 1260
- SLC, *see* Erythrocyte membrane sodium-lithium countertransport
- Small intestine  
 mucosa of, endotoxemia and sepsis effects on polyamine metabolism in, 28-33  
 thermal injury effects on glucose utilization by, 1161-1167
- Smoking  
 by aging women, 44  
 CAD and, 1377  
 high- versus low-nicotine cigarette, impact of, on REE, 923-926  
 by hypercholesterolemic patients, *see* Smoking by hypercholesterolemic subjects  
 in IDDM, WHR and, 269  
 lack of association between hyperinsulinemia and, 1551-1556  
 in NIDDM, *see* Smoking by NIDDM subjects  
 by premenopausal women, *see* Smoking by premenopausal women  
 and relationship between psychosocial stress and IRS, 1535  
 and urapidil effects on plasma Fn in hypertensive subjects, 1222  
 by young women on contraceptive steroids, 834
- Smoking by hypercholesterolemic subjects  
 by FH patients, GH and, 1417  
 and hematologic parameters in hypercholesterolemic thrombophilia, 967
- Smoking by NIDDM subjects  
 with macrovascular disease, 134  
 and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 877-879
- Smoking by premenopausal women  
 and lipid and CHO metabolic risk markers for CHD in non-obese premenopausal women, 329  
 obese, with VAT and SAT, 352
- SNS, *see* Sympathetic nervous system
- Sodium, *see* Monosodium glutamate; Na
- Somatostatin  
 cells producing, functional active receptors for IGF-I and IGF-II on, 759-766  
 octreotide as analog of, effects of, on glucose metabolism and insulin sensitivity in IDDM, 211-217  
 secretion of, due to A-4166, 184-189
- Sorbinil, *see* Peripheral nerves in STZ-DM, sorbinil effects on
- Sorbitol, relationship between concentrations of glutathione and, in erythrocytes of diabetic subjects, 611-613
- Soybean oil, effects of, on hyperglycemia and obesity, 1540, 1541
- Specific activity (SA)  
 isotope dilution technique versus constant SA technique in estimation of insulin effects on HGP, 82-91  
 moderate decline in, and HGP, 587-593
- Spectral analysis of 24-hour pattern of HS in obesity with NIDDM, 1342-1347
- Spectrometry, mass, with atmospheric pressure chemical ionization interface system, liquid chromatography-, *N*-acetylcystathionine and cyclic cystathionine sulfoxide in cystathioninuria identified with, 1312-1316
- Spectroscopy, <sup>31</sup>P magnetic resonance, to assess effects of nutritional status and inflammatory state on liver of elderly subjects, 1059-1061
- Spinal-cord injury (SCI), women with, HPO and HPT axes in, 718-722

- Spleen, CL316,243 effects on NE turnover in, SNS activity and, 788
- Splenocytes  
   mononuclear, L-NMMA effects on NO generation and, with mld-STZ, 940-946  
   reduced immune function and reduced metabolism of, in subjects implanted with MH 7777, 848-855
- Spontaneous hypertension, activity and phosphorylation of Na<sup>+</sup>/H<sup>+</sup> exchanger in vascular myocytes in, glucose effects on, 114-119
- Spontaneous non-insulin-dependent diabetes mellitus (NIDDM), function of pancreatic alpha cells in partial pancreatectomy as model of, 1360-1367
- Starvation  
   T<sub>3</sub> maximal binding capacity for T<sub>3</sub> receptor protein decreased by, 970-973  
   in untreated NIDDM, effects of, on plasma glucose and insulin concentrations, 492-497  
   *see also* Fasting
- Stearate, Lp metabolism of, in normolipidemic men, 1109-1118
- Stearic acid, effects of palmitic acid and, on serum lipids, Lps, and plasma CETP activity in young women, 143-149
- Steroids  
   anabolic androgenic, effects of abuse of, on serum ubiquinone and serum dolichol levels, 844-847  
   contraceptive, effects of proinsulin and insulin on plasma PAI-1 and t-PA in young women on, 833-838  
   *see also specific steroids*
- Sterols  
   plasma, cholestyramine and lovastatin effects on levels of, in sitosterolemic homozygous girl and her sitosterolemic heterozygous father, 673-679  
   *see also specific sterols*
- Strenuous exercise, effects of, on glycerol kinetics, 357-361
- Streptozotocin (STZ)  
   L-NMMA effects on mononuclear splenocytes and NO generation with mld-, 940-946  
   *see also* Streptozotocin-induced diabetes mellitus
- Streptozotocin-induced diabetes mellitus (STZ-DM)  
   ALC in, *see* Acetyl-L-carnitine in STZ-DM  
   cardioprotective effects of troglitazone in, 1168-1173  
   exercise effects on mitochondrial function of skeletal muscle of, 810-816  
   hypertension and, *see* Hypertension, and STZ-DM  
   rapid reversal of neurovascular effects of, with aminoguanidine, 1147-1152  
   sorbitinil in, *see* Peripheral nerves in STZ-DM, sorbitinil effects on tolrestat effects on nerve regeneration in, after crush injury, 1189-1195
- Stress  
   oxidative, and cICAM-1, HbA<sub>1c</sub>, and MDA level in NIDDM, 498-450  
   psychological, IRS and, 1533-1538  
   *see also* Insulin resistance syndrome, stress and
- Stress hormone (epinephrine, glucagon, norepinephrine, and cortisol)  
   effects of, on protein synthesis in skeletal muscle, albumin, and lymphocytes in normal adult subjects, 1388-1394  
   role of cortisol in metabolic response to, in conscious subjects, 571-578
- Stress test, effects of AVP/CRF test and, on HPA axis activity and its relationship to AN in premenopausal obese women with SAT and VAT, 351-356
- Structure of peripheral nerves, effects of ALC and sorbitinil on chemistry, function and, in STZ-DM, 902-907
- STZ, *see* Streptozotocin
- Subcutaneous adipose tissue (SAT)  
   HPA axis activity and its relationship to AN in premenopausal obese women with VAT and, effects of CRF/AVP and stress tests on, 351-356  
   in identical twins overfed for 5 years, 1045  
   in visceral obesity-insulin resistance-dyslipidemic syndrome, 885
- Submaximal exercise, and pivalic acid-induced carnitine deficiency, 1502
- Substrates  
   concentrations of, and pentoxifylline and indomethacin effects on HGP in healthy subjects, 1459-1460  
   effects of full-fat or reduced-fat diet on EE and oxidation of, in non-obese subjects, 1004-1010  
   PP thermogenesis and utilization of, after different CHO ingestion, 1235-1242  
   stress hormone effects on balance of, in conscious subjects, 574-576  
   substrate kinetics of CHO ingestion and CHO loading during prolonged exercise, compared, 415-423  
   theophylline effects on metabolism of, during exercise, 1153-1160  
   VLDLs as poor, for milk LPL in uremia, 686-690  
   *see also specific substrates*
- Sucrose, intestinal, L-arabinose inhibiting, after sucrose ingestion, 1368-1374
- Sucrose (S)  
   effects of long-term diet rich in, on endocrine pancreas in normal subjects, 1527-1532  
   HFHS diet effects on malonyl coenzyme A in obese salt-sensitive subjects, 519-525  
   ingestion of, L-arabinose inhibiting intestinal sucrose and suppressing glycemic response after, 1368-13741
- Sulfoxide, cyclic cystathionine, N-acetylcyclic cystathionine and, in cystathioninuria, LC/APCI-MS in identification of, 1312-1316
- Supplementation  
   effects of CHOs and dietary fat, on CHO metabolism during prolonged exercise, 915-921  
   sorbitinil and myo-inositol, effects of, on turnover of peripheral nerve polyphosphoinositide in STZ-DM, 320-327
- Swedish adolescents, insulin resistance in, 908-914
- Swedish men, CT-determined body composition of healthy Indian and, in relation to CV risk factors, 634-644
- Sympathetic nervous system (SNS)  
   activity of, and O<sub>2</sub> consumption in heart, hepatomesenteric bed, and brain of elderly and young men, 1487-1492  
   CL316,243 effects on activity of, 787-791
- Synthase, *see* Fatty acid synthase; Glycogen synthase; Nitric oxide synthase
- T, *see* Testosterone
- T<sub>3</sub>, *see* Triiodothyronine
- T<sub>4</sub>, *see* Thyroxine
- TAG (triacylglycerol), hepatic, OFS effects on fructose impact on metabolism of, 1547-1550
- Taurine, MH 7777 effects on concentrations of, 851
- TBK, *see* Total body K
- TC, *see* Total cholesterol
- T-cell leukemia, cachexia induced by, 645-651
- Testosterone (T)  
   DHEA effects on, in morbidly obese adolescents, 1013  
   free, *see* Free testosterone  
   GHPB regulation by, 1522  
   in hirsute women, *see* Testosterone in hirsute women  
   hormone replacement therapy effects on, in postmenopausal subjects, 1258, 1260

- Testosterone (T) (*Continued*)  
 impaired secretion of, in Bardet-Biedel syndrome children, 1230-1234  
 OA inhibiting cholesteryl esterase and cholesterol utilization for synthesis of, in Leydig cells, 293-299  
 plasma, protein effects on levels of, 1485  
 serum, *see* Serum testosterone  
 urinary excretion of E<sub>2</sub> and, by Chinese men, serum Lp concentrations and, 279-284
- Testosterone (T) in hirsute women  
 BMD and, 516  
 GnRH effects on, in severely hirsute hyperandrogenic women on, 25
- TG(s), *see* Triglycerides
- TGF- $\beta$  (transforming growth factor- $\beta$ ), role of, in glucose effects on proteoglycan mRNA expression, 1141-1142
- $\beta$  (beta)-Thalassemia major (TM), glucose intolerance in, related to insulin resistance and hepatic dysfunction, 652-657
- Theophylline, effects of, on substrate metabolism during exercise, 1153-1160
- Therapy  
 intensive, of adult-onset IDDM, insulin sensitivity and insulin reserve with, 1508-1513  
*see also specific therapies*
- Thermal injury (burn), effects of, on glucose utilization by skin, wound, small intestine, and skeletal muscle, 1161-1167
- Thermogenesis  
 postprandial, substrate utilization and, after different CHO ingestion, 1235-1242  
 relationship between glucose metabolism and, with and without prior exercise in obese NIDDM women, 747-752  
*see also entries beginning with term: Energy*
- Threonine, MH 7777 effects on concentrations of, 851
- Thrombophilia, hypercholesterolemic, 966-969
- Thromboplastin time, activated partial, in hypercholesterolemic thrombophilia, 967, 968
- <sup>3</sup>H-Thymidine, IGF-I and IGF-II effects on incorporation of, into DNA of insulin-, glucagon-, and somatostatin-producing cells, 763
- Thyroid  
 effects of thyroid status on glucose cycling by hepatocytes, 101-108  
 HPT axis in SCI women, 718-722  
*see also* Hyperthyroidism; Hypothyroidism; Triiodothyronine and *entries beginning with element: Thy-*
- Thyrotropin (TSH)  
 in Bardet-Biedel syndrome children, 1232, 1233  
 effects of T<sub>3</sub> on, in hyperthyroidism, 1030, 1031  
 ET-1 impact on basal and stimulated concentrations of, in men with and without nifedipine pretreatment, 658-661  
 in hyperthyroidism, 709  
 in SCI women, 718-722  
 serum, *see* Serum thyrotropin
- Thyrotropin-releasing hormone (TRH), plasma PRL level in men before and after stimulation with, following nifedipine and ET-1 treatment, 660
- Thyroxine (T<sub>4</sub>)  
 free, in Bardet-Biedel syndrome children, 1232, 1233  
 in hyperthyroidism, *see* Thyroxine in hyperthyroidism  
 serum, *see* Serum thyroxine
- Thyroxine (T<sub>4</sub>) in hyperthyroidism  
 effects of T<sub>3</sub> on, in hyperthyroidism, 1030, 1031  
 peripheral conversion of, to T<sub>3</sub>, GH effects on serum lipids and Lps and, increased, 1016-1020  
 plasma, 709
- Tissue lipids in obesity, pioglitazone effects on, 521
- Tissue plasminogen activator (t-PA)  
 effects of proinsulin and insulin on, in young women on contraceptive steroids, 833-838  
 fibrinolytic potential and, 1429
- Tissue uptake of insulin, glyburide effects on, in conscious subjects, 579-586
- TKBs (total ketone bodies), effects of plasma E and NE concentrations on, 1217, 1218
- $\beta$  (beta)-TM (thalassemia major), glucose intolerance in, related to insulin resistance and hepatic dysfunction, 652-657
- TNF, *see* Tumor necrosis factor; Tumor necrosis factor- $\alpha$
- Tobacco, *see* Smoking
- $\alpha$  (alpha)-Tocopherol, *see* Vitamin E
- Tolbutamide, effects of, on somatostatin and insulin secretion, 185
- Tolrestat, effects of, on nerve regeneration in STZ-DM after crush injury, 1189-1195
- Total body K (TBK)  
 and body composition of healthy Indian and Swedish men, 637  
 and influence of age, sex, and adiposity on metabolically active component of FFM, 993
- Total body water of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109
- Total cholesterol (TC)  
 AAS abuse effects on, 845  
 and abdominal AT distribution, metabolic risk factors and, 1121  
 in adolescents with insulin resistance, 909; *see also* Total cholesterol in obese adolescents  
 in CHD, *see* Total cholesterol in CHD  
 in FH, GH and, 1417, 1418  
 in FHLB, 1297  
 in FHTG and FDL, 1308  
 fibrinolytic potential and, 1429  
 GH therapy effects on, *see* Total cholesterol, GH therapy effects on  
 and gonadectomy effects on development of hypertension, albuminuria, and STZ-DM, 159  
 in HF diet-induced hyperglycemia and obesity, 1541  
 in high SFA diet, 553  
 in hospitalized subjects, 1558, 1559  
 hydrogenated fat diet effects on, 244  
 in IDDM, *see* Total cholesterol in IDDM  
 and insulin effects on levels of circulating vitamin E, 999, 1000  
 insulin resistance and, and insulin effects on intracellular Ca concentrations, 1405  
 in NIDDM, *see* Total cholesterol in NIDDM  
 of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109  
 OFS effects on, 1548  
 oral albuterol effects on, 714  
 palmitic and stearic acid effects on, 146  
 plasma, exercise effects on, 477  
 serum, *see* Serum total cholesterol  
 in STZ-DM, troglitazone effects on, 1169
- Total cholesterol (TC), GH therapy effects on, 1017  
 of GH therapy of GH-deficient men on, 372
- Total cholesterol (TC) in CHD  
 effects of high- versus low-glycemic CHOs on, 671  
 as lipid risk marker for CHD in non-obese premenopausal women, 330
- Total cholesterol (TC) in IDDM  
 intraperitoneal insulin effects on, 432  
 Lp, apo, and LDL size and, 1268, 1269
- Total cholesterol (TC) in NIDDM  
 and ACE and AGN gene polymorphism, 220

- Total cholesterol (TC) in NIDDM (*Continued*)  
 cardiovascular risk factors and RBC membrane SLC and, 962, 963  
 Lp, apo, and LDL size and, 1268, 1269  
 and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 877
- Total cholesterol (TC) in obese adolescents, 235  
 in morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA in, 1013
- Total gluconeogenesis (GNG) from glycerol with [2-<sup>13</sup>]glycerol, measurement of, 897-901
- Total glycerides in hyperlipidemia, 892
- Total hepatic nuclear protein, starvation effects on, 971
- Total ketone(s), relationship between plasma insulin, BP, and levels of, in normal, DM, and DKA subjects, 693
- Total ketone bodies (TKBs), effects of plasma E and NE concentrations on, 1217, 1218
- Total parenteral nutrition (TPN)  
 effects of GH therapy of hyperglycemia in multiple trauma subjects on, 450-456  
 with  $\omega$ -fish oil, effects of, on leukocyte membrane FA composition and leukotriene-synthesizing capacity in postoperative trauma, 1208-1213
- Total phospholipids (PLs), intraperitoneal insulin effects on, in IDDM, 432
- Total proteins in IDDM and NIDDM, blood cell membrane phospholipid composition and, 59
- Total triglycerides (TGs)  
 in FHTG and FDL, 1308  
 in NIDDM, cardiovascular risk factors and RBC membrane SLC and, 963  
 palmitic and stearic acid effects on, 146
- t-PA, *see* Tissue plasminogen activator
- TPN, *see* Total parenteral nutrition
- Tracer kinetics, muscle protein synthesis and degradation in anesthesia measured with, 1279-1283
- Training, *see* Exercise
- Trandolapril, effects of, alone or in combination with verapamil, on glucose transport in insulin-resistant skeletal muscle, 535-541
- Transaminase, aspartate, in  $\beta$ -thalassemia major, 653
- Transforming growth factor- $\beta$  (TGF- $\beta$ ), role of, in glucose effects on proteoglycan mRNA expression, 1141-1142
- Transpeptidase,  $\gamma$ -glutamyl, in FHTG and FDL, omega-FA and fenofibrate effects on, 1306
- Transplantation, 848-861  
 MH 7777, reduced immune function and reduced splenocyte metabolism in recipients of, 848-855  
 pancreas, effects of, on plasma Lp distribution and composition, 856-861  
 renal, protein oxidation in, 1319-1322
- Transposition, portal-caval, hyperinsulinemia and insulin resistance with, 120-125
- Trauma and injury  
 multiple, effects of GH therapy on hyperglycemia in subjects with, on TPN, 450-456  
 nerve crush injury, tolrestat effects on nerve regeneration in STZ-DM after, 1189-1195  
 postoperative, effects of parenteral fish oil on leukotriene-synthesizing capacity and leukocyte membrane FAs in, 1208-1213  
 thermal, effects of, on glucose utilization by skin, wound, small intestine, and skeletal muscle, 1161-1167  
 women with spinal cord, HPO and HPT axes in, 718-722
- TRH (thyrotropin-releasing hormone), plasma PRL level in men before and after stimulation with, following nifedipine and ET-1 treatment, 660
- Triacylglycerol (TAG), hepatic, OFS effects on fructose impact on metabolism of, 1547-1550
- Triglycerides (TGs)  
 and abdominal AT distribution, metabolic risk factors and, 1121  
 in adipocytes, Mg deficiency effects on glucose incorporation into, 840  
 in adolescents with insulin resistance, 909-911  
 in Bardet-Biedel syndrome children, 1231, 1233  
 in CHD, *see* Triglycerides in CHD  
 as CV risk factor in healthy Indian and Swedish men, 640  
 17 $\beta$ -estradiol effects on, in postmenopausal women, 828  
 exercise and, *see* Triglycerides, exercise and  
 fibrinolytic potential and, 1429  
 GH therapy effects and, *see* Triglycerides, GH therapy effects on  
 in HF diet-induced hyperglycemia and obesity, 1541  
 in high SFA diet, 553  
 in hospitalized subjects, 1558-1560  
 in hypercholesterolemia, *see* Triglycerides in hypercholesterolemia  
 in IDDM, *see* Triglycerides in IDDM  
 insulin and, *see* Triglycerides, insulin and  
 intramuscular, and muscle insulin sensitivity in nondiabetic subjects, 947-950  
 in IRS, 1535, 1536  
 low-fat diet effects on, in sitosterolemia, 674  
 medium-chain, *see* Medium-chain triglycerides  
 in morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA in, 1013  
 nandrolone decanoate effects on concentration of, 465  
 in NIDDM, *see* Triglycerides in NIDDM  
 in normolipidemic men, 1109, 1110, 1113-1114  
 in obesity, *see* Triglycerides in obesity  
 oral albuterol effects on, 714  
 palmitic and stearic acid effects on, 146  
 pancreatic islet, FA effects on glucose-regulated beta-cell function and, 981-986  
 plasma, *see* Plasma triglycerides  
 RBC membrane phospholipid composition and, 59  
 serum, *see* Serum triglycerides  
 in STZ-DM, troglitazone effects on, 1169  
 total, *see* Total triglycerides  
 in uremia, 688, 689  
 and urinary excretion of E<sub>2</sub> and T, 281, 282  
 voglibose effects on, in nondiabetic hyperinsulinemia, 734  
*see also* Hypertriglyceridemia
- Triglycerides (TGs), exercise and  
 and diet effects on glucose homeostasis and serum lipid levels, 436  
 and exercise effects on concentrations of serum TC and LDL-C related to apo E phenotype in boys and young adults, 798
- Triglycerides (TGs), GH therapy effects on  
 in FH, 1417, 1418  
 in GH-deficient men, 372  
 peripheral conversion of T<sub>4</sub> to T<sub>3</sub> and, 1017
- Triglycerides (TGs), insulin and  
 and insulin effects on intracellular Ca concentrations, insulin resistance and, 1405  
 and insulin effects on levels of circulating vitamin E, 999, 1000
- Triglycerides (TGs) in CHD  
 effects of high- versus low-glycemic CHOs on, 671  
 and lipid and CHO metabolic risk markers for CHD in non-obese premenopausal women, 330

- Triglycerides (TGs) in hypercholesterolemia  
in FH, 1417, 1418  
with thrombophilia, 967
- Triglycerides (TGs) in IDDM  
apo, Lp, and LDL size and, 1268, 1269  
progression of microalbuminuria and, 1103, 1104
- Triglycerides (TGs) in NIDDM  
and ACE and AGN gene polymorphism, 220  
cardiovascular risk factors and RBC membrane SLC and, 962  
Lp, apo, and LDL size and, 1268, 1269  
with macrovascular disease, 134  
in normotriglyceridemic NIDDM, 64, 67  
plasma, role of AT loss in exercise-induced improvement in, 1384  
and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 877  
serum, with amino acid polymorphism in HSL, 864
- Triglycerides (TGs) in obesity  
in obese adolescents, 235  
in obese 10-year-old girls, 471, 472  
in visceral obesity-insulin resistance-dyslipidemic syndrome, 885, 886
- Triiodothyronine ( $T_3$ )  
maximal binding capacity of, for  $T_3$  receptor protein, starvation effects on, 970-973  
serum, *see* Serum triiodothyronine  
*see also* Triiodothyronine in hyperthyroidism; Triiodothyronine receptor protein
- Triiodothyronine ( $T_3$ ) in hyperthyroidism  
effects of  $T_3$  on plasma glucagon, 1029-1033  
free, 709  
peripheral conversion of  $T_4$  to, GH effects on serum lipids and Lps and increased, 1016-1020
- Triiodothyronine ( $T_3$ ) receptor protein,  $T_3$  maximal binding capacity for, decreased by starvation, 970-973
- Triphosphatase, adenosine, *see*  $Na^+/K^+$  ATPase
- Triphosphate, adenosine, *see* ATP
- Triptorelin (D-Trp-6-luteinizing hormone-releasing hormone) for severely hirsute hyperandrogenic women, 25-27
- Troglitazone, cardioprotective effects of, in STZ-DM, 1168-1173
- Tropical oils, relative effects of high SFA levels in meat, dairy products and, on serum Lps and degradation of LDLs by mononuclear cells in men, 550-558
- Tryptophan, MH 7777 effects on concentrations of, 851
- TSH, *see* Thyrotropin
- Tubular cells, proximal, glucose loading-induced apoptosis of, 1348-1353
- Tumor necrosis factor (TNF), protein and, as determinants of plasma IGF-1 and albumin concentrations and their hepatic mRNAs in malnourished subjects, 1273-1278
- Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), effects of, on basal and insulin-stimulated glucose transport in muscle and fat cells, 1089-1094
- 24-hour pattern of HS in obesity with NIDDM, 1342-1347
- Twins  
identical, body weight recovery by, after 5 years of overfeeding, 1042-1050  
nephropathic IDDM, erythrocyte membrane Na/Li countertransport kinetics in, 1203-1207
- Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
- Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Tyrosine  
brain, IV  $\gamma$ -glutamyl tyrosine effects on catecholamine concentrations and, in normal subjects, 126-132  
MH 7777 effects on concentrations of, 851
- Tyrosine kinase  
IGF-I-stimulated activity of, 1477-1479  
severe resistance to insulin and IGF-I due to two mutations of tyrosine kinase domain of insulin receptor gene in leprechaunism, 1493-1500
- Ubiquinone, serum, effects of anabolic androgenic steroid abuse on serum dolichol and, 844-847
- UMR106 osteoblastic cells, effects of vitamin  $B_{12}$  on alkaline phosphatase activity in, and on proliferation of, 1443-1446
- Untreated non-insulin-dependent diabetes mellitus (NIDDM), effects of starvation on plasma glucose and insulin concentrations in, 492-497
- Urapidil, effects of, on plasma Fn in essential hypertension, 1221-1229
- Urate  
changes in, in lean and obese boys during puberty, 203-210  
in hospitalized subjects, 1558
- Urea in Bardet-Biedel syndrome children, 1231
- Urea nitrogen  
in hospitalized subjects, 1558-1560  
*see also* Urea nitrogen in NIDDM
- Urea nitrogen in NIDDM  
BUN in NIDDM with and without renal insufficiency, insulin effects on urinary phosphate excretion and, 783  
urinary excretion of, in starved untreated NIDDM subjects, 494
- Uremia, VLDLs in, as poor substrates for milk LPL, 686-690
- Uric acid  
serum, *see* Serum uric acid  
urinary excretion of, in starved untreated NIDDM subjects, 493  
*see also* Purine bases
- Urinary excretion  
albumin, *see* Albuminuria; Microalbuminuria; Urinary excretion, albumin, in IDDM; Urinary excretion, albumin, in NIDDM  
of L-arabinose and D-xylose, 1371  
Cl, phosphate, and cAMP, intrarenal glucagon action on, 385  
creatinine, *see* Urinary excretion, creatinine  
DHEAS, effects of moderate protein increase on insulin secretion and, 1483-1486  
 $E_2$  and T, by Chinese men, serum lipoprotein concentrations and, 279-284  
of ethanolamine plasmalogens in nephrotic syndrome, 824  
GH, and GH therapy for GH-deficient men, 363  
 $\gamma$ -glutamyl tyrosine, 131  
K, *see* Urinary excretion, K  
Na, *see* Urinary excretion, Na  
in NIDDM, *see* Urinary excretion in NIDDM  
orotic acid, effects of N-carbamyl glutamate on, in familial leucine-sensitive hypoglycemia, 959  
of purine bases induced by xylitol, glucagon effects on, 1354-1359  
of pyridinium cross-links of collagen in infancy, 510-514  
urate, in pubertal lean and obese boys, 204  
*see also* Aciduria
- Urinary excretion, albumin, in IDDM  
in adult-onset IDDM, intensive therapy and, 1512  
in nephropathic IDDM, RBC membrane Na/Li countertransport kinetics and, 1204
- Urinary excretion, albumin, in NIDDM  
cardiovascular risk factors and RBC membrane SLC and, 962, 963  
lack of relationship between insulin resistance and, 1062-1064  
Urinary excretion, creatinine, 281  
in starved untreated NIDDM subjects, 494

- Urinary excretion, K  
   intrarenal glucagon action on, 385  
   in starved untreated NIDDM subjects, 494
- Urinary excretion, Na  
   intrarenal glucagon action on, 385  
   in starved untreated NIDDM subjects, 494
- Urinary excretion in IDDM  
   albumin, *see* Urinary excretion, albumin, in IDDM  
   C-peptide, in subjects at high risk for IDDM, 873-875
- Urinary excretion in NIDDM  
   with and without renal insufficiency, phosphate, insulin and intrarenal effects on, 782-786  
   urea nitrogen excretion in starved untreated NIDDM subjects, 494  
   *see also* Urinary excretion, albumin, in NIDDM
- Valine, MH 7777 effects on concentrations of, 851
- Vanadyl sulfate (VS), effects of, on CHO and lipid metabolism in NIDDM, 1130-1136
- Vascular endothelial cells, LPC stimulating expression and production of MCP-1 mRNA in, 559-564
- Vascular myocytes, activity and phosphorylation of Na<sup>+</sup>/H<sup>+</sup> exchanger in, in spontaneous hypertension, glucose effects on, 114-119
- Vascular reactivity in metformin-treated fructose-hypertensive subjects, 1053-1055
- Vascular resistance, renal, intrarenal glucagon action on, 385
- Vascular smooth muscle cells (VSMCs), adhesive and proliferative properties of, impaired by nonenzymatic glycation of Fn, 285-292
- Vasopressin  
   effects of CRF/AVP and stress tests on HPA activity and its relationship to AN in premenopausal obese women with VAT and SAT, 351-356  
   role of, in regulation of gluconeogenesis, 392-395
- VAT, *see* Visceral adipose tissue
- $\dot{V}CO_2$  in multiple trauma, 454
- Ventricular hypertrophy, left, hypertension with, BNPs during ergometric exercise by patients with, 1326-1329
- Ventricular premature complexes (VPCs), hyperinsulinemia associated with, 1248-1253
- Verapamil, effects of trandolapril alone or in combination with, on glucose transport in insulin-resistant skeletal muscle, 535-541
- Very-low-density lipoprotein(s) (VLDLs)  
   effects of low-fat diet on, in sitosterolemia, 674  
   in FHLB, 1302  
   in IDDM and NIDDM, apo, Lp, and LDL size and, 1268, 1269  
   of normolipidemic men, myristate, palmitate, and stearate metabolism and, 1109  
   peroxidation of, antioxidant effects of 4-hydroxyestrone and 17 $\alpha$ -dihydroequilin on, 412, 413  
   serum, urapidil effects on, in hypertension, 1223  
   in uremia, as poor substrates for milk LPL, 686-690  
   *see also* Very-low-density lipoprotein-cholesterol
- Very-low-density lipoprotein-cholesterol (VLDL-C)  
   in CAD, 1379-1380  
   effects of GH therapy for GH-deficient men on, 372  
   in FHTG and FDL, 1308  
   in glomerular proteinuria, 726  
   hydrogenated fat diet effects on, 244  
   in hyperlipidemia, 892  
   in obesity, *see* Very-low-density lipoprotein-cholesterol in obesity  
   palmitic and stearic acid effects on, 146
- Very-low-density lipoprotein-cholesterol (VLDL-C) (*Continued*)  
   pancreas transplantation effects on, 858  
   and relationship of plasma TGs, HDL-C, and apo B to postheparin LPL activity, 263  
   urapidil effects on, in hypertension, 1223
- Very-low-density lipoprotein-cholesterol (VLDL-C) in obesity  
   in morbidly obese adolescents, effects of insulin resistance, lipids, and body weight on DHEA in, 1013  
   in obese adolescents, 235  
   in visceral obesity-insulin resistance-dyslipidemic syndrome, 885
- Vessel dilators (VSDs), circadian relationships between serum Ca, serum phosphate, and circulating, 1021-1028
- Visceral adipose tissue (VAT)  
   HPA axis activity and its relationship to AN in premenopausal obese women with SAT and, effects of CRF/AVP and stress tests on, 351-356  
   in identical twins after 5 years of overfeeding, 1045
- Visceral obesity  
   familial level of, 378-382  
   plasma HDL-C as correlate of visceral obesity-insulin resistance-dyslipidemic syndrome in men, 882-888
- Visceral organs  
   volume of, and body composition of healthy Indian and Swedish men in relationship to CV risk factors, 637, 638  
   *see also specific visceral organs*
- Vitamin A<sub>1</sub> (retinol), RA receptor transcripts and effects of RA and, on glucagon secretion in pancreatic islets and glucagon-secreting cell lines, 300-305
- Vitamin B<sub>12</sub>  
   effects of, on alkaline phosphatase activity in, and proliferation of bone marrow stromal osteoprogenitors and UMR106 osteoblastic cells, 1443-1446  
   in NIDDM with macrovascular disease, 134
- Vitamin E ( $\alpha$ -tocopherol)  
   circulating, insulin effects on levels of, 998-1003  
   plasma, hydrogenated fat diet effects on, 245  
   and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 877
- VLDL(s), *see* Very-low-density lipoprotein(s)
- VLDL-C, *see* Very-low-density lipoprotein-cholesterol
- $\dot{V}O_2$   
   exercise and, *see*  $\dot{V}O_2$ , exercise and  
   T-cell leukemia effects on, 647-648  
   theophylline effects on, during exercise and, 1156
- $\dot{V}O_2$ , exercise and  
   and endogenous opioid response to exercise in IDDM, 139  
   and pivalic acid-induced carnitine deficiency, 1504  
   *see also*  $\dot{V}O_2$ , prolonged exercise and
- $\dot{V}O_2$ , prolonged exercise and  
   effects of CHOs with MCTs and dietary fat supplementation on  $\dot{V}O_2$  during prolonged exercise, 916  
   and substrate kinetics during prolonged exercise, 419
- $\dot{V}O_{2max}$   
   and fibrinolytic potential, 1429  
   in NIDDM, 1384  
   *see also*  $\dot{V}O_{2max}$ , exercise and
- $\dot{V}O_{2max}$ , exercise and  
   and pivalic acid-induced carnitine deficiency, 1501, 1502, 1504  
   and relationship between glucose metabolism and thermogenesis with and without prior exercise in obese NIDDM women, 748  
   and strenuous exercise effects on glycerol kinetics, 358  
   *see also*  $\dot{V}O_{2max}$ , prolonged exercise

- $\text{VO}_2\text{max}$ , prolonged exercise  
effects of CHOs with MCTs and dietary fat supplementation on  $\text{VO}_2$  during prolonged exercise, 916  
and substrate kinetics during prolonged exercise, 418
- Voglibose, effects of, on dyslipidemia and insulin sensitivity in nondiabetic hyperinsulinemia, 731-737
- VPCs (ventricular premature complexes), hyperinsulinemia associated with, 1248-1253
- VS (vanadyl sulfate), effects of, on CHO and lipid metabolism in NIDDM, 1130-1136
- VSDLs (vessel dilators), circadian relationships between serum Ca, serum phosphate, and circulating, 1021-1028
- VSMCs (vascular smooth muscle cells), adhesive and proliferative properties of, impaired by nonenzymatic glycation of Fn, 285-292
- Waist-to-hip ratio (WHR)  
and abdominal AT distribution, metabolic risk factors and, 1120, 1121  
of adolescents with insulin resistance, 909, 910  
of CHD subjects, 670  
and diet-induced weight loss, *see* Waist-to-hip ratio, and diet-induced weight loss  
of healthy Indian and Swedish men, 637  
in hypercholesterolemic thrombophilia, 967  
and hyperinsulinemia associated with VPCs, 1250-1252  
of hypertensive subjects, urapidil effects on plasma Fn and, 1222  
of identical twins after 5 years of overfeeding, 1045  
of IGT subjects, 504  
and intramuscular TG content, 949  
of IRS subjects, 1535, 1536  
in lean subjects, interstitial insulin and, 952  
of nondiabetic Creole, Indian, and Chinese Mauritians, and relationship between weight gain and insulin resistance, 629, 631, 632  
of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109  
in obesity, *see* Waist-to-hip ratio in obesity  
and plasma oxidizability in NIDDM Mexican-Americans and non-Hispanic whites, 877, 879  
of postmenopausal women, 828  
psychosocial factors and, in IDDM subjects, 268-272  
and relationship between hepatic and peripheral insulin resistance and PAI-1, 1244  
and relationship of plasma TGs, HDL-C, and apo B to postheparin LPL activity, 263  
of smokers, 1552  
of  $\beta$ -thalassemia major subjects, 653  
and urinary excretion of T and  $\text{E}_2$ , 281  
of young women on contraceptive steroids, 834
- Waist-to-hip ratio (WHR), and diet-induced weight loss, 176  
and resistance and aerobic exercise effects on WHR, 181
- Waist-to-hip ratio (WHR) in obesity  
interstitial insulin and, 952  
in premenopausal obese women with VAT and SAT, 352  
in visceral obesity-insulin resistance-dyslipidemic syndrome, 885
- Water  
deuterated, in plasma C and FA synthesis measurement, number of incorporated deuterium atoms determined with, 817-821  
total body, of normolipidemic men, myristate, palmitate, and stearate Lp metabolism and, 1109
- Weight, *see* Body weight; Organ weight; Weight gain; Weight loss, diet-induced
- Weight gain  
L-fucose effects on, 231  
with long-term sucrose-rich diet, 1528  
relationship of insulin resistance to, in nondiabetic Creole, Indian, and Chinese Mauritians, 627-633
- Weight loss  
with IDDM, therapy and, 1510  
*see also* Weight loss, diet-induced
- Weight loss, diet-induced, 174-183  
decreased PP dietary fat oxidation following high-fat meal after, 174-178  
resistance and aerobic exercise effects on body composition and metabolism following, 179-183
- WHR, *see* Waist-to-hip ratio
- Women  
aging, four-compartment model of body composition in, 43-48  
exercising, *see* Women, exercising  
with PCOS, hormonal parameters in, 72-75  
SCI, HPO and HPT axes in, 718-722  
*see also* Hirsute women; Menstrual history; Non-hirsute women; Non-obese women; Pregnancy; Women, obese; Young women
- Women, exercising, 747-758  
glucose and lactate kinetics during short exercise by pregnant women, 753-758  
obese NIDDM, relationship between glucose metabolism and thermogenesis with and without prior exercise, 747-752  
regional FFA kinetics contributing to postabsorptive FFA flux in, 662-666  
*see also* Exercise
- Women, obese  
ACX effects on GH response to GHRH alone or combined with arginine in, 342-346  
hirsute, hormonal parameters in, 72-75  
with IGT, dysfunctional pancreatic islets in, 502-510  
with NIDDM, relationship between glucose metabolism and thermogenesis with and without prior exercise in, 747-752  
nondiabetic, CIPR in, 168-173  
premenopausal, with VAT and SAT HPA axis activity and its relationship to AN in, effects of CRF/AVP and stress tests on, 351-356  
*see also* Obesity
- Wound, thermal injury effects on glucose utilization by, 1161-1167
- Xylitol, glucagon effects on increase in plasma and urinary excretion of purine bases induced by, 1354-1359
- D-Xylose, effects of, on blood glucose after sucrose ingestion, 1370-1371
- Young adults  
apo E phenotype in, varying effects of exercise on serum TC and LDL-C concentrations related to, 797-803  
*see also* Young men; Young women
- Young men,  $\text{O}_2$  consumption in heart, hepatomesenteric bed, and brain of, sympathetic nervous activity with, 1487-1492
- Young women  
on contraceptive steroids, effects of proinsulin and insulin on plasma PAI-1 and t-PA in, 833-838  
effects of palmitic and stearic acids on serum lipids, Lps, and plasma CETP in, 143-149  
hirsute, menstrual history of, and current bone mineral density, 515-518